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Abstract 
Argonaute proteins are the core component of an RNA silencing complex. The 
human genome encodes four Argonaute paralogs –Ago1, Ago2, Ago3 and Ago4– 
proteins that are guided to target mRNAs by microRNAs. More than 500 
miRNAs are conserved between mammals, and each microRNA can repress 
hundreds of genes, regulating almost every cellular process. We still do not fully 
understand the molecular mechanisms by which miRNAs regulate gene 
expression. Although we understand many aspects of microRNA biogenesis and 
formation of the RNA-induced silencing complex, much less is known about the 
subsequent steps leading to target mRNA regulation.  
Mammalian microRNAs rarely have complete complementarity to their 
target mRNAs so, instead of endonucleolytic cleavage by Ago2, microRNAs 
destabilize or repress translation of target mRNAs. Here I explored the 
functional limits of Argonaute proteins bound to their targets directly and 
indirectly through microRNAs in mammalian cells. I revealed the different 
abilities for Argonaute proteins bound at multiple sites in a target to generate 
cooperativity in silencing based on the extent of pairing between the microRNA 
and target mRNA.  Further, I harnessed the endogenous microRNA silencing 
mechanism to repress an mRNA that is not a direct target of the microRNA by 
tethering the RNA-induced silencing complex to the 3´ UTR of an mRNA. This 
strategy allows tissue-specific gene silencing due to the limited endogenous 
expression profile of the recruited microRNA. Efforts made herein further our 
 vii  
mechanistic knowledge of microRNA-induced gene silencing in mammalian cells 
and advance microRNA-based strategies toward treating human disease. 
 viii  
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Chapter I: Introduction 
Introduction 
The discovery that small RNAs can silence gene expression through RNA 
interference identified a fundamentally important regulatory mechanism for 
biology (Fire et al., 1998). Its application has had a huge impact on basic research 
and it is anticipated that mammalian RNA silencing will allow discoveries and 
solutions for unmet challenges in human health. Although much is known about 
the mechanism of RNA interference in model organisms and some RNAi- based 
human therapeutics are in development, we are still ignorant of many details 
specific to its function in mammalian cells (Ghildiyal and Zamore, 2009; Joshua-
Tor and Hannon, 2010; Vaishnaw et al., 2010). This thesis project was undertaken 
with the hope that we could advance our understanding of mammalian 
microRNA silencing, while restricting our methods so as to remain true to 
physiological conditions.  
Argonaute proteins are the core of the RNA induced silencing complex 
(RISC) and provide an anchor for the small RNA that guides a RISC to its target 
mRNA and prevents protein expression. A member of the Argonaute family of 
proteins functions in all RNA silencing effector complexes (Tabara et al., 1999; 
Tabara et al., 2002; Hammond et al., 2001; Hutvágner et al., 2001; Catalanotto et 
al., 2002; Martinez et al., 2002; Mourelatos et al., 2002; Djikeng et al., 2003; Shi et 
al., 2004). The human genome encodes four Argonaute paralogs, Ago1, Ago2, 
Ago3 and Ago4. Argonaute proteins contain a P-element induced wimpy testis 
(PIWI) domain that is structurally homologous to RNase H from bacteria, and 
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typically cleave their target RNAs after the nucleotide paired to the tenth base of 
the small RNA guide (Elbashir et al., 2001a; Elbashir et al., 2001b; Tolia and 
Joshua-Tor, 2007). Cleavage requires three key amino acids—D, D, H—that form 
a magnesium-binding catalytic triad that promotes nucleophilic attack by 
hydroxide on the phosphodiester bond (Figure 1.1, 1.2) (Kanaya et al., 1996; 
Haruki et al., 2000; Martinez and Tuschl, 2004; Schwarz et al., 2004; Song et al., 
2004; Rivas et al., 2005). 
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Figure 1.1: Conservation of the amino acid sequence of the PIWI domain of mammalian Argonautes. 
Figure 1.2: Coordination of a magnesium ion for endonuclease activity. 
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Of the four human Argonautes, only Ago2 has the ability to catalyze site-
specific, small RNA-directed endonucleolytic target cleavage (Liu et al., 2004; 
Song et al., 2004; Meister et al., 2004). Like Ago2, Ago3 contains an apparent 
catalytic triad, but unlike Ago2, it lacks endoribonuclease activity. For Ago1 and 
Ago4 there is no catalytic triad, explaining their lack of endoribonuclease activity 
(Meister et al., 2004; Rivas et al., 2005; Azuma-Mukai et al., 2008). Extensive, but 
not complete, complementarity between a small RNA guide and an mRNA is 
required for Argonaute-catalyzed target cleavage (Hutvágner and Zamore, 2002; 
Schwarz et al., 2002; Haley and Zamore, 2004; Liu et al., 2004; Meister et al., 2004; 
Rivas et al., 2005). In contrast, small RNAs with only partial complementarity to 
their target mRNAs, especially those bearing mismatches near the cleavage site, 
cannot direct endonucleolytic cleavage of their target (Holen et al., 2002), but 
instead reduce the stability of the target mRNA (Guo et al., 2010) and, in some 
conditions, cause translational repression (Doench et al., 2003; Doench and 
Sharp, 2004). 
Since the identification of Ago2 as the endoribonucleolytic component of 
mammalian RISC, there has been little advancement in our understanding of the 
function of the individual Argonaute proteins (Liu et al., 2004; Meister et al., 
2004). Does Ago2 require nuclease activity as part of its normal cellular duties? 
How is functional specificity established for the different Argonaute family 
members? Argonaute expression patterns in human tissues overlap and most 
cultured mammalian cell lines express all four proteins in different proportions 
(Sasaki et al., 2003; Meister et al., 2004). Disruption of the mouse Ago2 gene 
produced an embryonic-lethal phenotype, while other Argonautes are 
dispensable for mammalian development, suggesting that Argonaute proteins 
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are not redundant, but might be functionally specialized (Liu et al., 2004; 
Schmitter et al., 2006).  
Argonaute family of proteins 
The Argonaute family of proteins is conserved in plant, animal and fungi 
kingdoms. Argonaute proteins exist in eubacteria and archea, hence, small 
nucleic acids may have guided regulation since cellular life began. Subsequent 
diversification of the small RNA guides allowed Argonautes to acquire 
specialized roles. Phylogenetic analysis separates the Argonautes into three 
clades, Ago-like, PIWI , and worm Argonautes (WAGO), that reflect their 
function in RNA silencing pathways. The Argonaute family is defined by the 
presence of both the Piwi Argonaute Zwille (PAZ) domain, that binds to the 3´ 
end of the small RNA, and Piwi domains (Carmell et al., 2002; Ma et al., 2004). 
Ago-like proteins transcriptionally and post-transcriptionally regulate targets 
using microRNAs (miRNAs) and small interfering RNAs (siRNAs) as guides in 
plants, animals and fission yeast (Tolia and Joshua-Tor, 2007). PIWI-like proteins 
are specific to animals and they function by using PIWI-interacting RNAs 
(piRNAs) as guides to silence transposons in germ cells and ovarian follicle 
tissues (Aravin et al., 2007; Brennecke et al., 2007; Brennecke et al., 2008; Li et al., 
2009; Malone et al., 2009). Although thought to be specific to gonadal cells, PIWI 
mRNA is also expressed in brain and kidney (Sharma et al., 2001). Identification 
of piRNAs in dendrites of mouse hippocampus showed that they function to 
repress translation of mRNA targets that regulate dendritic spine formation (Lee 
et al., 2011). The WAGO clade contains 18 Argonaute proteins that are specific to 
C. elegans. WAGO proteins use secondary small RNAs containing 5´ -
triphosphates that are synthesized by an RNA-dependent RNA polymerase from 
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RNA templates. WAGO protein function is not 
completely understood, however, WAGO 
proteins silence endogenous mRNA targets 
when guided by exogenous dsRNA (Tabara et 
al., 1999; Yigit et al., 2006). WAGO proteins also 
regulate chromosome structure and segregation 
(Claycomb et al., 2009; Conine et al., 2010; Gu et 
al., 2009). 
microRNA biogenesis  
miRNAs are 21–23 nt long RNAs that 
direct Argonaute proteins to bind to and repress 
complementary mRNA targets. More than 500 
miRNAs are conserved between mammals, and 
each miRNA can repress hundreds of genes, regulating almost every cellular 
process (Bartel, 2009; Chiang et al., 2010). Individual miRNAs are often produced 
only in specific cell types or developmental stages (Landgraf et al., 2007). 
miRNAs are transcribed from their own genes by RNA polymerase II (Bracht et 
al., 2004; Lee et al., 2004). Consequently, miRNA primary transcripts (pri-
miRNAs) begin with 5´ 7-methylguanosine caps and end with 3´ poly(A) tails 
(Figure 1.3). The pre-miRNA, a ~65 nt stem-loop structure that contains the 
miRNA and its corresponding miRNA* within its stem, resides within the pri-
miRNA. Cleavage of the pri-miRNA by the ribonuclease III (RNase III) enzyme, 
Drosha, releases the pre-miRNA stem-loop, which bears the 2 nt 3´ overhanging 
ends characteristic of cleavage by RNase III enzymes (Lee et al., 2003; Han et al., 
2006). The pre-miRNA is then exported to the cytoplasm, where its loop is 
Figure 1.3: microRNA biogenesis 
pathway. 
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removed by a second, RNase III enzyme, Dicer, that specifically recognizes the 
pre-miRNA structure, including its 2 nt 3´ overhanging end, and cuts both 
strands (Han et al., 2004; Yi et al., 2003; Bohnsack et al., 2004; Lund et al., 2004; 
Zeng and Cullen, 2004). The resulting miRNA/miRNA*  (miRNA-5p/miRNA-
3p) duplex is then loaded into the RISC loading complex (RLC) which, in 
humans, consists of Argonaute, Dicer, and TAR-RNA binding protein (TRBP), in 
a process facilitated by hydrolysis of ATP and central mismatches (Yoda et al., 
2010).  The requirement for Dicer in the RLC has been called into question 
because immunodepletion of human Dicer supports RNAi in vitro and in Dicer 
null mouse ES cells (Martinez et al., 2002; Kanellopoulou et al., 2005; Murchison 
et al., 2005). Following loading, one strand of the miRNA duplex departs from 
the Argonaute protein by an unknown cleavage-independent mechanism where 
release of the discarded strand is promoted by mismatches in the seed and 3´ 
middle region of the miRNA/miRNA* duplex (Yoda et al., 2010). The result is a 
mature, active miRNA:protein complex called miRISC.  
Although the canonical miRNA biogenesis pathway requires two RNase 
III enzymes, Drosha and Dicer, there is an alternative mechanism that does not 
require Drosha recognition and cleavage. Mirtrons are a subclass of pre-miRNAs 
that are excised from intron lariats from their pri-miRNAs by the spliceosome 
then, after debranching, fold into Dicer substrates (Okamura et al., 2007; Ruby et 
al., 2007; Berezikov et al., 2007; Babiarz et al., 2008; Chiang et al., 2010; Chong et 
al., 2010). Another interesting exception to the canonical biogenesis mechanism is 
Dicer-independent miR-451 that was discovered while investigating the 
requirement for Ago2 expression in embryonic mouse development (Cheloufi et 
al., 2010).  
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In small RNA deep-sequencing libraries from mice that express a 
catalytically inactive Ago2, mature miR-451 was not observed (Cheloufi et al., 
2010). Analysis of the structure of the precursor to miR-451 showed that the stem 
of the pre-miRNA was only 17 nucleotides long and the mature miRNA strand 
sequence extended into the loop region and complementary arm of the hairpin. 
This arrangement of the hairpin is incompatible with Dicer processing of 
miRNAs. In mutant Ago2 cells, the mature miR-451 was not observed, but the 40 
nt precursor, a product of Drosha, was detected by northern probes to both arms 
of the precursor miRNA.  
The miR-451 precursor was detected in Ago2-immunoprecipitates, suggesting 
that Ago2 was processing pre-miR-451. Deep sequencing of small RNAs showed 
that Ago2 generated an intermediate 3´-hydroxyl end at the position consistent 
with endonucleolytic cleavage by Ago2 (Elbashir et al., 2001a). The authors 
predicted that the Ago2 product is most likely trimmed further by an unspecified 
exoribonuclease because deep sequencing revealed a distribution of 3´ ends that 
contained non-templated uracils. Although no other known miRNAs are 
processed by this alternative biogenesis mechanism, the requirement for Ago2 to 
process miR-451 explains why animals have retained Ago2, the only catalytic 
Argonaute, despite the fact that very few miRNAs cleave their targets (Yekta et 
al., 2004; Davis et al., 2005). 
Deciphering miRNA function 
  While RNA interference is a powerful tool to determine biological functions 
of each gene, artificially introducing or inhibiting miRNA function can provide 
clues to their function in normal cellular processes and human disease. The 
molecular function of an individual miRNA can be discovered by inhibiting it 
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and measuring the changes in the levels of each mRNA or protein in the cell or 
by evaluating other phenotypic changes such as developmental defects, cell 
proliferation, organ function or behavior.  
Small RNAs in RISC are inhibited from regulating their targets when they 
bind with perfect 
complementarity to a 
competitor 
oligonucleotide that 
contains 
modifications to 
prevent its cleavage. 
Antisense oligonucleotides (ASO) are single stranded DNA or RNA molecules 
that bind other nucleic acids by Watson-Crick base pairing. Chemical 
modification of the ribose backbone of ASOs prevents Ago2-mediated cleavage 
of the ASO and improves their in vitro and in vivo stability, as well as their in 
vivo delivery (Figure 1.4). 2´-O-methyl modified ASOs complementary to a 
miRNA bound to an Argonaute protein are effective miRNA inhibitors when 
introduced by lipid-mediated transfection into cultured human cells or by 
injection in whole nematodes. Antagomirs are synthetic ASOs that contain 2´-O-
methyl-modified ribose sugars, terminal phosporothioates and at the 3´end, a 
cholesterol group, which helps deliver the antagomir to cells. ASOs modified to 
contain 2´, 4´methylene bridges, called locked nucleic acids (LNAs), are 
especially potent due to structural constraints forcing them into the C3´endo 
conformation. Restricting the conformation of the nucleotide imparts increased 
RNA:RNA melting temperature by 2.4° C per modification. The unique target 
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Figure 1.4: Chemical modifications of RNA. 
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mRNA-binding properties of a miRNA bound to an Argonaute protein allow 
LNA modified ASOs to inhibit miRNAs when pairing only to the 8 nucleotides 
as nearly all the binding specificity comes from the seed sequence (Obad et al., 
2011).  Such tiny LNAs can inhibit miRNA families that share the same seed 
sequence. Unconjugated tiny LNAs, when delivered systemically to mice, 
showed uptake in normal cells and breast tumors where they inhibited the 
targeted miRNAs (Obad et al., 2011).  
 ASOs function, at least in part, as competitive inhibitors of miRNAs, 
suggesting that miRNA-binding RNA transcripts may also sequester and thereby 
inhibit specific miRNAs. Expressing such decoy transcripts could provide an 
alternative to using proprietary oligonucleotide chemistries and delivery 
formulations, enabling researchers to examine the consequence of inhibiting each 
known miRNA in a particular cell or model animal or plant (Ebert et al., 2007; 
Loya et al., 2009; Todesco et al., 2010). Moreover, miRNA-binding transcripts can 
be expressed from viral vectors, allowing the development of anti-miRNA gene 
therapy approaches. The first demonstration of such transcripts, miRNA decoys 
or sponges, inhibiting miRNA function preceded the discovery that plants 
naturally use such miRNA-binding transcripts to reduce the activity of specific 
miRNAs (Franco-Zorrilla et al., 2007). 
microRNA stability 
In addition to directing the mechanism of target silencing, the extent to 
which a target and miRNA pair has been shown to affect the stability of the 
miRNA. In 2002, it was shown that an endogenous miRNA could cleave multiple 
exogenous mRNA targets to which it paired perfectly (Hutvágner and Zamore, 
2002). However, it was not known if a single miRISC, with partial pairing to its 
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target was able to direct regulation of multiple target mRNA molecules.  
Baccarini et al. (2011) tested the multiple-turnover hypothesis by inhibiting the 
biogenesis of a miRNA that targeted a stably expressed GFP reporter gene. 
Careful quantitation showed that the number of target transcripts a miRNA 
regulated was more than the number of molecules of miRNA, indicating that 
miRISC was capable of multiple-turnover. The target was not destroyed during 
silencing, due to the bulged miRNA: target pairing, and it continued to be 
silenced after blocking biogenesis of the miRNA. If miRISC was not multiple-
turnover, then following the inhibition of biogenesis, an increase in target 
expression should have occurred. The decay rate of the miRNA was measured in 
the presence of a perfect target or a target that paired only to the 5´ end of the 
miRNA or a bulged target. The decay rate was faster with the perfectly pairing 
target than for the bulged pairing target or the target that paired only to the 5´ 
end of the miRNA (Baccarini et al., 2011). Their analysis supports a model in 
which the degree of complementarity between the target and the miRNA not 
only directs target silencing, but also influences the stability of the miRNA.  
  The first evidence for target-dependent destabilization of miRNAs was 
observed with the use of synthetic, chemically modified ASOs to inhibit miRNAs 
in mammalian cells (Krutzfeldt et al., 2005).  At the same time the Zamore lab 
was investigating the enzyme Hen1 which, in plants and flies, methylates the 2´ 
hydroxyl of the 3´ terminal nucleotide of siRNAs (Park et al., 2002; Li et al., 2005; 
Yu et al., 2005; Horwich et al., 2007; Pelisson et al., 2007; Saito et al., 2007). 
Modification by Hen1 of miRNAs and siRNAs in flies occurs after loading in 
Ago2, but small RNAs that load in Ago1 are not modified by Hen1 (Horwich et 
al., 2007). When there is extensive complementarity to target, the 3´ end of the 
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guide RNA in Ago2 must release from the PAZ domain of the Argonaute protein 
in order to pair with and cleave the target (Tomari and Zamore, 2005; Wang et 
al., 2008). For small RNAs in Ago2, Hen1 methylation at the 3´ terminal 
nucleotide protects the small RNA from being uridylated and becoming a 
substrate for exonucleolytic degradation (Ameres et al., 2010; Ameres et al., 
2011). The methylation of an siRNA in Ago2 protects its 3´ end and allows 
multiple rounds of target cleavage by a single RISC. In contrast, human 
Argonautes are orthologs of fly Ago1 and small RNAs in human cells are not 
terminally methylated. miRNAs in mammalian Argonautes generally have less 
extensive pairing to their target mRNAs, this allows the 3´ end of the miRNA to 
remain bound in the PAZ domain and prevents uridylation and exonucleolytic 
degradation of the miRNA, preserving its capacity to silence multiple target 
mRNAs (Wang et al., 2008; Ameres et al., 2010).  
In worms, target-dependent destabilization of miRNAs has not been 
observed, but recent work indicates that the stability of a miRNA* strand can be 
increased in the presence of a complementary target (Chatterjee et al., 2011). The 
authors call this target-mediated miRNA protection (TMMP) and propose that 
this may be a post-loading proofreading mechanism to sort miRNAs into 
Argonautes because in worms preferential strand loading in RISC, driven by 
thermodynamic asymmetry of miRNAs, is not prevalent. Considered together, 
these mechanisms suggest an intimate dynamic between miRNAs and their 
target mRNAs. 
Small RNA sorting into Argonaute proteins 
Expression of four mammalian Argonaute paralogs might reflect a 
biological specialization. For example, each Argonaute protein could prefer to 
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load a specific type of small RNA trigger, such as a double stranded siRNA or a 
miRNA, thereby sorting the small RNAs, based on their structure or sequence, 
into a specific Argonaute protein.  
 Evidence supporting a small RNA sorting hypothesis stems from the 
discovery of sorting of small RNAs in other organisms. In C. elegans, miRNAs 
sort into Argonaute orthologs, Argonaute-like gene 1 and 2 proteins, ALG-1 and 
ALG-2, but siRNAs load into RNAi defective 1 protein, RDE-1. In Drosophila, 
each small RNA duplex or miRNA-miRNA*, is structurally interrogated by the 
Argonaute proteins, dAgo1 and dAgo2 before it is loaded in RISC. Drosophila 
Ago2 prefers to load a guide strand of the duplex that is more stably paired at its 
5´ end or has more central pairing to its partner strand, and Drosophila Ago1 
prefers to load the strand of a miRNA/miRNA* whose 5´ end contains central 
mismatches (Forstemann et al., 2007; Steiner et al., 2007; Tomari et al., 2007; 
Czech et al., 2009; Okamura et al., 2009; Ghildiyal et al., 2010). In Arabidopsis 
thaliana, sorting of trigger RNAs into Argonautes is directed by the identity of the 
5´ nucleotide (Mi et al., 2008; Montgomery et al., 2008; Takeda et al., 2008; Wu et 
al., 2009). The crystal structure of a MID domain from a eukaryotic Ago protein, 
human Ago2, in complex with nucleoside monophosphates (AMP, CMP, GMP, 
and UMP) mimicking the 5´ end of miRNAs, shows that there are specific 
contacts made between the base of UMP or AMP and a rigid loop in the MID 
domain (Frank et al., 2010). The loop structure discriminates against CMP and 
GMP, but AMP and UMP bind with up to 30-fold higher affinity. Thus 
nucleotide specific interactions in the MID domain of eukaryotic Ago proteins 
explain the observed preference for U or A at the 5´ end of miRNAs (Lewis et al., 
2005). 
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Several studies looked for a mammalian Argonaute small RNA sorting 
mechanism. In Jurkat cells, an immortalized line of human T lymphocyte cells, 
the identity of miRNAs that immunoprecipitated with endogenous Ago2 and 
Ago3 overlapped, indicating that Argonaute proteins are not specialized for their 
interaction with small RNAs (Azuma-Mukai et al., 2008). The strongest, yet not 
convincing, evidence for functional specialization of the Argonaute proteins 
comes from inducible Argonaute knockout mouse embryonic stem cells. In 
mouse embryonic stem cells expressing a single exogenous Argonaute protein, 
some preference based on the structure of the exogenously supplied siRNA was 
detected in reporter assays: Ago1 and Ago2 were more effective than Ago3 and 
Ago4 at silencing a luciferase reporter when the siRNA was a perfectly pairing 
duplex, and all Argonautes could silence the luciferase reporter when the siRNA 
duplex contained central bulges (Su et al., 2009). Analysis of human RISC 
assembly using epitope-tagged Argonaute proteins ruled out a structurally-
driven sorting mechanism for exogenous siRNAs containing miRNA/miRNA*-
like pairing structures and revealed that they can load in any Argonaute protein. 
However, it did show that perfect siRNA duplexes in vitro could be loaded only 
into Ago2, because they require slicer activity to cleave the passenger strand 
(Matranga et al., 2005; Yoda et al., 2010).  
Target pairing specialization  
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Since there is no rigid sorting mechanism for small RNAs into mammalian 
Argonaute proteins, perhaps the specialization of Argonautes is determined at 
the next step in the pathway, by sensing the structure of the miRNA:mRNA 
target pairing. The crystal structure of prokaryotic Argonaute protein from 
Thermus thermophilus with a DNA guide strand and an RNA target revealed 
molecular details that are consistent with known characteristics of miRNAs. For 
example, target recognition is directed by the seed sequence of a miRNA, 
nucleotides 2 to 8 from the 5´ end of the guide strand (Figure 1.5) (Brennecke et 
al., 2005; Lewis et al., 2005; Bartel, 2009). This region of a miRNA was identified 
by computational clustering analysis of the target pairing requirement in 
evolutionarily conserved miRNAs and proven experimentally to direct target 
recognition and regulation by RISC (Lewis et al., 2003; Rajewsky and Socci, 2004; 
Lewis et al., 2005; Grimson et al., 2007; Baek et al., 2008; Selbach et al., 2008; 
Friedman et al., 2009).  
 The structural analyses of Argonaute protein from T. thermophilus with a 
guide RNA showed that the phosphodiester backbone contacts the MID/PIWI 
lobe of the protein, forcing the seed nucleotide bases 2 to 6 to face the exterior of 
the protein in a continuous A-form helical arrangement that allows hydrogen 
bonding to the target mRNA (Ma et al., 2005; Parker et al., 2005). The bases in the 
3´ region of the guide RNA were not pre-ordered. The asymmetry for ordered 
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Figure 1.5: Seed region of a microRNA (yellow) and 3´ supplemental pairing (orange). 
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arrangement of the bases in the structure is consistent with biochemical 
energetics of RISC function showing that 3´ complementarity between target and 
guide RNA is not required for target cleavage, but does contribute to binding 
stability (Haley and Zamore, 2004; Ameres et al., 2007).  
 The pre-ordered arrangement of seed nucleotides 2-6 explains why a 
position 5 bulged nucleotide, or loop-out, in the guide strand does not allow 
cleavage and silencing of a target mRNA, whereas a bulge at the same position in 
the mRNA target does allow target cleavage (Wang et al., 2008). Even when 
targeting six-sites in the 3´ UTR of a luciferase reporter in HeLa cells, there was 
no silencing of a reporter by an siRNA that had a loop-out in the guide strand at 
position 5 of the seed region yet was perfectly paired to target at every other 
position (unpublished data, Wee and Zamore). In C. elegans, a target site for let-7 
in the 3´ untranslated region (UTR) of lin-41 forms a bulge in the target at the 
nucleotide that is paired to the nucleotide at position 5 of let-7, and is able to 
silence a reporter target when one there is an additional target site nearby that 
does not contain a bulge at position 5, showing that the geometry of a target 
bulge in the seed region is tolerated by Argonaute proteins (Lee et al., 2003; Vella 
et al., 2004). 
 Apart from the seed region, the next most conserved target pairing region 
in miRNA families is to four contiguous nucleotides at positions 13-16 and is 
called 3´ supplemental pairing (Figure 5) (Grimson et al., 2007). The seed-
nucleation model for target recognition by a guide RNA proposed that a 
conformation shift in the Argonaute protein is required in order for the guide 
RNA to pair completely to target beyond the seed region, allowing the paired 
guide and target to form two helical turns (Bartel, 2009).  The seed nucleation 
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model proposes that a thermodynamic shortcut to allow pairing beyond the 
seed, but avoid a conformational shift in the protein, could be to sacrifice central 
pairing to the target and restart contiguous pairing at positions 13-16 of the 
guide. The reduced target affinity caused by having mismatches in the central 
region of the guide can be energetically offset by not requiring the 
conformational shift in the Argonaute protein in order for the 3´ end of the guide 
to pair with the target. Allowing 3´ supplementary pairing to target, after the 
centrally unpaired region, avoids the energetic cost of release of the central 
region of the miRNA from the Argonaute protein during target pairing. 
When T. thermophilus Argonaute was crystallized with a 19 nt target RNA, 
the target paired to the guide RNA from position 2 to position 16 of the guide 
strand (Wang et al., 2009).  Mismatches at positions 10 and 11 of the guide RNA 
caused disorder in the structure between positions 12-19 so that the 3´ end of the 
guide strand was retained in the PAZ domain. A guide strand that paired 
perfectly only up to position 12 or 15 with target was prevented from slicing the 
target, when the 3´ end was retained in the PAZ domain. In contrast, a 3´ 
truncated guide strand, pairing to only 9 nucleotides of target, was able to cleave 
the target. This data supports the mechanistic distinction between silencing by 
catalytic Ago2 and the non-catalytic Argonautes based on extent of pairing. It has 
been proposed that in order for Ago2 to cleave target, the 3´ end of the guide 
RNA must release from the PAZ domain (Wang et al., 2009). More extensive 
pairing to the target would favor cleavage of target by Ago2, but cleavage would 
be inhibited until pairing propagated to the 3 ´end. However, multiple rounds of 
target cleavage by Ago2 are favored when the 3´ end of the guide is mismatched 
or competitively blocked. Thus it appears that release of the target cleavage 
 17  
product when paired to the 3´ end of the guide RNA is the limiting step in target 
cleavage (Haley and Zamore, 2004; Ameres et al., 2007). Finally, 3´ supplemental 
or compensatory pairing contributes little to target-binding specificity and 
affinity, and might be dispensable for silencing by non-catalytic Argonaute 
proteins, since most miRNAs do not cleave their targets (Doench and Sharp, 
2004; Yekta et al., 2004; Brennecke et al., 2005; Davis et al., 2005; Lewis et al., 2005; 
Lim et al., 2005; Grimson et al., 2007; Baek et al., 2008; Selbach et al., 2008; 
Friedman et al., 2009; Shin et al., 2010). 
Argonaute protein mechanisms for silencing   One of the unsolved mysteries of small RNA silencing is the mechanism 
through which miRNAs regulate the expression of targets. The first miRNA 
target interaction was discovered in C. elegans (Lee et al., 1993). The 3´ UTR of the 
lin-14 mRNA contained 7 sites with extensive, but not complete complementarity 
to the lin-4 miRNA. Mutation of either lin-4 or lin-14 genes produced the same 
defect in developmental transitions of larvae, causing the mis-expression of 
proteins at incorrect stages of development resulting in improper execution of 
cell fates in the developing worm, called a heterochronic mutant phenotype 
(Ambros and Horvitz, 1984; Chalfie et al., 1981; Horvitz and Sulston, 1980; 
Sternberg and Horvitz, 1984; Sulston and Horvitz, 1981; Lee et al., 1993; 
Wightman et al., 1993). Interestingly, deletion of some of the complementary 
sequences caused a weaker phenotype than when all were deleted from the 3´ 
UTR of lin-14. None of the mutants showed a change in abundance of lin-14 
mRNA, however, mutation of the sequence in the 5´ end of lin-4 caused 
persistent expression of the LIN-14 protein, suggesting that an RNA:RNA 
interaction, lin-4 binding to the lin-14 3´ UTR, inhibited translation (Lee et al., 
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1993). The discovery of another small RNA, let-7, which paired to the 3´ UTR of 
lin-41 mRNA, showed that this mechanism for regulation was not exclusive to 
worms, because the let-7 nucleotide sequence and temporal expression pattern 
was conserved in Drosophila embryos and across bilateral animals (Pasquinelli et 
al., 2000; Reinhart et al., 2000).  
Similarity in the antisense nature of regulation of lin-14 and lin-41 by lin-4 
and let-7 together with their hairpin-like precursor structure led to the confluence 
of miRNA mediated silencing and two similar gene silencing phenomena: co-
suppression in plants and RNA interference discovered in worms (Fire et al., 
1991; Guo and Kemphues, 1995; Baulcombe, 1996; Fire et al., 1998). Biochemical 
studies in plants, worms and the establishment of an in vitro system from 
extracts of syncitial blastoderm of Drosophila embryos quickly led to the 
discovery that the trigger for silencing was processed from long double stranded 
RNA (dsRNA) into a small RNA duplex which directed nuclease activity of a 
ribonucleoprotein, RISC containing Argonaute 2 (Tuschl et al., 1999; Hamilton 
and Baulcombe, 1999; Hammond et al., 2000; Parrish et al., 2000; Zamore et al., 
2000; Hammond et al., 2001). A major breakthrough in the field was made by 
using synthetic small RNA duplexes, that bypassed the need for a long double 
stranded RNA precursor trigger, to silence endogenous mRNAs. This allowed 
transient transfection of siRNAs into cells and overcame the antiviral Protein 
Kinase RNA-activated (PKR) response triggered by long dsRNA in mammalian 
cells (Elbashir et al., 2001a).  
Soon after, two important discoveries moved the field forward. First, an 
endogenously programmed miRNA in RISC when presented with a target 
mRNA to which it paired with perfect complementarity, caused cleavage and 
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destruction of multiple target mRNAs in vitro (Hutvágner and Zamore, 2002).  
Reciprocally, Doench and Sharp showed that an exogenously supplied siRNA 
that paired imperfectly, with central bulges, to a target did not direct target 
cleavage, but instead caused the mRNA target to be translationally repressed, 
similar to lin-4: lin-14 in worms (Doench et al., 2003; Doench and Sharp, 2004). 
They could still detect mRNA from the luciferase reporter target on a Northern 
blot, but the luciferase protein activity was decreased. These two studies led to 
the model that the degree of complementarity between a small RNA and its 
target determined the mechanism of silencing. Extensive pairing with target 
mRNA could cause cleavage and an endogenously loaded miRNA was capable 
of directing cleavage of a target to which it paired with perfect complementarity, 
as was an exogenously supplied siRNA. Sharp and Doench showed that an 
siRNA could act like a miRNA: when the siRNA had central bulges or 
mismatches to multiple target sites in the 3´ UTR of a reporter mRNA, the siRNA 
caused translational repression. 
Translational repression or mRNA destabilization?  
Several large-scale proteomic analyses support bioinformatically-based 
predictions that a single miRNA can repress hundreds of target mRNAs (Lewis 
et al., 2003; Rajewsky and Socci, 2004; Lewis et al., 2005; Grimson et al., 2007; 
Baek et al., 2008; Selbach et al., 2008; Friedman et al., 2009). After years of studies 
on the mechanism of miRNA target regulation, two opposing models remain for 
how miRNAs effect silencing of their mRNA targets. One model is that miRNAs 
reduce the translation efficiency of an mRNA, without decreasing mRNA 
abundance, and the other model proposes that the reduced protein level is a 
result of mRNA destabilization by miRNA-directed decapping or deadenylation. 
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Two groups examined the impact of inhibiting a miRNA or its over-expression 
on translational efficiency by quantitative mass spectroscopy of metabolically 
labeled proteins. One study concluded that the dominant effect for certain targets 
was decreased translational efficiency (Selbach et al., 2008), while another group 
concluded that there was a strong correlation between the decrease in mRNA 
and protein abundance effected by miRNAs (Baek et al., 2008). These studies 
may have conflicting results because measurement of the mRNA levels by 
microarray analysis from a single time point can be distorted by comparison to 
protein quantitation after metabolic labeling— a process occurring over a period 
of time.  However, a more quantitative analysis was carried out that 
quantitatively measured ribosome density by deep sequencing analysis of 
ribosome protected mRNA fragments and compared them to the mRNA array or 
RNA-seq data (Ingolia et al., 2009; Guo et al., 2010). The ribosome protected 
fragment analysis measures levels of mRNAs in the cell and the effect of the 
miRNA on the mRNA level can be cross-correlated to the amount of ribosome 
protected fragments of mRNA, eliminating the time discrepancy between mRNA 
and protein measurements of the previous studies. This method also reports on 
the levels of thousands of mRNAs, in contrast to the proteomic analyses, which 
skews the data toward more highly expressed proteins. Using the more 
quantitative ribosome profiling approach, two groups showed that a majority of 
the reduced protein output corresponded to destabilization of the mRNA targets, 
however, for some remaining target mRNAs there was a decrease in ribosome 
density consistent with the model for inhibition of translation (Hendrickson et 
al., 2009; Guo et al., 2010).  
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Translational repression at initiation or elongation? 
For those mRNA targets not destabilized by their miRNAs, there is 
controversy for the mechanism of repression. Translation can be inhibited at the 
initiation step or at the elongation step. Repression of a target mRNA depends on 
disruption of the interaction between the 5´ cap and poly-A tail. miRNA binding 
to the 3´ UTR could block translation initiation, by preventing binding of the 40S 
ribosome initiation complex through competition for cap binding proteins 
(Mathonnet et al., 2007; Thermann and Hentze, 2007). In Drosophila, Ago1 blocks 
a step after cap recognition, whereas Ago2 binds to eIF4E and specifically blocks 
eIF4E-eIF4G interaction that is required for translation initiation (Iwasaki et al., 
2009). Interestingly, when Drosophila Ago2 is bound to target mRNA, the affinity 
of Ago2 for eIF4E is dramatically enhanced (Iwasaki et al., 2009). Data also 
suggest that a target mRNA can be repressed even if it is not adenylated at its 3´ 
end, while messages containing an adenosine cap, instead of a guanosine cap, or 
a viral internal ribosome entry site are not subject to repression by miRNA 
binding to the 3´ UTR (Humphreys et al., 2005; Pillai et al., 2005; Wang et al., 
2006; Wu et al., 2006; Wakiyama et al., 2007; Eulalio et al., 2008; Eulalio et al., 
2009; Iwasaki et al., 2009). 
Alternatively, elongation could be inhibited if miRNA binding caused 
ribosomes to stop translocating. In mammalian cells, evidence for inhibition of 
translation initiation is supported by polysome gradient analysis that showed let-
7 binding or Ago2 protein tethered to the 3´ UTR of a target mRNA shifted the 
density of the target because fewer ribosomes bound to it than to a control target 
not bound by let-7 or tethered to Ago2 (Pillai et al., 2005).  In contrast, in C. 
elegans, no loss of ribosome density occurred for the lin-14 and lin-28 mRNAs 
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when bound by lin-4 miRNA, suggesting repression occurs post-initiation (Moss 
et al., 1997; Olsen and Ambros, 1999; Seggerson et al., 2002). Between the first 
and second larval stages there is a 10-fold change in LIN-14 protein, but by 
comparison of wild-type worms to the lin-4 miRNA mutant, lin-4 miRNA causes 
only a 4-fold change in LIN-14 protein, suggesting that the additional decrease in 
protein is caused by destabilization of lin-14 mRNA (Wightman et al., 1993; 
Bagga et al., 2005). A unified model in support of inhibition of translational 
elongation and resolving discrepancies between ribosome density on a target 
will be more difficult and may prove to be target or cell type specific. 
Adding to the uncertainty, insertion of a stem-loop structure in the 5´ UTR 
that prevented translation initiation still allowed de-adenylation and decay of 
target mRNA to occur upon miRNA binding to the 3´ UTR in mammalian cells, 
suggesting that miRNA binding can still cause target destabilization even in the 
absence of ongoing translation (Mishima et al., 2006; Wu et al., 2006; Eulalio et 
al., 2007; Wakiyama et al., 2007; Eulalio et al., 2009). Whether or not 
deadenylation is the direct result of miRNA binding to the 3´ UTR or a 
consequence of bound miRISC preventing circularization between 5´ cap and 
polyA tail is unclear because there is currently no system that allows one to 
understand the kinetics of miRNA-mediated translational repression. An 
explanation for the inconsistent results obtained from the various model systems 
is that the outcome of miRNA binding to a target may be specific to the cell type 
or that translation initiation of a target is initial response, followed by 
destabilization.  
Localization of silenced targets 
Repression of a target by an Argonaute protein may be influenced by 
 23  
other proteins recruited to an mRNA after miRISC binding. GW182 protein binds 
to Ago proteins through an Ago-hook motif and tethering of GW182 to a 3´ UTR 
of a target mRNA causes repression independent of a small RNA (Behm-
Ansmant et al., 2006; Till et al., 2007). Humans have three GW182 paralogs: 
TNRC6A, TNRC6B and TNRC6C (Eulalio et al., 2007). GW182 causes 
posttranscriptional regulation of a subset of mRNAs by localizing them to 
cytoplasmic foci called processing-bodies, or P-bodies (Liu et al., 2005b; Meister 
et al., 2005). GW182 is a component of P-bodies which are thought to be the 
cytoplasmic destination of silenced target mRNAs where the target is decapped 
and degraded, 5´ to 3 ´ by the exonuclease Xrn1 (Lim et al., 2005; Liu et al., 2005a; 
Pillai et al., 2005; Valencia-Sanchez et al., 2006). Although localization of miRISC- 
bound targets to P-bodies was an attractive hypothesis, in cell-free extracts 
targets are still silenced, arguing against localization to P-bodies as a requirement 
for silencing (Chu and Rana, 2006). In Drosophila, Ago1 requires GW182 for 
translational repression and ATP-dependent deadenylation, whereas Ago2 
represses translation independent of GW182 (Iwasaki et al., 2009).  
 Stress granules are cytoplasmic RNA granules that contain Ago2 as well as 
translation initiation factors. The presence of Ago2 in stress granules allows for 
the possibility that silenced targets are sequestered to stress granules and 
suggests that target mRNAs may be detained there while waiting to be 
reinitiated for translation (Parker and Sheth, 2007). Target mRNAs that are 
bound by Ago2 may be able to be reinitiated for translation, whereas targets 
bound by Ago1 may be destabilized through decapping and deadenylation in P-
bodies. Far from the original hypothesis that the extent of pairing between target 
and miRNA determines the mechanism for silencing, it may be that individual 
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Ago proteins and their ability to recruit other proteins may dictate the mode of 
target silencing (Iwasaki et al., 2009). A model where the identity of the 
Argonaute bound to a target effects different mechanisms of silencing may also 
be the reason that some targets are translationally repressed, while the majority 
of targets are destabilized.  
Cooperative function of miRNAs 
Cooperativity is used to describe the complex interactions between 
molecules during ligand binding and multimolecular complex assembly. A 
classical example of cooperativity is oxygen binding to hemoglobin, where the 
fourth and last oxygen binds more tightly than the first. Essential to 
cooperativity is that interactions between molecules are linked through 
structures.  Configurational cooperativity means that pre-organization of the first 
and second bound molecules increases the affinity for a third molecule (Whitty, 
2008). In a target mRNA with multiple binding sites for miRNAs, the effect can 
be to increase the dependence of the output, expression of protein, on the 
concentration of the miRNA, causing a sharper dose-response threshold for 
silencing.   
The potential for cooperative silencing by miRNAs was first considered 
when it was discovered that the 3´ UTR of lin-14 mRNA contained multiple 
target sites for lin-4 and soon after target sites for lin-4 and let-7 were identified in 
the 3´ UTR of lin-14 and lin-28 mRNAs (Lee et al., 1993; Wightman et al., 1993; 
Reinhart et al., 2000). The presence of multiple candidate sites in 3′ UTR 
sequences is a useful predictor of an mRNA being regulated by miRNA (Lewis et 
al., 2003). Sharp and Doench observed that an exogenous siRNA that paired with 
a central bulge to a reporter target with four sites in its 3´ UTR was able to cause 
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more repression than a reporter bearing two sites. In their system, there was an 
increase in repression that is typical of each target site contributing 
independently to repression, but the data suggested that there might be 
cooperativity in silencing by imperfectly pairing siRNAs. In their reporter 
system, an siRNA that paired perfectly to the target reporter mRNA showed no 
increase in repressive capacity when multiple sites existed in the target reporter, 
an expected result, because a perfectly pairing siRNA can cleave that target 
mRNA and need only cleave at one site to silence the reporter.  
The concept of cooperativity was further pursued to determine how near 
to each other target sites needed to be in order to cause cooperative effects. By 
altering the spacing between the seed-matched target sites for endogenous let-7 
in the 3´ UTR of a reporter mRNA, a minimum cooperative distance was 
determined to be between 13 and 35 nucleotides (Saetrom et al., 2007).  Another 
analysis of cooperativity in silencing between two sites for miR-124 or two 
miRNAs, miR-1 and miR-133, showed repression was not greater than the 
multiplicative effect of independent silencing until the distance separating the 
two target sites was between 8 and 40 nucleotides (Grimson et al., 2007). In this 
case, the repression observed for the two cooperative sites was more than the 
amount of repression predicted by multiplying, or the product of, the repression 
observed for each site acting alone in separate reporters. Though none of these 
analyses showed biochemical cooperativity, the potential remains for multiple 
co-expressed miRNAs to cooperatively regulate target mRNAs. In flies, the 
E(spl) and Bearded mRNAs contain multiple target sites within a cooperative 
distance of each other for miR-2 (two sites) and miR-4 (three sites), respectively 
(Lai et al., 2005). In worms, lin-14 (two lin-4 sites), lin-41 (two let-7 sites), lin-28 (a 
 26  
let-7 and a lin-4 site), hbl-1/lin-57 (four let-7 sites), and cog-1 (two lsy-6 sites) 
mRNAs are targets for miRNAs and contain multiple sites within a cooperative 
configuration (Wightman et al., 1991; Moss et al., 1997; Reinhart et al., 2000; 
Abrahante et al., 2003; Johnston and Hobert, 2003). The mammalian Hmga2 
mRNA contains seven sites for let-7 in its 3´ UTR, two of which are within 
cooperative distance of each other (Mayr et al., 2007). Cooperative miRNA 
function to repress target mRNAs would ensure that targets are sensitive to 
small changes in the levels of their cognate co-expressed miRNAs.  
Chapter II of this thesis provides an analysis of biochemical cooperativity 
in silencing of a target mRNA by four different siRNAs that pair to different 
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Figure 1.6: Hill coefficient measures the degree of cooperativity. 
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extents at multiple sites in the 3´ UTR of a luciferase reporter mRNA. The role of 
Argonaute proteins was assessed by using mouse embryonic fibroblast cells 
derived from Ago knockout mice. Cooperativity in silencing was determined by 
measuring luciferase activity as a function of siRNA concentration and fitting the 
data to the Hill equation. The Hill coefficient is a measure of cooperativity in a 
biological system. When a system exhibits cooperativity, ligand bound to a site in 
a macromolecule enhances binding of subsequent ligands to the macromolecule 
and the Hill coefficient quantifies this effect. It measures the fraction of a 
macromolecule saturated by bound ligands as a function of the ligand 
concentration (Hill, 1910; Holt and Ackers, 2009). In the reporter system, the 
mRNA target is the macromolecule and the siRNA-RISC is the ligand. A Hill 
coefficient greater than 1 indicates positive cooperativity while a value of 1 
indicates complete independence for binding (Figure 1.6).  
  Ago2 silenced a target mRNA without cooperativity when the siRNA 
paired with perfect complementarity to the mRNA target (Broderick et al., in 
press). Further, silencing by a perfect siRNA was non-cooperative even when 
Ago2 was unable to cleave the target: a catalytically inactive mutant Ago2 non-
cooperatively silenced a target mRNA bearing multiple target sites. This 
contradicts the assumption that silencing caused by a perfect siRNA:mRNA 
target pairing was non-cooperative because Ago2 can cleave the target mRNA. 
This suggests that the geometry of the perfect pairing between the guide RNA 
and the target prevent Ago2 protein from adopting a conformation that allows 
cooperative binding or interaction with other proteins, causing both nearby and 
adjacent binding sites to act independently. In the absence of Ago2, cooperative 
interactions by non-catalytic Agos bound through a perfect siRNA:target pairing 
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at multiple sites facilitated silencing. This suggests that Ago2 is sensitive to the 
geometry of a small RNA: target pairing. In contrast, the non-catalytic 
Argonautes, Ago1, Ago3, and Ago4, are capable of cooperative silencing 
irrespective of the geometry of the siRNA:target pairing. For silencing in 
mammalian cells, the geometry of the small RNA: target pairing and the identity 
of the Argonaute protein in RISC both determine whether or not cooperativity 
facilitates silencing of a target mRNA.  
The configuration of target sites contributes to the capacity for 
cooperativity. Argonaute proteins show a differential ability to facilitate 
cooperative silencing between target sites: target sites must be surprisingly near 
to each other to cause cooperative silencing by Ago1 (Broderick et al., in press). 
When three adjacent target sites were separated by 19 nt, cooperativity in 
silencing was lost, in the absence of Ago2. Ago1, Ago3 and Ago4 could not 
silence three sites separated by 19 nt with a perfect or a bulged pairing. Only 
Ago2 could silence the reporter with a perfect or a bulged pairing at non-
adjacent sites. For non-adjacent sites, only Ago2 can silence at the intracellular 
RISC concentration achieved at the highest amount of siRNA transfected, likely 
because in the absence of cooperativity, the intracellular concentration of Ago1-, 
Ago3-, and Ago4-RISC is less than the dissociation constant for target binding for 
these Argonaute:siRNA complexes. 
microRNA therapeutics 
miRNAs regulate one-third of genes in the human genome ( Bartel, 2009; 
Friedman et al., 2009). They have been implicated in pathways of disease like 
cancer, metabolic disease, viral infection, and immune disease. miRNAs provide 
the specificity determinants for Argonaute proteins to bind to and repress 
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expression of target mRNAs. Mutations occurring in miRNAs can lead to 
abnormal processing of a miRNA during biogenesis. Further, mutation of 
miRNA target sites within an mRNA can cause inappropriate regulation of a 
target mRNA. A specific instance of this situation is mutation in miR-96 of the 
nucleotide at position 5. Mutation at this position within the seed sequence 
decreases the level of expression of miR-96 and impairs target mRNA repression 
(Mencia et al., 2009). This single nucleotide mutation is associated with 
autosomal dominant, high-frequency, hearing loss in humans.  
 In addition to mutation of the sequence of miRNAs or their target sites, 
some miRNAs are deleted or their expression is reduced in some diseases. 
Chromosomal translocations that join two previously unlinked fragments of the 
genome together can cause inappropriate expression of a miRNA or target 
mRNA. In cancer, expression of most miRNAs is lower than normal due to 
deletions at 
breakpoints and 
fragile sites. miR-15 
and 16 are 
frequently deleted in 
B-cell lymphocytic 
cancer and  their 
expression is 
reduced by 80% in 
prostate cancer (Medina et al., 2008). Thus many miRNAs function similar to 
tumor suppressor genes. Replacement of miRNAs that have tumor suppressor 
function might augment traditional cancer chemotherapy. Expression of 
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Figure 1.7: Types of exogenous small RNAs for expression in cells. 
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exogenous small RNAs in cells is possible through transient or stable transfection 
or viral transduction of a pri-miRNA transgene, pre-miRNA, mature 
miRNA/miRNA*, small interfering RNA (siRNA) or short hairpin RNA (Figure 
1.7). Using this strategy, intratumoral injection of exogenous let-7 was found to 
block tumor development in a mouse model of non-small cell lung cancer 
(Johnson et al., 2007; Esquela-Kerscher et al., 2008; Kumar et al., 2008; Trang et 
al., 2010).  
miRNAs can restrict the expression of traditional gene therapy approaches 
that replace defective protein-coding genes, underlying many genetic diseases. 
Limiting the expression of a therapeutic transgene to the correct tissue is a 
challenge, even when using a tissue specific promoter to express the transgene, 
because transgene expression occurs in non-target tissues due to leaky promoter 
control. Combining miRNA regulation with gene therapy is a strategy to ‘de-
target’ expression of the transgene in non-target tissues.  
Incorporation of miRNA target sites in the 3´ UTR of transgenes provides 
a way to prevent the expression of the transgene in tissues that express the 
corresponding miRNA. For example, miR-122 is specifically expressed in 
hepatocytes and incorporation of miR-122 binding sites in the 3´ UTR of a 
systemically delivered transgene will prevent its expression in liver, but not 
other tissues. This strategy was used to restrict the expression of a transgene in a 
lentiviral vector to astroglial cells (Colin et al., 2009). Starting with a lentivirus 
engineered to preferentially infect neurons and glia, miR-124 target sites were 
inserted in the 3´ UTR to prevent transgene expression in neuronal cells, which 
express miR-124, and allow transgene expression in glial cells, which do not 
express miR-124. Injection of the vector into the hippocampus in mice produced 
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transgene expression in astrocytes and Bergmann glial cells, but not in pyramidal 
neurons or Purkinje cells. Since each site is only 21 nt long, binding sites for 
multiple, tissue-specific miRNAs can be incorporated in the 3´ UTR, 
extinguishing transgene expression in many different tissues simultaneously. 
Silencing an mRNA by tethering RISC   Many human diseases are caused by genes being expressed, when they 
should not be. Other diseases are produced by mutant genes that produce a 
defective protein product. For example, patients suffering from the devastating 
inherited neurodegenerative disorder, Huntington’s disease, have both a normal 
copy of the huntingtin gene and a mutant, disease-causing copy. Turning off the 
disease gene, while retaining expression of the normal gene, would almost 
certainly cure the disease. Similarly, when viruses such as HIV infect human 
cells, they turn on their own genes to assist the spread of infection. Turning off 
invading viral genes—such as the HIV protease gene—would likely stop the 
viral infection. With few exceptions, current drugs are designed to block the 
action of protein products, not turn off the genes that direct production of the 
protein. Thus, HIV infection is treated with protease inhibitors, small molecule 
drugs that block HIV protease function, rather than blocking production of the 
HIV protease protein in the first place, because no strategy for turning off disease 
genes has been demonstrated to be clinically safe and effective. Toward that end, 
the goal is to develop novel nucleic acid reagents that turn off a gene in a specific 
tissue or cell type affected by disease or infection. 
The RNAi pathway is the best-known example of a larger set of cellular 
pathways known as RNA silencing pathways (reviewed in Ghildiyal and 
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Zamore, 2009). The small RNAs that trigger RNAi are called small interfering 
RNAs.  Since its discovery in 1998 (Fire et al., 1998), RNAi has emerged as the 
dominant method for blocking gene function in human cells. Although siRNAs 
hold great promise as human therapeutics and have rapidly become the standard 
method for target validation in cultured cells, siRNA technology is limited by 
our inability to deliver siRNAs only to a specific tissue or cell type and by the 
undesirable and unpredictable ability of siRNAs to turn off genes beyond those 
they were designed to target (Jackson et al., 2003). 
miRNAs are a second class of small RNAs that turn genes off in animals 
and plants (Bartel, 2004). When these natural small RNAs bind to an mRNA, they 
block it from being translated into protein. The human genome contains more 
than 500 and perhaps as many as 1000 miRNAs, many of which are expressed 
only in specific cell types or tissues or during specific stages of vertebrate 
development (Landgraf et al., 2007). As much as one-third of all human genes 
have been proposed to be intrinsically regulated by miRNAs (Bartel, 2009; 
Friedman et al., 2009). Moreover, many viruses produce their own miRNAs; 
these are not normally made by the host cells, so they provide a new opportunity 
to identify infected cells (Cullen, 2009). 
During my thesis research, I developed a novel strategy that recruits an 
endogenous miRNA to an mRNA not normally regulated by that miRNA, 
thereby blocking the mRNA from being translated into protein. Recruiting the 
miRNA to the mRNA effectively turns that gene off. The strategy uses 
oligonucleotide ‘tethers’ to recruit endogenous miRNAs to novel mRNA targets, 
turning off their expression (Figure 1.8). Each tether contains a region that binds 
the mRNA target and a region that binds the miRNA to be recruited, thereby 
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bringing the two together. This method is designed to harness the spatial and 
temporal specificity of miRNAs, so that the tethers trigger target mRNA 
repression only in cells where a specific miRNA species is expressed. This 
method can also be used to block viral gene expression in infected cells, which, 
unlike uninfected cells, will express viral miRNAs. Proof-of concept and 
preliminary experimental data are discussed on Chapter III. 
Figure 1.8: A modified RNA oligonucleotide (blue) binds an endogenous miRNA (red) and tethers RISC 
to the 3´ UTR of an mRNA. 
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Chapter II: Argonaute protein identity and pairing geometry determine 
cooperativity in mammalian RNA silencing. 
 
Chapter II was a collaborative effort. Experimental plan and experiments were 
the author’s own except for Supplemental Figure 2.S2, added in revision, which 
was a joint effort by the author and William E. Salomon. 
Sean P. Ryder contributed intellectually to the mode of data analysis and 
interpretation and made this work far better than its original inception. His 
intellect was critical to the review process.
The manuscript was written by the author and edited by Phillip D. Zamore. 
This chapter is in press at RNA Journal. 
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Abstract 
Small RNAs loaded into Argonaute proteins direct silencing of complementary 
target mRNAs. It has been proposed that multiple, imperfectly complementary 
small interfering RNAs or microRNAs, when bound to the 3′ untranslated region 
of a target mRNA, function cooperatively to silence target expression. We report 
that in cultured human HeLa cells and mouse embryonic fibroblasts, Argonaute1 
(Ago1), Ago3 and Ago4 act cooperatively to silence both perfectly and partially 
complementary target RNAs bearing multiple small RNA-binding sites. Our data 
suggest that for Ago1, Ago3, and Ago4, multiple, adjacent small RNA-binding 
sites facilitate cooperative interactions that stabilize Argonaute binding. In 
contrast, small RNAs bound to Ago2 and pairing perfectly to an mRNA target 
act independently to silence expression. Non-cooperative silencing by Ago2 does 
not require the endoribonuclease activity of the protein: a mutant Ago2 that 
cannot cleave its mRNA target also silences non-cooperatively. We propose that 
Ago2 binds its targets by a mechanism fundamentally distinct from that used by 
the three other mammalian Argonaute proteins. 
Keywords: Argonaute; cooperativity; microRNA; miRNA; RNAi; siRNA; RNA 
silencing 
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Introduction 
In plants and animals, small silencing RNAs such as small interfering RNAs 
(siRNAs) and microRNAs (miRNAs) provide the specificity determinants for 
Argonaute proteins. A small RNA guide bound to an Argonaute protein is called 
the RNA-induced silencing complex (RISC) (Hammond et al., 2000; Hannon, 
2002; Du and Zamore, 2007; Matranga and Zamore, 2007; Ghildiyal and Zamore, 
2009); binding of RISC to the 3′ untranslated region (UTR) of an mRNA silences 
its expression (Lee et al., 1993; Wightman et al., 1993; Olsen and Ambros, 1999; 
Lai, 2002; Doench et al., 2003; Grimson et al., 2007). Argonaute proteins are 
structural homologs of RNase H that typically cleave their target RNAs after the 
nucleotide paired to the tenth base of the small RNA guide (Elbashir et al., 2001a; 
Elbashir et al., 2001b; Tolia and Joshua-Tor, 2007). Cleavage requires three key 
amino acids—D, D, H—that form a magnesium-binding catalytic triad, which 
promotes nucleophilic attack by hydroxide on the phosphodiester bond (Kanaya 
et al., 1996; Haruki et al., 2000; Martinez and Tuschl, 2004; Schwarz et al., 2004; 
Song et al., 2004; Rivas et al., 2005). 
The human genome encodes four Argonaute paralogs—Ago1, Ago2, 
Ago3, and Ago4, and most cultured mammalian cell lines express all four 
proteins, albeit in different proportions (Meister et al., 2004). Of the four 
mammalian Argonautes, only Ago2 retains the ability to catalyze site-specific, 
small RNA-directed endonucleolytic target cleavage (Liu et al., 2004; Meister et 
al., 2004). Like Ago2, Ago3 contains an apparent catalytic triad, but unlike Ago2, 
it lacks endoribonuclease activity. For Ago1 and Ago4 there is no catalytic triad, 
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explaining their lack of endoribonuclease activity (Meister et al., 2004; Rivas et 
al., 2005; Azuma-Mukai et al., 2008). Extensive, but not complete, 
complementarity between a small RNA guide and an mRNA is required for 
Argonaute-catalyzed target cleavage (Hutvágner and Zamore, 2002; Schwarz et 
al., 2002; Haley and Zamore, 2004; Liu et al., 2004; Meister et al., 2004; Rivas et al., 
2005). In contrast, small RNAs with only partial complementarity to their target 
mRNAs, especially those bearing mismatches near the cleavage site, cannot 
direct endonucleolytic cleavage of their target (Holen et al., 2002), but instead 
reduce the stability of the target mRNA (Guo et al.) and, in some conditions, 
cause translational repression (Doench et al., 2003; Doench and Sharp, 2004). 
Experimental and computational analyses suggest that a single miRNA 
can regulate hundreds of genes, because a target mRNA need only pair with the 
seed sequence of a small RNA—comprising nucleotides 2 through 7 or 8—to 
recruit RISC and promote repression (Lewis et al., 2003; Doench and Sharp, 2004; 
Rajewsky and Socci, 2004; Brennecke et al., 2005; Krek et al., 2005; Lewis et al., 
2005; Lim et al., 2005; Grimson et al., 2007; Baek et al., 2008; Selbach et al., 2008; 
Friedman et al., 2009). Multiple, partially complementary small RNAs, when 
bound to the 3′ UTR of a luciferase reporter target mRNA, may function 
cooperatively to repress its translation (Doench et al., 2003; Bartel and Chen, 
2004), and most mRNAs contain multiple potential miRNA-binding sites in their 
3′ UTRs (Lee et al., 1993; Wightman et al., 1993; Reinhart et al., 2000; Abrahante et 
al., 2003; Lin et al., 2003; Bartel, 2004; Grimson et al., 2007; Friedman et al., 2009). 
However, the molecular basis for cooperativity in small RNA silencing remains 
unknown. 
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Here, we show that both the nature of siRNA:mRNA target pairing and 
the identity of the Argonaute protein to which the small RNA is bound 
determine whether multiple target sites act cooperatively to recruit RISC. Small 
RNAs that pair perfectly to multiple target sites silenced non-cooperatively when 
the small RNA guide acts through Ago2, whereas silencing directed by either 
perfectly or imperfectly pairing small RNAs bound to Ago1, Ago3, or Ago4 acted 
cooperatively to silence mRNA bearing multiple small-RNA-binding sites. 
Cooperativity required adjacent sites. Surprisingly, non-cooperative silencing by 
perfectly pairing small RNAs bound to Ago2 did not require target cleavage, as 
catalytically inactive mutant Ago2 silenced essentially as well as wild-type. 
Finally, we find that computationally predicted modes of miRNA:target pairing 
required far more small RNA to achieve repression than more extensively but 
still incompletely paired small RNA guides. We propose that cooperative 
binding of RISC to multiple adjacent sites, combined with high intracellular 
concentrations of miRNAs, allows robust regulation of mRNA targets by Ago1, 
Ago3, and Ago4. 
Results 
Experimental paradigm 
At least three distinct regulatory mechanisms could explain the enhanced 
silencing of reporter mRNAs containing multiple miRNA-binding sites (Fig. 2.1). 
A cooperative binding model posits that the binding of a miRNA:Argonaute 
protein complex to one site increases the affinity of a second miRNA:Argonaute 
complex for an adjacent site (Fig. 2.1A). In this model, the binding of the first 
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bulged siRNA would have a higher dissociation constant, KDA than subsequent 
binding events, KDB and KDC; we predict that the amount of siRNA required to 
silence a reporter would decrease with an increasing number of target sites as 
cooperativity between bound Argonautes increases. Such cooperativity in small 
RNA-directed silencing might arise from direct interactions between adjacent 
Argonaute proteins. Alternatively, a pair of Argonaute proteins might be 
bridged by one or more additional proteins. In a cooperative function model, 
multiple miRNA:Argonaute complexes bind to the target mRNA independently, 
but the interaction of one miRNA:Argonaute complex could recruit binding 
proteins which block translation of the target mRNA or decrease the stability of 
the target (Fig. 2.1B). Historically, such protein targets of RISC have been 
envisioned to include components or regulators of the ribosome, but more likely 
correspond to factors that promote accumulation of the target RNA in a P-body, 
where it would be degraded (Guo et al.; Liu et al., 2005; Rehwinkel et al., 2005; 
Eulalio et al., 2007; Parker and Sheth, 2007). In the cooperative function model, we 
predict that the presence of three bulged siRNAs on the target would have a 
lower inhibitory constant, KiABC than for the presence of two (KiAB) or one (KiA) 
bulged siRNA; the amount of siRNA required to silence a reporter would 
decrease with increasing number of target sites occupied by Argonautes and/or 
a protein factor X until the concentration of Argonaute or factor X becomes 
limiting. Finally, in a multiple independent sites model, each miRNA:Argonaute 
complex binds and acts independently, but the presence of multiple miRNA-
binding sites in the target increases its effective miRNA occupancy: i.e., the 
probability that the target mRNA is bound by at least one miRNA is increased by 
the presence of multiple sites (Fig. 2.1C). Such statistical effects cause the 
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macroscopic binding constant, K, representative of all possible combinations of 
target mRNA with n sites where at least one site is occupied, would be 
determined by the statistical factors of identical microscopic binding constants, k, 
to give a fractional saturation of target: [1/n]k (Cantor and Schimmel, 1980). If we 
assume that the IC50 is governed by binding and that the microscopic binding 
constant for a single site is essentially identical to the macroscopic binding 
constant for the one-site target, then we expect the IC50 for the three-site target to 
be 1/3(IC50, one-site target). 
In contrast to the cooperativity ascribed to miRNA-directed changes in 
mRNA stability or translation, small RNA-guided target cleavage—that is, 
RNAi—is thought to be non-cooperative, with each RISC acting independently at 
each complementary site on the target mRNA. The presence of multiple, 
independent small RNA-binding sites in a target would increase its effective 
occupancy by RISC: the probability that the target mRNA is cleaved by at least 
one molecule of RISC is increased by the presence of multiple sites. 
To evaluate the efficacy of silencing and the extent of cooperativity 
directed by a small silencing RNA bound at one or multiple sites on an mRNA, 
we established an experimental system comprising six Renilla luciferase reporter 
plasmids, each expressing an mRNA bearing one to six identical, adjacent target 
sites in its 3′ UTR (Fig. 2.2, left). We tested four siRNAs whose guide strands pair 
to different extents with the target sites (Fig. 2.2, top). The four siRNAs enabled 
evaluation of four siRNA:mRNA target RNA binding modes— perfect pairing, 
bulged pairing (mismatched at positions 9 and 10 of the guide strand), seed 
pairing with supplemental 3′ pairing (matching the target at positions 2–8 and 
13–16 of the guide strand), and seed-only pairing (paired only at positions 2–8 of 
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the guide strand). Each siRNA duplex was designed to ensure preferential 
loading of its guide strand into RISC (Schwarz et al., 2003). Because all of our 
experiments comparing distinct modes of miRNA:target pairing employed a 
common target reporter mRNA, our strategy avoids differences in local target 
mRNA structure that might confound interpretation. 
For each of the 24 reporter-siRNA combinations tested in HeLa cells, we 
calculated the concentration of siRNA required to achieve half-maximal silencing 
(IC50) and the Hill coefficient (nH), a measure of cooperativity, using dose-
response data from at least 12 independent experiments, each evaluating 
silencing at ≥10 siRNA concentrations and spanning a 2,000-fold concentration 
range. For each siRNA, we confirmed that the siRNA was inherently active by 
validating its ability to silence a Renilla luciferase reporter containing a single, 
fully complementary siRNA-binding site (Fig. 2.3). For the four siRNAs, the 
mean IC50 values ± standard deviation for the corresponding perfect, single-site 
reporter mRNA ranged from 0.27 ± 0.22 nM to 1.33 ± 0.78 nM, establishing that 
all four siRNAs were active. 
Silencing by perfect pairing at multiple sites is not cooperative 
Next, we targeted each reporter for silencing by a perfect siRNA to determine if 
increasing the number of target sites reduced the amount of siRNA needed to 
silence the reporter. Based on the multiple independent sites model, we anticipated 
that a reporter mRNA bearing more target sites would be more likely to recruit 
RISC and would therefore show a reduced IC50 for a fully complementary 
(“perfect”) siRNA. Instead, our data suggest that RISC neither binds nor 
functions appreciably better when the target contained multiple sites (Fig. 2.2). In 
fact, reporter mRNAs bearing three (IC50 = 0.75 ± 0.93 nM), four (IC50 = 0.25 ± 0.09 
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nM), five (IC50 = 0.41 ± 0.33 nM) or six (IC50 = 0.30 ± 0.14 nM) perfect sites had 
essentially indistinguishable IC50 values and were silenced only slightly better 
than a reporter bearing a single perfect site (IC50 = 0.63 ± 0.25 nM). None of the 
six reporters displayed positive cooperativity with the perfectly matched siRNA, 
with the Hill coefficients ranging from nH = 0.8 ± 0.2 (six-site reporter) to 1.2 ± 0.2 
(four-site reporter). None of the Hill coefficients were significantly different from 
nH = 1 (p-value > 0.05; Supplemental Fig. 2.S1). Moreover, when the same perfect 
siRNA was used to silence a reporter bearing three sites separated by 19 nt, the 
IC50 and the Hill coefficient were similar to the mRNA reporter with a single site 
(IC50 = 0.37 ± 0.39 nM, nH = 1.0 ± 0.2, Fig. 2.4). 
In general, silencing by the perfect siRNA was well described by a 
sigmoidal curve with a Hill coefficient of one, irrespective of the number of sites 
(Fig. 2.2, left). We conclude that, when guided by a perfectly pairing siRNA, each 
RISC acts independently from other RISCs that bind to nearby target sites. 
Multiple, bulged sites act cooperatively 
Central internal loops—or “bulges”—typically block siRNA- or miRNA-directed 
target cleavage, the most potent post-transcriptional silencing mechanism (Holen 
et al., 2002; Du et al., 2005; Dahlgren et al., 2008; Huang et al., 2009). Consistent 
with that view, effective silencing by a small RNA that forms a central bulge 
when paired to its target site required a higher concentration of siRNA than did 
the corresponding perfect siRNA, even when comparing multiple bulged sites to 
a single perfect site (Table 2.1 and Fig. 2.2). In fact, we were unable to achieve 
half-maximal silencing of a Renilla luciferase reporter bearing one or two bulged 
sites even at 20 nM transfected siRNA. For a reporter bearing six bulged sites, the 
IC50 was nearly three times greater than that for perfect sites. Unlike silencing 
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mediated by perfect sites, silencing via bulged sites showed positive 
cooperativity, with a Hill coefficient of 2.5 ± 0.8 (p = <0.0001 for six sites; Table 
2.1). 
Seed matches and supportive pairing 
Although bulged sites have been shown to effectively silence both reporter 
mRNAs and endogenous genes (Zeng et al., 2002; Doench et al., 2003; Doench et 
al., 2003), they rarely occur for natural miRNAs and their endogenous targets 
(Lewis et al., 2003; Vella et al., 2004; Yekta et al., 2004; Brennecke et al., 2005; 
Lewis et al., 2005; Grimson et al., 2007). Instead, miRNAs generally pair with the 
mRNAs they regulate at positions 2–8 of the guide strand, the seed sequence 
(Lewis et al., 2003; Brennecke et al., 2005; Krek et al., 2005; Lewis et al., 2005). 
Additional base pairs between the mRNA and miRNA positions 13–16 (Grimson 
et al., 2007) and target adenosines flanking the seed match sequence at position 1 
(t1A) and 9 (t9A) (Lewis et al., 2005) enhance the likelihood that a miRNA will 
regulate a putative mRNA target. 
We tested seed-matched (t1A) sites with supplemental 3′ pairing and seed 
only (t1A) sites for their ability to regulate reporter mRNA bearing one to six 
siRNA-binding sites. A seed match plus supplemental 3′ pairing required far 
more siRNA to achieve silencing equivalent to the bulged sites (Fig. 2.2). For 
example, the bulged siRNA regulated the three-site reporter with an IC50 = 1.9 ± 
0.5 nM, whereas half-maximal silencing for the same reporter with the siRNA 
pairing with both the seed and supplemental 3′ nucleotides could not be 
achieved even using 20 nM siRNA. With six sites in the reporter, the siRNA with 
seed plus supplemental 3′ pairing achieved an IC50 = 3.7 ± 1.4 nM. The seed 
siRNA was even less potent, reaching half-maximal silencing at an siRNA 
 45  
concentration of 10 ± 2.4 nM only for the reporter mRNA with six sites; the IC50 
could not be reliably determined for mRNAs with fewer than six sites. Our data 
suggest that the intracellular concentration of functional miRISC exceeds the 
RISC concentration we achieved using transfected, synthetic siRNA duplexes. 
Most studies of small RNA-directed silencing report the extent of 
repression (“fold-repression”) for a single concentration of small RNA. To permit 
comparison of our data to those in the published literature, we used our data to 
calculate the observed “fold repression” of the multiple-site reporters by the 
seed-only siRNA (Supplementary Table 2.S1). Like Grimson et al. (2007) before 
us, we observe a ≥ 1.4-fold repression of targets bearing two or more small RNA-
binding sites when using the seed-only siRNA. For three or more sites, the 
observed repression, which ranged from 1.8- to 4.8-fold, was significantly 
different from that predicted by a multiple, independent sites model (0.002 ≤ p ≤ 
0.04; Supplementary Table 2.S1). 
Cooperativity requires adjacent target sites 
Silencing for bulged sites displayed positive cooperativity for all multiple-site 
reporter mRNAs for which we could measure the IC50 and Hill coefficient. To test 
if the sites need to be adjacent in order to observe positive cooperativity, we 
altered the sequence of every other target site in the six-site Renilla luciferase 
mRNA to create a three-site reporter in which 19 nucleotides separate each site 
targeted by the siRNAs (Fig. 2.4A). Silencing of this expanded three-site reporter 
mRNA by the bulged siRNA required >15-fold more siRNA and showed no 
evidence of cooperativity (IC50 ≥ 20 nM; nH = 0.8 ± 0.1; Fig. 2.4A) relative to the 
reporter mRNA in which the three sites were adjacent (IC50 = 1.3 ± 0.8 nM; nH = 
1.6 ± 0.4; Fig. 2.4B). 
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In theory, these data might reflect reduced target-site accessibility in the 
expanded three-site reporter (Brown et al., 2005; Ameres et al., 2007; Tafer et al., 
2008). We view this as unlikely. First, both the adjacent and expanded three-site 
reporters were silenced equally well by a perfectly pairing siRNA (IC50 = 0.37 ± 
0.39 nM versus 0.22 ± 0.15 nM; Fig. 2.4C,D). Second, antisense oligonucleotide-
directed RNase H cleavage at each of the target sites occurred with similar rates 
(6.1, 6.0 and 6.6 nM  min-1 for sites 1, 2 and 3 respectively) (Supplemental Fig. 
2.S2). Finally, the RNase H cleavage kinetics fit better to a model of independent 
action compared to a dependent, sequential model for cleavage at each site 
(Supplemental Fig. 2.S2). 
Silencing by the perfectly paired siRNA was non-cooperative for both the 
expanded (nH = 1.0 ± 0.2) and original (nH = 1.1 ± 0.1) three-site reporter mRNAs 
(Fig. 2.4C,D). The observation that cooperative silencing by a small RNA requires 
that fewer than 19 nt separate the RISC-binding sites to promote efficient, 
cooperative silencing suggests that cooperativity springs from interactions 
between adjacent Argonaute-siRNA complexes, rather than cooperative 
recruitment of proteins involved in subsequent steps in repressing mRNA 
expression. 
Ago2-RISC binding prevents cooperative silencing 
A simple explanation for why Ago2 acts non-cooperatively to silence a multiple-
site reporter with a perfect guide is that silencing reflects the endonucleolytic 
activity unique to mammalian Ago2. To test this idea, we evaluated silencing of 
the six-site reporter mRNA in three mouse embryonic fibroblast (MEF) cell lines 
derived from an Ago2 knockout mouse: Ago2–/– MEFs, Ago2–/– MEFs 
reconstituted with mouse Ago2, and Ago2–/– MEFs reconstituted with a mutant 
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mouse Ago2 in which aspartic acid 669 was changed to alanine (D669A) 
(O'Carroll et al., 2007). The D669A mutant Ago2 cannot cleave an RNA target 
(Liu et al., 2004). In Ago2–/– MEF cells, the perfect siRNA and the bulged siRNA 
were both cooperative: nHperfect = 1.6 ± 0.4, p =0.03, and nHbulged = 1.8 ± 0.3, p =0.006 
(Fig. 2.5A). These data suggest that Ago1, Ago3 and Ago4 bind cooperatively to a 
reporter mRNA bearing multiple small RNA-binding sites, irrespective of the 
nature of small RNA:target pairing. 
As expected, repression mediated by a perfectly pairing siRNA was non-
cooperative (nHperfect = 1.0 ± 0.1) in Ago2–/– MEFs reconstituted with over-expressed 
Ago2 (Fig. 2.5B, Fig. 2.6). In contrast, silencing directed by the bulged siRNA in 
the Ago2-reconstituted cells was cooperative (nHbulged = 1.5 ± 0.2, p =0.02; Fig. 2.5B). 
To test whether the apparent cooperativity observed in reconstituted Ago2 MEF 
cells was caused by Ago2 over-expression, we measured silencing in Ago1–/– 
MEF cells, which express far less Ago2 mRNA and protein than reconstituted 
Ago2–/– MEF cells (Fig. 5D, Fig. 6, Supplemental Table 2.S2). (All four Argonautes 
are expressed in the HeLa line we used [Supplemental Fig. 2.S3].) We detected no 
cooperativity for silencing by the perfect siRNA in the Ago1–/– MEFs (nHperfect = 1.1 
± 0.1). However, silencing by the bulged siRNA was cooperative (nHbulged = 1.7 ± 
0.2, p =0.003), suggesting that Ago2 is capable of cooperative silencing (Fig. 
2.5D). 
To test whether Ago3 or Ago4 contributes to the cooperativity that we 
observed for a bulged siRNA in the Ago1–/– MEFs, we used siRNAs to deplete 
Ago3 and Ago4 mRNAs before transfecting the reporter plasmids and bulged 
siRNA. Ago4 mRNA was reduced 50% compared to Ago1–/– MEF cells 
transfected with a control siRNA. By qRT-PCR, we detected Ago3 mRNA two 
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threshold cycles after detection of Ago1 mRNA in the Ago1–/– MEF cells, 
indicating that its expression is probably functionally inconsequential in our 
analysis (data not shown). The level of Ago3 protein in Ago1–/– MEFs was very 
low and our attempts to reduce it further by RNAi were unsuccessful 
(Supplemental Fig. 2.S4A). Under these conditions, nH for silencing by the bulged 
siRNA was not significantly different from the null hypothesis (non-cooperative 
binding), although the Hill coefficients for the bulged and perfect siRNAs were 
significantly different (nHbulged = 1.8 ± 0.5 versus nHperfect =1.0 ± 0.1, p = 0.03; 
Supplemental Fig. 2.S4B). 
As a final test of the idea that non-cooperative silencing reflects target 
cleavage, we analyzed silencing directed by a perfectly pairing siRNA in Ago2–/– 
MEFs reconstituted with D669A mutant Ago2. In the cells reconstituted with 
catalytically inactive Ago2, the single-site reporter was not silenced by the 
perfect siRNA (Supplemental Fig. 2.S5). Surprisingly, cells reconstituted with 
catalytically inactive Ago2 exhibited non-cooperative silencing of the six-site 
reporter by a perfect siRNA (nHperfect =1.1 ± 0.1), while silencing by a bulged siRNA 
displayed positive cooperativity (nHbulged =1.5 ± 0.3, p =0.04) (Fig. 2.5C). This 
unexpected result suggests that target cleavage per se is not required for non-
cooperative silencing mediated by Ago2. Rather, both the identity of the 
Argonaute protein and the nature of pairing between the small RNA and its 
target determine if RISC bound to multiple sites in the 3′ UTR of an mRNA can 
collaborate to generate cooperativity in silencing. 
Only Ago2-RISC can repress a reporter with non-adjacent sites 
In HeLa cells, the mRNA with the expanded target sites (Fig. 2.4A) was less 
efficiently silenced by a bulged siRNA than an mRNA in which the three sites 
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were adjacent (Fig. 2.4B). We propose that RISCs bound to adjacent sites 
collaborate to achieve efficient silencing. Is Ago2 required to silence an mRNA in 
which the small RNA binding sites cannot collaborate? We tested silencing of the 
expanded three-site reporter mRNA by the perfect and bulged siRNAs in the 
Ago2–/– MEFs. Silencing of the expanded three-site reporter was completely 
dependent on Ago2: little or no silencing was observed in the Ago2–/– MEFs for 
either type of small RNA:target pairing (Fig. 2.7C,D). In contrast, both perfect 
and bulged siRNAs cooperatively silenced the reporter bearing three adjacent 
small RNA-binding sites in the Ago2–/– MEFs (Fig. 2.7A,B). Notably, in the 
absence of Ago2, silencing by the perfect siRNA of the reporter containing three 
adjacent sites was highly cooperative (nHperfect = 2.1 ± 0.3, p =0.007). We conclude 
that for widely spaced sites, only Ago2 can silence at the intracellular RISC 
concentration achieved at the highest amount of siRNA transfected, likely 
because in the absence of cooperativity, the intracellular concentration of Ago1-, 
Ago3-, and Ago4-RISC is less than the KD for target binding for these 
Argonaute:siRNA complexes. 
Reconstituting the Ago2–/– MEFs with either wild-type or catalytically 
inactive mouse Ago2 rescued silencing of the expanded three-site reporter (Fig. 
2.7E–J). Silencing showed no significant cooperativity for the perfect siRNA in 
MEFs reconstituted with wild-type (nHperfect = 1.1 ± 0.1) or catalytically inactive 
Ago2 (nHperfect = 1.2 ± 0.2). Silencing by the bulged siRNA was cooperative for both 
the wild-type Ago2-reconstituted (nHbulged = 1.6 ± 0.1, p =0.02; Fig. 2.7F), and the 
catalytically inactive Ago2 MEFs (nHbulged = 1.3 ± 0.2, p =0.03; Fig. 2.7H). 
Intriguingly, in the absence of Ago1, silencing of the expanded three-site reporter 
by the bulged siRNA was highly cooperative (nHbulged = 2.5 ± 0.2, p =0.006; Fig. 2.7J). 
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Discussion 
In our assays, Ago2 non-cooperatively silenced mRNAs bearing multiple, 
perfectly complementary small RNA-binding sites, even when its 
endoribonuclease activity was inactivated by mutation. This finding is 
surprising, because we and others have assumed that endonucleolytic cleavage 
by Ago2 explained its lack of cooperativity in silencing when guided by a 
perfectly pairing siRNA. Clearly, a more complex explanation is warranted. We 
suggest that the Ago2 conformation associated with perfect small RNA:target 
pairing precludes protein:protein interactions, causing both nearby and adjacent 
binding sites to act independently. Alternatively, Ago2 protein, when guided by 
a small RNA that pairs extensively with its target mRNA might be bound by 
proteins that prevent its association with factors promoting cooperativity. 
Silencing via multiple small RNA-binding sites is likely always 
cooperative for Ago1, Ago3 or Ago4, irrespective of the type of pairing between 
the small RNA and its target. We suggest that these non-catalytic Argonaute 
proteins adopt a single conformation when bound by different modes to their 
mRNA targets or that the conformations produced by both perfect and bulged 
small RNAs are compatible with protein:protein interactions between adjacent 
RISC molecules. Intrinsic differences between Ago2 and Ago1, Ago3, and Ago4 
may dictate the combination of Ago proteins capable of cooperative silencing. 
 
Cooperativity versus statistical effects for closely apposed target sites 
We find that multiple, imperfect binding sites need to be surprisingly close in 
order to mediate cooperative silencing. Our data fundamentally agree with 
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previous reports, but differ quantitatively in the precise inter-site distance that 
supports cooperativity (Grimson et al., 2007; Bartel, 2009). We note that the 
precise inter-site distance that supports cooperative interactions may reflect the 
intracellular concentrations of Argonaute proteins and associated factors, as well 
as the local structure or sequence of the mRNA target. When testing silencing of 
a two-site reporter, Grimson et al. observed that a seed-matched siRNA 
transfected at 25 nM cooperatively silenced a reporter bearing two 3′ UTR target 
sites spaced 8–40 nt apart (counting the number of nucleotides between the 3′ 
end of the first site and the 5′ end of the second site); expanding the distance to 
56 nt disrupted cooperative silencing (Grimson et al., 2007). We note that these 
authors defined cooperativity as an excess of silencing when the observed 
repression for a two-site reporter was compared to the product of the repression 
observed for each site acting alone. Enhanced silencing measured in this way 
may correspond to true cooperativity or may simply reflect the statistical effects∗ 
of multiple independent sites. Our Hill analyses distinguish between these two 
possibilities and suggest that RISCs bound to adjacent sites cooperate to confer 
greater silencing than would be expected from statistical effects alone. 
 
                                                
∗Statistical effects result from the simultaneous occupancy of multiple, independent binding sites 
of similar affinities even in the absence of cooperativity (Cantor and Schimmel, 1980). This effect, 
with increasing site occupancy causes a steep threshold response that appears non-additive. In 
contrast, cooperativity results in the concerted loading of sites at a lower overall concentration of 
ligand (e.g., miRISC) and a sharp dose-response to a relatively small increase in ligand 
concentration. 
 52  
Supplemental 3′  pairing reduces the amount of small RNA required to repress an 
mRNA 
The amount of siRNA required to repress an mRNA target is determined by the 
number of small RNA-binding sites, the spacing of the sites, and the extent of 
complementarity beyond the seed sequence at each site. Compared to an mRNA 
in which the siRNA seed sequence alone paired with the small RNA-binding 
sites, an mRNA in which seed-pairing was supplemented with additional 3′ base 
pairs required slightly less siRNA to achieve comparable repression, particularly 
for multi-site target RNAs (Table 2.1, Fig. 2.2). These data reinforce the view that 
has emerged from previous computational analyses of miRNA target binding: 3′ 
supplemental pairing provides a small but measurable increase in the affinity of 
a small RNA for its target (Grimson et al., 2007). 
Nonetheless, it is striking how much more siRNA is needed to regulate a 
target containing small RNA-binding sites with a seed-match only or a seed-
match plus supplementary pairing, compared to a target containing sites that 
fully pair to the small RNA but for a central bulge. While our current data do not 
permit direct estimation of the binding affinity of a small RNAs for a reporter 
mRNA within a cell, they suggest that one explanation for the remarkably high 
intracellular abundance of some miRNAs is that most miRNAs bind weakly to 
the mRNAs they regulate. 
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Materials and Methods 
Plasmids 
Renilla luciferase vector pRL-TK (Promega, Madison, WI, USA) containing target 
sites for CXCR4 and a modified linker sequence (Doench et al., 2003) was 
mutated from TAG to CTC (lower case letters in the oligonucleotides) at 
nucleotides 387–389 of the Renilla luciferase open reading frame to generate 
mismatches with seed positions 5, 6, and 7 of the siRNA guide strand by PCR-
directed mutagenesis using DNA oligonucleotides: 5′-CTT GTT TGG CAT TTC 
ATT ACt ccT ATG AGC ATC AAG ATA AGA TC-3′ (sense), 5′-GAT CTT ATC 
TTG ATG CTC ATA Gga gTA ATG AAA TGC CAA ACA AG-3′ (antisense). 
Mutagenesis was confirmed by sequencing, and then 5′ phosphorylated oligos 
containing the target sites and pairing to create appropriate ends were cloned 
into the XbaI and ApeI sites of the mutant pRL-TK. Supplemental Table S3 lists 
the sequences of the DNA oligonucleotides used to construct target sites. 
psiCheck2 (Promega) reporters were constructed by digesting psiCheck2 with 
NheI and NotI and inserting the 3′ UTR target site-containing NheI–NotI fragment 
from the mutant pRL-TK vectors. Table 2 lists the oligonucleotide sequences 
used to generate plasmid reporters. Dual Reporter Luciferase assays were 
conducted using Dual Luciferase Assay Reagents (Promega) in a Veritas 
Microplate Luminometer (Turner Biosystems, Sunnyvale, CA, USA) according to 
the manufacturers’ directions. 
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Cell Culture and Transfection 
HeLa CCL2 cell cultures were maintained at 37ºC and 5% CO2 in DMEM 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat inactivated FBS 
(Invitrogen) and 50 U/ml penicillin and streptomycin (Invitrogen). MEF cells 
were cultured in DMEM (Invitrogen) supplemented with 15% heat inactivated 
FBS (Invitrogen), 50 U/ml penicillin and streptomycin (Invitrogen), 0.1 mM 
NEAA (Invitrogen), 2 mM glutamine (Invitrogen). Cells were seeded at a density 
of 0.1 × 106 cells per well in 24 well plates in DMEM (Invitrogen) containing 10% 
heat inactivated FBS (Invitrogen). Twenty-four hours later, cells were washed 3 
times in 500 µl PBS (Invitrogen), and then 400 µl DMEM with serum was added 
to each well. Renilla luciferase plasmid (0.025 mg), firefly luciferase plasmid 
pGL3 (0.025 mg), and 20 nM siRNA were mixed with 99 µl DMEM and 1 µl 
DharmaFECT Duo (Dharmacon, Lafayette, CO, USA) per well. A control siRNA 
(CXCR4) was used to equalize the total amount of siRNA in each transfection. 
Cells are incubated with 0.5 ml final volume of DMEM plus serum containing 
100 µl of transfection reagent nucleic acid mixture for 24 h. 
siRNA Annealing 
Single-stranded guide and passenger siRNA strands (Supplemental Table S4; 
Dharmacon) were annealed by incubating 10 µM each strand in 500 µl annealing 
buffer (100 mM potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mM 
magnesium acetate) for 1 min at 90°C, followed by 1 h at 37°C. 
Luciferase Assays 
Cells were washed once in 500 µl PBS and lysed in 100 ml of Passive Lysis Buffer 
(Promega) at room temperature for 20 min in 24 well plates. For each well 10 µl 
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lysate was read in triplicate using dual luciferase reagents (Promega) in a Turner 
Biosystems luminometer controlled by Veritas software (Turner). Renilla 
luciferase activity for each concentration of transfected siRNA was normalized to 
the corresponding firefly luciferase activity. 
Data Analysis 
The individual biological replicates for normalized Renilla luciferase activity 
versus siRNA concentration was fit using Igor Pro 6.10 (Lake Oswego, Oregon, 
USA) to the Hill equation to determine IC50 and nH. Fitting was weighted using 
the standard error of each mean value. Throughout this study, the standard 
deviation is reported for mean IC50 and nH values. The Hill coefficients from each 
replicate were subjected to the Student’s t-test to determine p-values at 95% 
confidence using GraphPad Prism (La Jolla, CA, USA). 
Statistical Testing 
To test if the individual Hill coefficients from the replicates of each experiment 
followed a Gaussian distribution, data were subjected to the Kolmogorov–
Smirnov, D’Agostino & Pearson omnibus and Shapiro-Wilk normality tests. By 
all three tests, all Hill coefficient data was normally distributed. The p-values at 
95% confidence were calculated using an unpaired, one sample, two-tailed 
Student’s t-test (GraphPad Prism; La Jolla, CA, USA) to test whether nH was 
significantly different from the null hypothesis that nH = 1 (i.e., non-cooperative). 
An unpaired, two-tailed Student’s t-test with Welch’s correction at 95% 
confidence, which does not assume equal variances, was used to test the 
significance of differences in nH a perfect and bulged siRNA. For non-normally 
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distributed fold-repression data, we used the non-parametric Wilcoxon Signed-
Rank test at 95% confidence to determine p-values. 
Western Blotting 
Forty micrograms cell lysate in cell lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 
1% v/v NP-40) containing Complete, mini, EDTA-free protease inhibitor (Roche, 
Indianapolis, IN, USA) were separated by 4–20% HEPES-SDS-PAGE and 
transferred at 4°C in Tris-bicine buffer to nitrocellulose membrane overnight at 
30 V. Membranes were blocked in 5% w/v milk-TBST (100 mM Tris Cl pH 7.5, 
150 mM NaCl, 0.1% TWEEN 20) for 1 h and incubated overnight at 4°C with 
primary antibody diluted in 3% milk-TBST. Rabbit anti-human and mouse Ago2 
antibody (Cell Signaling Technologies, Danvers, MA, USA) (Li et al., 2010) or 
rabbit anti-human and mouse Ago1 antibody (MBL International, Woburn, MA, 
USA) was diluted 1:1,000 and rabbit anti-actin antibody (Bethyl Laboratories, 
Montgomery, TX, USA) was diluted 1:5,000. After three 5 min washes in TBST 
the membranes were incubated 1 h with secondary goat anti-rabbit HRP-
conjugated antibody (GE Healthcare, Piscataway, NJ, USA) diluted 1:10,000. 
After five, 5 min washes in TBST, the membranes were incubated for 5 min in 
Super Signal West-Dura Extended Duration Substrate (Pierce, Rockford, IL, 
USA). Chemiluminescent signal was recorded using an LAS-4000 (Fuji, Tokyo, 
Japan). 
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Figure 2.1. Models for cooperativity in silencing. 
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FIGURE 2.1. Potential sources of cooperativity in the repression of a target 
mRNA by the small RNA-directed Argonaute complex, RISC. (A) Cooperative 
binding. RISC binding at multiple target sites increases site occupancy by 
mutually stabilizing subsequent binding of RISCs. (B) Cooperative function. 
RISC binding at multiple sites may increase the likelihood that repressive factors, 
such as nucleases, are recruited to the mRNA. (C) Multiple independent sites. 
Each RISC functions independently, so the multiple sites increase the probability 
of repression, but do not influence each other. 
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Figure 2.2: Silencing of  Rr luciferase mRNA by siRNA pairing to different extents at multiple sites. 
!
"!
#
$
#$
%
&'
(
)*
+
,
-
.
!
"!
#
$
#$
%
&'
(
)*
+
,
-
.
!
"!
#
$
#$
%
&'
(
)*
+
,
-
.
!
"!
#
$
#$
%
&'
(
)*
+
,
-
.
!
"!
#
$
#$
%
&'
(
)*
+
,
-
.
!
"!
#
$
#$
%
&'
(
)*
+
,
-
.
%&! #$% & #$'
()
*#
! #$+, & #$-* ./
()
*#
0 -# ./ ()
*#
0 -# ./
%&! #$% & #$,
()
*#
! '$%% & #$+, ./
%&! '$' & #$'
()
*#
! #$1* & #$%, ./
%&! '$- & #$-
()
*#
! #$-* & #$#% ./
%&! '$- & #$,
()
*#
! #$2' & #$,, ./
%&! -$* & #$3
()
*#
! #$31 & #$2* ./
%&! -$, & #$3
()
*#
! ,$1 & '$2 ./
%&! '$1 & #$3
()
*#
! #$3' & #$-# ./
%&! '$1 & #$*
()
*#
! #$3, & #$+' ./
%&! '$, & #$*
()
*#
! '$% & #$* ./
()
*#
0 -# ./ ()
*#
0 -# ./
()
*#
0-# ./
()
*#
4 '' ./
%&! -$* & #$%
()
*#
! +$, & ,$, ./
%&! '$% & #$*
()
*#
! '#$# & -$2 ./
()
*#
4 '* ./
()
*#
4 -# ./
()
*#
0 -# ./
()
*#
0 -# ./
#
#$*
'$#
()
*#
0 -# ./
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
56789:;< ./
#
#$*
'$#
56789:;< ./ 56789:;< ./ 56789:;< ./
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
#
#$*
'$#
*= >
!
"!#$"$"
#!$###!$""###>,=
%%%%%%%
"
$#!"$"$$"#$$$"#!!$"$,=? ? *=
*= >
!
"!#$"$"
#!$#
""$!""#"!>,=
%%%%%%% %%%%
"
$#!"$"$
$"#$
$$"#!!$"$,=? ? *=
*=> "$"!#$"$##!$!"""$!##">,=
%%%%%%%% '%%%%%%%%%%
$"$#!"$"
$
$"#$$$"#!!$,=? ? *=
%&! #$3 & #$-
()
*#
! #$,# & #$'2 ./
#$#' #$' ' '# #$#' #$' ' '# #$#' #$' ' '# #$#' #$' ' '#
6789: @A7BC
D89:
56789:;< ./
%&! '$3 & #$-
()
*#
! 1$* & 3$' ./
#
#$*
'$#
#$' ' '# '##
56789:;< ./
%&! -$- & '$#
()
*#
! '#$- & 3$+ ./
#
#$*
'$#
#$' ' '# '##
!
"!
#
$
#$
%
&'
(
)*
+
,
-
.
!"#$"%& '""()*+,"( '""( !+*' ./0.1
.
A
D
E
C
F
G
H
6
7I
C
6
.
2
/
3
4
1
.55 6781
*=> "$"!#$"$""$!"""$!##$$>,=
%%%%%%%%%%%%%%%%%%%(
$"$#!"$"$$"#$$$"#!!$",=? ? *=
 69  
FIGURE 2.2. Extent of pairing and target site number determine both efficacy 
and cooperativity in small RNA-directed silencing in HeLa cells. Silencing of a 
Renilla luciferase reporter mRNA bearing 1–6 target sites in its 3´ UTR, relative to 
a firefly luciferase internal control, was determined at different siRNA 
concentrations. Pairing between the siRNA guide (red) to the 3´ UTR sites (black) 
is shown at top. IC50 and Hill coefficient (nH) were calculated for each dose-
response curve. Throughout this study, values are reported as mean ± standard 
deviation for IC50 values and nH; error bars indicate standard error for ≥ 12 
biological replicates. The curves correspond to the concentration-dependence of 
silencing expected for the mean IC50 and nH values.
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Figure 2.3: Validation of siRNAs. 
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FIGURE 2.3. siRNA validation in HeLa cells. Each siRNA was functional in 
silencing a reporter containing a single perfect target site. (A) Perfect siRNA. (B) 
Bulged siRNA. (C) siRNA with seed plus supplementary 3′ pairing (nts 13–16). 
(D) siRNA with only seed pairing. The curves correspond to the concentration-
dependence of silencing expected for the mean IC50 and nH values (± standard 
deviation) calculated from 3 independent trials.
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Figure 2.4: Silencing of Rr luciferase mRNA by siRNA pairing to three adjacent or non-adjacent sites. 
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FIGURE 2.4. Cooperative binding of RISC requires adjacent target sites in HeLa 
cells. Three sites spaced 19 nt apart (A) require more siRNA to achieve half-
maximal silencing, compared to three adjacent sites (B), and act non-
cooperatively. In contrast, a perfectly matched siRNA silences a three-site 
reporter with sites separated by 19 nt (C) or a reporter with three adjacent sites 
(D) with equal efficacy and without detectable cooperativity. The three adjacent-
site experiments in this figure were performed independently from those in Fig. 
2. A one sample, two-tailed Student’s t-test was used to calculate the p-values at 
95% confidence for the Hill coefficients to determine if nH was significantly 
different from the null hypothesis: nH = 1 (i.e., non-cooperative).
 74  
 
Figure 2.5: Silencing of Rr luciferase by a perfect or bulged pairing to six sites in MEFs. 
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FIGURE 2.5. Silencing in Ago2–/– MEFs or Ago2–/– MEFs reconstituted with 
mouse Ago2 or catalytically inactive, mutant Ago2D669A  or Ago1–/– MEFs. (A) In 
the absence of Ago2, silencing by a perfect site (nH = 1.6 ± 0.4, p = 0.03) is equally 
cooperative as a bulged site (nH = 1.8 ± 0.3, p = 0.006). (B) Mouse Ago2 expression 
restored non-cooperative silencing by the perfect siRNA (black; nH = 1.0 ± 0.1); 
silencing directed by a bulged siRNA became less cooperative (red; nH = 1.5 ± 0.2, 
p = 0.02) than in the absence of Ago2 (red in (A); nH = 1.8 ± 0.3). (C) Catalytically 
inactive mouse Ago2D669A likewise restored non-cooperative silencing by a perfect 
siRNA (black; nH = 1.1 ± 0.1), but silencing by the bulged siRNA (red; nH = 1.5 ± 
0.3, p = 0.04), was cooperative. (D) In the absence of Ago1, silencing by the 
perfect siRNA was not cooperative (black; nH = 1.1 ± 0.1) but silencing by the 
bulged siRNA was cooperative (red; nH = 1.7 ± 0.2, p = 0.003). A one sample, two-
tailed Student’s t-test was used to calculate the p-values at 95% confidence for the 
Hill coefficients to determine if nH was significantly different from the null 
hypothesis: nH = 1 (i.e., non-cooperative).
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Figure 2.6: Argonaute protein levels in MEFs cells. 
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FIGURE 2.6. Ago1 and Ago2 protein levels in MEF cells. Ago2 was detected by 
Western blotting using a rabbit anti-Ago1 antibody that recognizes both mouse 
and human Ago1 and a rabbit anti-Ago2 antibody that recognizes both mouse 
and human Ago2. Ago protein levels were normalized to actin, and the level of 
Ago protein in wild-type MEFs was set to 1. Data are mean ± standard deviation 
for three trials. Inset shows representative data from a single experiment. 
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 Figure 2.7: Silencing of Rr luciferase mRNA at three non-adjacent sites requires 
Ago2. 
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FIGURE 2.7. In the absence of Ago2, effective silencing requires adjacent sites. 
(A,B) Both perfect (nH = 2.1 ± 0.3, p = 0.007) and bulged (nH = 1.5 ± 0.3, p = 0.04) 
adjacent sites were silenced cooperatively in the absence of Ago2. (C,D) In Ago2–
/– MEFs, three target sites spaced 19 nt apart did not silence the reporter. (E,F) 
Expressing mouse Ago2 in the Ago2–/– MEFs allowed three distant sites to silence 
the reporter. (G,H) Expressing catalytically inactive, mutant Ago2D669A also 
allowed three distant sites to silence the reporter. (I,J) In the Ago1–/– MEFs the 
three distant sites silenced the reporter. A one sample, two-tailed Student’s t-test 
was used to calculate the p-values at 95% confidence for the Hill coefficients to 
determine if nH was significantly different from the null hypothesis: nH = 1 (i.e., 
non-cooperative). 
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Table 2.1. Concentration-dependence and cooperativity for distinct siRNA:target 
pairing modes using reporters bearing one to six siRNA-binding sites.  
N.D., not determined. IC50 values (nM) and Hill coefficients (nH) of the fitted 
curves are reported as mean values ± standard deviation for the IC50 and Hill 
coefficients for at least 12 trials. 
Perfect Bulged Seed plus 13–16 Seed only Number 
of sites 
IC50 n
H IC50 n
H IC50 n
H IC50 n
H 
1 0.63 ± 0.25 0.9 ± 0.1 >20 N.D. >20 N.D. >20 N.D. 
2 1.99 ± 0.63 0.9 ± 0.2 >20 N.D. >20 N.D. >20 N.D. 
3 0.75 ± 0.93 1.1 ± 0.1 1.9 ± 0.5 1.0 ± 0.5 >20 N.D. >20 N.D. 
4 0.25 ± 0.09 1.2 ± 0.2 0.83 ± 0.61 1.7 ± 0.5 ~11 N.D. ~20 N.D. 
5 0.41 ± 0.33 1.2 ± 0.3 0.81 ± 0.20 1.7 ± 0.8 6.3 ± 3.3 2.5 ± 0.9 ~15 N.D. 
6 0.30 ± 0.14 0.8 ± 0.2 0.87 ± 0.45 2.5 ± 0.8 3.7 ± 1.4 2.3 ± 0.8 10.0 ± 2.4 1.9 ± 0.5 
 
 81  
Argonaute protein identity and pairing geometry 
determine cooperativity in mammalian RNA silencing 
Jennifer A. Broderick, William E. Salomon, Sean P. Ryder, Neil Aronin and 
Phillip D. Zamore 
Supplemental Methods 
Quantitative RT-PCR 
Cells were harvested and total RNA purified using Trizol (Invitrogen, Carlsbad, 
CA, USA) according to manufacturer’s protocol, then 10 µg RNA was treated 
with 20 units of Turbo DNase (Ambion, Austin, TX, USA) in 100 µl at 37°C for 20 
min. RNA was extracted with 100 µl acid phenol (EMD Chemicals, Gibbstown, 
NJ, USA) and precipitated using 0.1 volume 3 M sodium acetate (pH 5.2) and 2.5 
volumes absolute ethanol. Precipitated RNA was washed with 900 µl 70% 
ethanol and then dissolved in 50 µl water. RNA purity and concentration was 
determined by absorbance. RNA (0.1 µg) was reversed transcribed using 
Superscript III Reverse Transcriptase (Invitrogen) with oligo(dT) primers 
(Invitrogen) according to manufacturer’s protocol. A parallel reaction containing 
water instead of reverse transcriptase provided a negative control. After reverse 
transcription, quantitative PCR was performed using 1 µl of the cDNA reaction. 
PCR reactions (25 µl) used SYBR green PCR mix (Bio-Rad Laboratories, Hercules, 
CA, USA) and specific primers (Supplemental Table S5). PCR conditions were: 
94°C, 4 min, then 40 cycles of 94°C, 15 sec; 60°C, 15 sec; 72°C, 30 sec; 72°C, 7 min 
using an Opticon 2 instrument (Bio-Rad). PCR data was analyzed using the 2–∆∆CT 
method (Livak and Schmittgen, 2001) and DART PCR (Pfaffl, 2001; Peirson et al., 
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2003). Cycle number data was analyzed by normalizing the cycle threshold for 
Argonaute mRNA to that of GAPDH. For the analysis of mRNA in MEF cells, the 
levels of Argonaute mRNA were normalized first to the cycle threshold for 
GAPDH, then to the cycle threshold for Argonaute mRNA from wild-type MEF 
cells. 
RNAi Transfections 
Cells were seeded at a density of 3 x 106 cells in 100 mm plates in DMEM 
(Invitrogen) containing 15% heat inactivated fetal bovine serum (FBS; 
Invitrogen). Twenty-four hours later, cells were washed 3 times in 5 ml PBS 
(Invitrogen), and then 8.8 ml DMEM containing 10% v/v FBS was added to each 
well. Each siRNA (20 nM) was transfected in 1.2 ml DMEM and 20 µl 
DharmaFECT 1 transfection reagent (Dharmacon; Table S3). Cells were 
incubated with 10 ml DMEM containing 10% FBS and 1.2 ml transfection 
reagent/nucleic acid mixture for 16 h. Next, the cells were washed 3 times with 
PBS, then grown in DMEM supplemented with 15% FBS, 50 U/ml penicillin and 
streptomycin (Invitrogen), 0.1 mM non-essential amino acids (Invitrogen), 2 mM 
glutamine (Invitrogen). Twenty-four hours later, the cells were seeded into 24-
well plates at 0.1 × 106 cells per well. 
Western Blotting 
Western blotting was as described in the main text except 40 µg each protein 
lysate was resolved by 5% SDS-PAGE and transferred to nitrocellulose 
membrane in Tris-glycine buffer overnight at 4°C at 30V. Mouse anti-
human/anti-mouse Ago3 antibody (Active Motif, Carlsbad, CA, USA) (Azuma-
Mukai  et al., 2008), diluted 1:1000, was used to detect Ago3. 
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RNase H Cleavage 
Target accessibility was measured by the ability of an antisense oligonucleotide 
(5′-mGmCmU mAdTdA dAdTdG dAdAdA dTdGdC dCmCmG mCmG-3′ [m, 
2′-O-methyl]) to direct RNase H cleavage at the target sites of the synthetic RNA 
target containing the expanded three target sites (generated by in vitro 
transcription and gel purified). The purified RNA was capped with guanylyl 
transferase, S-adenosylmethionine, and [α-32P] guanosine triphosphate and then 
gel purified. Cleavage reactions were assembled on ice in 60 mM Tris-HCl, pH 
7.8, 60 mM KCl, 2.5 mM MgCl2 and contained 700 nM synthetic RNA target, 7 
µM antisense oligonucleotide, and 50 U/ml f.c. RNase H (New England Biolabs, 
Ipswich, MA, USA). The reaction was incubated at 37°C; cleavage was stopped 
by adding 8M urea, 25 mM EDTA, pH 8.0, 0.025% w/v xylene cyanol FF, 0.025% 
w/v bromophenol blue. RNA was resolved by urea-denaturing, polyacrylamide 
gel electrophoresis and analyzed using a FLA-9000 phosphorimager (Fuji) at 50 
µm resolution. 
 
Supplemental References 
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Supplemental Table 2.S1. Observed fold-repression of 1–6 site reporters for seed 
only and seed plus 3′ supplemental pairing siRNAs transfected at 20 nM. 
Expected fold repression was calculated as the repression for one site, to the 
power of the number of sites in the reporter (n), 1.13n for seed and 1.32n for seed 
plus 3′ supplemental. Wilcoxon Signed-Rank test was used to determine the p-
value for significance of the observed fold-repression compared to that expected 
as calculated from the reporter containing a single target site. 
  Fold-repression  
 Number 
of sites 
 
Observed 
(median; 
minimum–maximum) 
Expected 
 
 
p-value 
(Wilcoxon 
rank test) 
     
1 1.1  1.1  
2 1.4; 1.0–2.8  1.2 N.S. 
3 1.8; 1.3–5.0 1.5 0.03 
4 2.2; 1.3-7.7  1.6 0.003 
5 4.8; 1.1–14 1.9 0.04 S
ee
d
 o
n
ly
 s
iR
N
A
 
6 4.1; 1.4–18  2.1 0.002 
     
1 1.3 1.3  
2 1.5; 0.7–3.0 1.7 N.S. 
3 2.5; 1.1–5.7 2.3 N.S. 
4 2.0; 1.1–5.6 3.0 N.S. 
5 4.8; 1.7–21 4.0 N.S. 
S
ee
d
 p
lu
s 
3′
 s
u
p
p
le
m
en
ta
l 
p
ai
ri
n
g
 
6 8.4; 3.5–27 5.3 N.S. 
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Supplemental Table 2.S2. Change in Argonaute mRNA abundance, compared 
to wild-type MEF cells; standard deviations are for three technical replicates. 
MEF 
Genotype 
Argonaute 
mRNA  
mean ± standard 
deviation 
   Ago1  0.31 ± 0.04 
Ago2  0.73 ± 0.06 
Ago3  0.61 ± 0.05 Ago1
–/– 
Ago4  0.63 ± 0.11 
   Ago1  0.55 ± 0.07 
Ago2  0.024 ± 0.00 
Ago3  0.20 ± 0.02 Ago2
–/– 
Ago4  0.24 ± 0.09 
   Ago1  0.63 ± 0.05 
Ago2  36 ± 3 
Ago3  0.26 ± 0.05 
Ago2–/– 
+ 
Ago2 
Ago4  0.09 ± 0.03 
    Ago1  2.2 ± 0.3 
Ago2  17 ± 1 
Ago3  0.61 ± 0.05 
Ago2–/– 
+ 
Ago2D669A 
Ago4  0.33 ± 0.05 
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Supplemental Table 2.S3. Oligonucleotides used to produce reporter plasmids. 
Target sites Sequences (sense, antisense)  
1 
5′-CTA GAG GCA TTT CAT TAT AGC TAT GGG CC-3′,5′- CAT AGC TAT AAT 
GAA ATG CCT-3′ 
2 
5′-CTA GAG GCA TTT CAT TAT AGC TAT GGC ATT TCA TTA TAG CTA TGG 
GCC-3′, 5′- CAT AGC TAT AAT GAA ATG CCA TAG CTA TAA TGA AAT GCC 
T-3′ 
3 5′-CTA GAG GCA TTT CAT TAT AGC TAT GGC ATT TCA TTA TAG CTA TGG CAT TTC ATT ATA GCT ATG GGC C-3′, 5′- CAT AGC TAT AAT GAA ATG 
CCA TAG CTA TAA TGA AAT GCC ATA GCT ATA ATG AAA TGC CT-3′ 
4 
5′-CTA GAG GCA TTT CAT TAT AGC TAT GGC ATT TCA TTA TAG CTA TGG 
CAT TTC ATT ATA GCT ATG GCA TTT CAT TAT AGC TAT GGG CC-3′, 5′- 
CAT AGC TAT AAT GAA ATG CCA TAG CTA TAA TGA AAT GCC ATA GCT ATA 
ATG AAA TGC CAT AGC TAT AAT GAA ATG CCT-3′ 
5 
5′-CTA GAG GCA TTT CAT TAT AGC TAT GGC ATT TCA TTA TAG CTA TGG 
CAT TTC ATT ATA GCT ATG GCA TTT CAT TAT AGC TAT GGC ATT TCA TTA 
TAG CTA TGG GCC-3′, 5′- ATA GCT ATA ATG AAA TGC CAT AGC TAT AAT 
GAA ATG CCA TAG CTA TAA TGA AAT GCC ATA GCT ATA ATG AAA TGC CAT 
AGC TAT AAT GAA ATG CCT-3′ 
6 
5′-CTA GAG GCA TTT CAT TAT AGC TAT GGC ATT TCA TTA TAG CTA TGG 
CAT TTC ATT ATA GCT ATG GCA TTT CAT TAT AGC TAT GGC ATT TCA TTA 
TAG CTA TGG CAT TTC ATT ATA GCT ATG GGC C-3′,5′- CAT AGC TAT AAT 
GAA ATG CCA TAG CTA TAA TGA AAT GCC ATA GCT ATA ATG AAA TGC CAT 
AGC TAT AAT GAA ATG CCA TAG CTA TAA TGA AAT GCC ATA GCT ATA ATG 
AAA TGC CT-3′ 
3-site expanded 
5′-CTA GAG GCA TTT CAT TAT AGC TAT AAA CGG GAC GGC GCA CGC GGG 
CAT TTC ATT ATA GCT ATA AAC GGG ACG GCG CAC GCG GGC ATT TCA TTA 
TAG CTA TGG GCC-3′,5′-CAT AGC TAT AAT GAA ATG CCC GCG TGC GCC 
GTC CCG TTT ATA GCT ATA ATG AAA TGC CCG CGT GCG CCG TCC CGT TTA 
TAG CTA TAA TGA AAT GCC T-3 
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Perfect target 
for bulged 
siRNA 
5′-CTAGATGGCATTTCACGGATAGCTATGGGCC-3′,  
5′-CATAGCTATCCGTAAGATGCCAT-3′ 
Perfect target 
for seed plus 
13–16 siRNA 
5′-CTAGACTGTTCATTGACGTATAGCTAGGGCC-3′,  
5′-CTAGCTATACGTCAATGAACAGT-3′ 
Perfect target 
for seed siRNA 
5′-CTAGAGGGTTACGGGACGTATAGCTAGGGCC-3′,  
5′-CTAGCTATACGTCCCGTAACCCT-3′ 
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Supplemental Table 2.S4. Synthetic siRNAs used in this study. 
siRNA Guide strand Passenger strand 
perfect 5′-AUAGCUAUAAUGAAAUGCCUU-3′ 5′-GGCAUUUCAUUAUAGCUAGUU-3′ 
bulged (10-11) 5′-AUAGCUAUCCGUGAAAUGCCA-3′ 5′-GCAUUUCACGGAUAGCUAGUU-3′ 
seed plus 13-16 5′-GAGCUAUACGUCAAUGAACAG-3′ 5′-GUUCAUUGACGUAUAGCUAUU-3′ 
seed 5′-GAGCUAUACGUCCCGUAACCC-3′ 5′-GUUACGGGACGUAUAGCUAUU-3′ 
CXCR4 5′-GUGUUAGCUUUGUGAAAACUU-3′ 5′-GUUUUCACAAAGCUAACAACG-3′ 
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Supplemental Table 2.S5. Synthetic siRNAs used to deplete Ago3 and Ago4; 
PCR primers used in this study. 
siRNA Guide strand Passenger strand 
Ago3 5′-UUUGCAAAGAUAGUUGUGCUU-3′ 5′-GCACAACUAUCUUUGCAACUU-3′ 
Ago4 5′-UAAGGAAGCAUCCUGGUUCUU-3′ 5′-GAACCAGGAUGCUUCCUUCUU-3′ 
control 5′-GUGUUAGCUUUGUGAAAACUU-3′ 5′-GUUUUCACAAAGCUAACAACG-3′ 
 
PCR Oligos Forward primer Reverse primer 
Ago1 5′-GTACGGCGGCCGGAACCGGGCCATTG-3′ 5′-CAAGGTTGACCCTGGATAGGCATC-3′ 
Ago2 5′-GGAGGTCTGTAACATTGTGGCAGGAC-3′ 5′-GCCCAGTCACGTCTGTCATCTCATCT-3′ 
Ago3 5′-GGAATTAGACAAGCCAATCAGCA-3′ 5′-AGGGTGGTCATATCCTTCTGGA-3′ 
Ago4 5′-CTAACAGACTCCCAGCGTGTCA-3′ 5′-GACTGGCTGGCCGTCTAGTCA-3′ 
GAPDH 5′-CGCTCTCTGCTCCTCCTGTT-3′ 5′-CCATGGTGTCTGAGCGATGT-3′ 
Mouse Ago1 5′-CCCAGAAACAGTGTCGAGAAG-3′ 5′-TCCCTGCATCCTTGGAAATC-3′ 
Mouse Ago2 5′-ATTCAGTTCTACAAGTCCACCC-3′ 5′-CTGATAGTCCTTCTCCAGCTTG-3′ 
Mouse Ago3 5′-ATACAGCCAATCCACTTCCTG-3′ 5′-ATCTTTTCCACCTTCCCCAG-3′ 
Mouse Ago4 5′-AAAGGTTGGAAAGGGTCTGG-3′ 5′-TGGTGATTTTGCCTGGGAAG-3′ 
Mouse GAPDH 5′-CTTTGTCAAGCTCATTTCCTGG-3′ 5′-TCTTGCTCAGTGTCCTTGC-3′ 
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Supplemental Figures 
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Figure 2.S1. p-values for Hill coefficients. 
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FIGURE 2.S1. Analysis of the statistical significance of Hill coefficients presented 
in Fig. 2. Individual values for the Hill coefficient of each replicate experiment (n 
= 12), were analyzed using Student’s t-test to determine if the experimentally 
determined Hill coefficient was significantly different at a 95% confidence level 
from a theoretical Hill coefficient equal to 1. 
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Figure 2.S2. Independence of cleavage at three non-adjacent targets sites by RNase in vitro. 
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FIGURE 2.S2. Each site in the expanded three-site reporter is equally accessible. 
We examined the accessibility of each site by measuring its sensitivity to 
oligonucleotide-directed RNase H cleavage. Cleavage at each site occurred with 
similar initial rates (v0 ~ 6.1, 5.9 and 6.6 nM min-1) and with kinetics that were 
consistent with a model assuming independent and unordered (i.e., random) 
rather than dependent and sequential cleavage of each site. (A) Oligonucleotide-
directed RNase H cleavage of the expanded three-site reporter mRNA. (B) 
Expected results (from computer modeling) for independent and dependent 
binding models. (C) Quantification of the data in (A).
 96  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 2.S3. Argonaute mRNA levels in HeLa cells relative to GAPDH. 
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FIGURE 2.S3. The relative abundance of Argonaute mRNAs, normalized to 
GAPDH, was determined by qRT-PCR for the HeLa cell line used in Figures 2–4. 
mRNA for Argonaute 2 was most abundant; relative  levels were Ago2 > Ago3 > 
Ago1 and Ago4. Data is reported as mean ± standard deviation for three 
technical replicates. 
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Figure 2.S4. Argonaute 3 protein level in Ago1-/- MEFs (A) and silencing of Rr luciferase by 
perfect or bulged siRNA after RNAi for Argonaute 3 and Argonaute 4 (B). 
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FIGURE 2.S4. Endogenous Ago2 silences bulged sites cooperatively. (A) Ago3 
protein abundance, relative to Tubulin, was measured by western blot. (RNAi 
against Ago3 and Ago4 in the Ago1–/– MEFs halved the amount of Ago4 mRNA 
[data not shown].) (B) A bulged siRNA silenced the six-site reporter 
cooperatively (nHbulged = 1.8 ± 0.5), compared to silencing by the perfect siRNA 
(nHperfect = 1.0 ± 0.01) in Ago1–/– MEF cells in which Ago3 and Ago4 had been 
depleted by RNAi. 
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Figure 2.S5. Silencing by catalytically inactive Ago2 requires binding at multiple sites by a 
perfect pairing. 
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FIGURE 2.S5. A single target site reporter is not silenced in Ago2–/– MEFs 
reconstituted with catalytically inactive Ago2D669A (Ago2–/– + Ago2D669A; left). As 
controls, silencing of the one-site reporter in Ago1–/– MEF cells (right) and 
silencing of the six-site reporter in Ago2–/– + Ago2D669A (middle) is shown.  
Silencing of the six-site reporter by catalytically inactive Ago2D669A occurs without 
cooperativity nHperfect = 1.1 ± 0.1). 
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 Chapter III: Oligonucleotide tethers recruit RISC to an mRNA and 
silence its expression. 
This chapter explores ideas that are pending patent by the author, Phillip D. 
Zamore and Neil Aronin.  
USPTO App. No. 20060293267, “Dual functional oligonucleotides for use as anti-viral 
agents” Broderick JA and Zamore PD. 
USPTO App. No. 20050256072, “Dual functional oligonucleotides for use in repressing 
mutant gene expression” Broderick JA, Aronin N, Zamore PD 
All data presented in this chapter is the author’s own. This manuscript is 
unpublished. 
Summary 
Harnessing an endogenous miRNA to induce gene silencing may restrict 
silencing of a co-expressed gene to a specific cell type. A molecule that—in 
principle—could combine antisense technology and RNAi is a 2´-O-methyl 
oligonucleotide “tether” that contains a 5´ region complementary to an 
endogenous miRNA in RISC and a 3´ region complementary to the target 
mRNA. 2´-O-methyl oligonucleotides incorporate in each nucleotide a methoxyl 
group in place of the ribose 2´ hydroxyl, thereby conferring endonuclease 
resistance. 2´-O-methyl oligonucleotides bind tightly to complementary 
sequences in siRNAs and miRNAs in the RISC and are irreversible inhibitors of 
small RNA function in Drosophila embryo lysates, HeLa cell lysates, and in vivo in 
HeLa cells and C. elegans larvae. The 2´-O-methyl oligonucleotide used to inhibit 
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a miRNA in RISC can be extended by adding sequence that is complementary to 
a target mRNA. This “tether” could recruit RISC to a target mRNA. A 2´-O-
methyl oligonucleotide tether would be expected to function only when two 
conditions are met. First, the tether must be complementary to a region of the 
endogenous miRNA that recruits the RISC. Second the tether must bind the 
target mRNA through complementary base pairing. If the required miRNA or 
target mRNA is not present in the cell then the tether should not function. More 
than one target site in the 3´ untranslated region (UTR) of a target mRNA is 
necessary to induce silencing of the mRNA when there is imperfect pairing 
between the miRNA and the target. Therefore binding of a single tether to a non-
targeted mRNA should not suffice to cause silencing. Only when multiple tether 
molecules bind the target is robust silencing anticipated. Thus, oligonucleotide 
tethers should be significantly more specific than either traditional antisense or 
siRNA methods, where partial pairing of the nucleic acid to an mRNA unrelated 
in sequence to the intended target can elicit an ‘off-target’ response. In addition, 
during viral infection tethers may be able to recruit viral miRNAs in RISC to 
silence viral or host genes that promote or are required for viral propagation. 
Preliminary data confirm the prediction: an oligonucleotide tether that recruits 
the let-7 miRNA to silence an exogenous reporter gene, in HeLa cells and mouse 
embryonic fibroblast cells, directs robust silencing using only nanomolar 
concentrations of oligonucleotide. This chapter contains data from the proof of 
concept experiments and the initial characterization of the mechanism of gene 
silencing by oligonucleotide tethers. 
 104  
Introduction 
Small noncoding RNAs (~21-23 nucleotides long), called microRNAs (miRNAs), 
guide the endogenous pathway of mRNA silencing (Figure 3.1). Most miRNAs 
reside in their own genes, distinct from the mRNAs whose stability or translation 
they regulate (Bartel, 2004; Cai et al., 2004). miRNA expression is often tissue 
specific  and developmentally important (Pasquinelli and Ruvkun, 2002; Olsen 
and Ambros, 1999). Many animal miRNAs are phylogenetically conserved and 
some show organ-specific expression (Sempere et al., 2004; Landgraf et al., 2007). 
Endogenous miRNAs establish right and left neuronal symmetry in C. elegans 
(Johnston and Hobert, 2003; Ambros et al., 2003). miRNAs have been proposed 
to temporally regulate development of the mammalian central nervous system 
(Krichevsky et al., 2003; Kim et al., 2004). miRNAs are transcribed by RNA 
polymerase II as primary microRNAs (pri-miRNAs) (Lee et al., 2004; Bracht et al., 
2004). RNase III endonuclease Drosha (Lee et al., 2003), together with the small 
dsRNA-binding protein DGCR8 (Denli et al., 2004; Gregory et al., 2004; Han et 
al., 2004) convert pri-miRNAs to pre-miRNAs, ~70 nt stem-loop structures. 
Drosha establishes the 5´or 3´ end of the miRNA. Pre-miRNAs are moved to the 
cytoplasm by Exportin-5 (Yi et al., 2003; Bohnsack et al., 2004; Lund et al., 2004; 
Zeng and Cullen, 2004). In the cytoplasm, the RNase III enzyme Dicer converts 
pre-miRNAs into mature double stranded miRNAs ~25 nt long called miR/miR* 
(or miR-5p/miR-3p). The miRNA duplex is assembled into an Argonaute 
protein, forming the RNA-induced silencing complex (RISC), and the miR* 
strand is destroyed. The miRNA guides RISC to bind a target mRNA. When 
incorporated into RISC, miRNAs direct the post-transcriptional silencing of their  
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Figure 3.1. MicroRNA biogenesis pathway. 
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mRNA targets. Like siRNAs, plant and animal miRNAs can direct cleavage of 
their mRNA targets when the two are extensively complementary, but cause 
destabilization or repress mRNA translation when they are not (Hutvágner and 
Zamore, 2002; Doench et al., 2003; Doench and Sharp, 2004). 
Because the specificity of RISC is determined by base pairing between the 
miRNA and its target mRNA, RISC specificity can, in theory, be modified by 
oligonucleotides. Current methods for regulating gene expression using 
antisense oligonucleotides or RNAi allow exogenous nucleic acids to repress 
expression of cellular genes. However, each of these methods has specific 
limitations. A concern for antisense technology is that unmethylated CpG 
(Cytosine-phosphate-Guanine) dinucleotides activate mammalian B cells and 
natural killer cells in culture (Krieg et al., 1995). DNA and RNA antisense 
oligonucleotides have a short half-life in vivo, so chemical modification of the 
oligonucleotides is required to stabilize them against nucleolytic degradation 
and to improve their biodistribution and pharmokinetics. Some modified 
antisense oligonucleotide chemistries that improve antisense performance in vitro 
show toxicity and lethal side effects in animal studies (Crooke, 2004). But most 
importantly, antisense technology has shown poor efficacy in vivo, perhaps 
because it does not exploit a robust biological pathway. In contrast, RNAi 
technology uses a powerful cellular pathway for repressing gene expression.  
However, chemically unmodified siRNAs may prove unstable in vivo, and—
unlike antisense technology—siRNA delivery methods are in their infancy. 
Expression of siRNAs by viral vectors in vivo, as an alternative strategy to the 
use of synthetic siRNAs, is fraught with the same difficulties plaguing all gene-
therapy approaches: the difficulty of developing long lasting viral vectors, 
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producing therapy-grade, high titer virus stocks, and by the inherent immuno-
stimulatory side effects associated with all current viral vectors. Clearly, a 
technology is needed that combines the delivery and stability of antisense 
technology with the robust target-specific silencing elicited by siRNAs.  
Furthermore, the silencing effects of neither antisense nor RNAi technology can 
be restricted to a particular cell type.  
Harnessing an endogenous miRNA to induce gene silencing may restrict 
silencing to a specific cell type.  A molecule that—in principle—could combine 
antisense technology and RNAi is a 2´-O-methyl oligonucleotide “tether” that 
contains a 5´ region complementary to an endogenous miRNA in RISC (miRNA-
programmed RISC (miRISC)) and a 3´ region complementary to the target 
mRNA (Figure 2). 2´-O-methyl oligonucleotides incorporate in each nucleotide a 
methoxyl group in place of the ribose 2´ hydroxyl of RNA, thereby conferring 
endonuclease resistance (Sproat et al., 1989; Iribarren et al., 1990). 2´-O-methyl 
oligonucleotides bind tightly to complementary sequences in siRNAs and 
miRNAs in RISC and are irreversible inhibitors of small RNA function in 
Drosophila embryo lysates, HeLa cell lysates, and in vivo in HeLa cells and C. 
elegans larvae (Hutvagner et al., 2004; Meister et al., 2004).  The 2´-O-methyl 
oligonucleotide can be extended by adding sequence that is complementary to a 
target mRNA, creating a tether that could recruit miRISC to a target mRNA. 
A 2´-O-methyl oligonucleotide tether would be expected to function only when 
two conditions are met. First, the tether must be complementary to a region of 
the endogenous miRNA in RISC. Second, the tether must bind the target mRNA 
through complementary base pairing (Figure 3.2). If either the required miRNA 
or target mRNA is not present in the cell, then the tether should not function. The  
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Figure 3.2. Oligonucleotide tether binds a miRNA in RISC and the 3´ UTR of mRNA. 
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work described in Chapter II of this thesis shows that more than one target site in 
the 3´ untranslated region (UTR) of a target mRNA is necessary to induce 
silencing of the mRNA; increasing the number of target sites within an mRNA 
increases the level of silencing. Therefore binding of a single tether to an 
unintended mRNA should not suffice to cause silencing. Only when multiple 
tether molecules bind the target is robust silencing anticipated (Figure 3.3).  
Thus, oligonucleotide tethers should be significantly more specific than either 
traditional antisense or siRNA methods, where partial pairing of the nucleic acid 
to an mRNA other than the intended target can elicit an ‘off-target’ response 
(Jackson et al., 2003).  
Results 
The oligonucleotide tether is designed to be bifunctional. One end of the tether 
recruits, through nucleotide base pairing, a miRNA that has been incorporated 
into RISC (Figure 3.3). The other end of the tether binds the target mRNA 
through base pairing. The expected result is that the tethering of RISC will inhibit 
expression of protein from the mRNA. Preliminary data confirm the prediction: 
an oligonucleotide tether that recruits endogenous let-7 miRNA to silence an 
exogenous reporter gene in HeLa cells and mouse embryonic fibroblast cells 
(MEFs) directs robust silencing using only nanomolar concentrations of 
oligonucleotide. The proof of principle experiment showed that the tether 
silenced a reporter luciferase mRNA by recruiting RISC to six sites in the 3´ UTR.  
To test this, we designed a tether that had 24 nucleotides of complementarity to 
multiple sites in the 3´ UTR of a luciferase reporter and 21  
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Figure 3.3. Oligonucleotide tether (Blue) binds to miRNA (Red) and recruits RISC to multiple sites in the 
3´ UTR. 
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nucleotides of complementarity to an exogenous guide siRNA in RISC. To 
examine oligonucleotide tether function in the absence of the recruited miRNA, 
we tested a tether that functions by recruiting a plant miRNA, miR-166. Since 
miR-166 is not expressed in HeLa cells, the tether silences only when miR-166 is 
transfected as an asymmetric siRNA into the cells (Schwarz et al., 2003). This 
system allows assessment of any antisense effects of the tether alone. When 24 
nucleotides of the oligonucleotide tether are complementary to the target sites in 
the 3´ UTR of a luciferase reporter and miR166 is transfected in the culture, we 
expected that RISC would be recruited to the mRNA through the exogenous 
miR-166. Using an in vivo reporter assay to test the ability of a tether to recruit 
RISC to luciferase mRNA expressed in HeLa cells, luciferase activity is reduced 
by 80-90%. Notably, the tether has little or no effect on reporter expression when 
the recruited miRNA is not present in the cells (Figure 3.4, “tether plus GFP 
siRNA”).  Thus, the tethers function in a miRNA-dependent, rather than an 
antisense, mode.  
 To test the ability of the tether to recruit an endogenously expressed 
miRNA in RISC, we used a tether that has complementarity to let-7 miRNA. The 
control to which all experimental samples were compared was a culture that 
received an oligonucleotide tether that cannot bind the target sites in the 3´ UTR 
of the luciferase mRNA because it contains the sense sequence instead of the 
complement of the target sequence. Recruiting an endogenous miRNA, let-7, in 
RISC to the 3´ UTR of the luciferase mRNA silenced the reporter by more than 
60% (Figure 3.4). Mouse embryonic fibroblast cells derived from Ago1 or Ago2 
null mice were used to determine which Argonaute protein in RISC, when 
tethered to the luciferase reporter mRNA, mediates silencing. The IC50 for  
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Figure  3.4. Silencing of Rr luciferase mRNA by tethering RISC to target sites in the 3´ UTR. 
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silencing by the tether that targeted six sites in the 3´ UTR of the luciferase 
reporter mRNA and paired to let-7 in RISC was determined in wild-type MEF 
cells, and MEF cells derived from Ago1 -/- or Ago2 -/-  mice. In wild-type MEF 
cells, which express all four Argonaute proteins, the IC50 for silencing by the 
tether that paired perfectly to let-7 was 0.08 ± 0.01 nM (Figure 3.5A). 
Interestingly, in the absence of Ago1, the IC50 for silencing by the perfectly 
pairing tether was 0.11 ± 0.02 nM– similar to the IC50 for silencing in wild-type 
MEF cells (Figure 3.5A,B). The level of Ago2 protein in Ago1-/- MEF cells is 2 fold 
higher than in wild-type MEF cells. This suggest that silencing by a tether is not 
limited by the concentration of Ago2, so it was surprising that the IC50 for 
silencing did not decrease in the Ago1 -/-. This can be confirmed in the Ago2 -/- 
MEF cells that are cells reconstituted with wild-type Ago2 which expresses 30 
fold more Ago2 protein than wild-type MEFs to see if the IC50 for silencing 
decreases with more Ago2. In the absence of Ago2, the tether silenced with an 
IC50 of 0.17 ± 0.11 nM (Figure 3.5C). The maximum amount of silencing in the 
Ago2 -/- MEF cells was 2 fold less than in the wild-type MEF cells. This suggests 
that Ago1, Ago3 and Ago4 proteins are less efficient at mediating silencing when 
tethered to a target mRNA, probably because their expression in MEF cells is 
lower than the KD required to achieve silencing.   
 One consideration we had for the tether strategy was that providing a 
perfect target for a miRNA could cause destabilization of the miRNA (Ameres et 
al., 2010). To see if the extent of pairing to the miRNA changed the ability of the 
tether to silence the reporter containing six sites, we designed tethers pairing  
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Figure 3.5. Silencing by a tether that binds let-7 in wild-type mouse embryonic fibroblast cells (A) or 
cells lacking Ago1 (B) or Ago2 (C).  
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partially to let-7: a bulge at nucleotides 9-10, seed plus 13-16 and a seed only 
pairing (Figure 3.6).   
In wild-type MEF cells, the tethers pairing to the seed or the seed plus 
positions 13-16 of let-7 did not silence the reporter when targeting six sites in the 
3´ UTR (Figure 3.7A,B). In contrast, more extensive pairing to let-7 caused 
silencing: a bulged pairing to let-7 silenced the reporter with an IC50 of 0.46 ± 0.02 
nM (Figure 3.7C).  Maximum silencing by the bulged pairing to let-7 was similar 
to that achieved by the perfect pairing (Figure 3.7C,D). At 10 nM, the perfect and 
bulged pairing tethers achieved 80% of the silencing caused by the siRNA that 
bound directly to the mRNA and paired perfectly to six target sites (Figure 
3.7C,D,E).  These results suggest that Ago proteins can mediate silencing without 
being bound directly to the target mRNA and that a tether can exploit 
endogenous miRNAs to recruit RISC to a target mRNA that is not normally 
regulated by miRNAs.  
To figure out the minimal sequence of complementarity required to 
specifically bind the target mRNA and the minimal sequence required to recruit 
RISC through the oligonucleotide tether to the target mRNA, I did experiments 
with a tether that binds to exogenously transfected miR-166 in HeLa cells. To 
further analyze the function of the tether to specifically bind the target mRNA, 
truncations of the tether were made to determine the minimal sequence needed 
to silence the six-site reporter. The 3´ end of the tether was reduced from 24 to 
21,18,15,12 and 9 nucleotides in length while retaining all 21 nucleotides of  
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Figure 3.7. Silencing of a six-site reporter mRNA by tethers that 
pair to different extents with let-7 or an siRNA that pairs perfectly 
to target sites. 
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pairing to the miR-166. The 5´ end of the tether that is required to recruit RISC 
was also truncated. Truncations of the original 21 nucleotide sequence 
complementary to a miRNA within the oligonucleotide tether were made in two 
nucleotide increments to 19, 17, 15, 13, 11, and nine nucleotides. Luciferase 
expression from the reporter was silenced by 80% with 10 nM of tether that 
paired to the target with 15 or more nucleotides at six sites (Figure 3.8A). When 
the tether was truncated at its 5 ´ end, 13 nucleotides was the shortest extent of 
complementarity to miR-166 that silenced the luciferase reporter (Figure 3.8B). 
Based on these results we have shortened the sequence of the tethers from 45 nt 
to 28 nt (Figure 3.9). To silence a reporter mRNA, an oligonucleotide tether need 
only contain  ~28 nucleotides, 15 of which are specificity determinants for the 
target mRNA and 13 of which recruit the miRNA-programmed RISC.  
 To increase the specificity of the tether for pairing to the target sequences, 
locked nucleic acids (LNAs) were incorporated into the tether. LNAs contain 2´, 
4´methylene bridges that increase the specificity of oligonucleotides by 
constraining the ribose sugar moiety into the 3´-endo conformation, 
preorganizing the bases for pairing. LNAs increase the RNA:RNA melting 
temperature of the oligonucleotide by 2.4ºC per base (Nielsen et al., 1999; Braasch 
and Corey, 2001). We compared tethers that contained either the LNA or 2´-O-
methyl modified RNA. One tether recruited an exogenously transfected miR-166 
(Figure 3.10A) and one recruited endogenous let-7 (Figure 3.10B). The 2´-O-
methyl modified tether that recruited miR-166 silenced the reporter by 80% when 
miR-166 was co-transfected, but not when GFP siRNA was co-transfected (Figure  
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Figure 3.8. Silencing of six-site reporter by 
tethers with different extents of pairing to 
target mRNA (A) or miRNA (B). 
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Figure 3.9.  Tethers 28 nt in length silenced the luciferase reporter 
(right). Sequence of the tether that binds the miRNA was reduced to 13 
nt from 21 nt and the sequence that paired to target was reduced to 15 nt 
from 24 nt of target pairing (left). 
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Figure 3.10. Silencing of a six-site reporter by 10 nM of 
tether with 2´-O-methyl or LNA modifications, pairing to 
miR-166 (A) or  endogenous let-7 (B). 
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3.10A). We tested two separate LNA modified tethers that differed in the 
placement of the LNAs within the sequence of the tether. LNA1 was not as  
effective as the 2´-O-methyl modified tether to silence the reporter in the 
presence of miR-166 (Figure 3.10A). LNA2 caused silencing even in the absence 
of miR-166, possibly because the LNA modified tethers cause RNase H digestion 
of the target mRNA. We also tested tethers that contained either the LNA or 2´-
O-methyl modified RNA and recruited let-7 to the reporter (Figure 3.10B). These 
tethers should silence the reporter using endogenous let-7 and not require 
transfection of let-7. As expected, the tethers containing either type of RNA 
modifications and that recruited let-7 were able to silence the reporter by > 50% 
(Figure 3.10B). The let-7 tethers silenced the reporter to lesser degree than tethers 
that used the exogenous miR-166, a result that might be due to competition for 
endogenous targets of let-7 in the cell.  Shorter tethers, substituted with LNAs, 
were not more effective than the 2´-O-methyl tethers that recruit miR-166. A 
tether that contains 15 nt of sequence pairing to the target mRNA and 13 
nucleotides of complementarity to a siRNA guide stand in RISC is necessary and 
sufficient to recruit RISC and induce silencing of the target reporter mRNA. By 
incorporating LNA substitutions into the tether sequence, the number of 
nucleotides required to silence the target mRNA might be reduced from 28 nt to 
less than 20 nt. Tethers that recruit other miRNAs may have increased 
effectiveness due to sequence specific effects.  
 Post-transcriptional gene silencing can occur by two mechanisms. 
Translational inhibition prevents the target mRNA from being translated by the 
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ribosome into protein by preventing translation initiation or blocking 
translational elongation of the target mRNA. Destabilization of target mRNA is 
thought to be the dominant form of silencing in animal cells.  To determine if the 
reporter target mRNA is destabilized when tethered to RISC, we measured 
mRNA levels in HeLa cells by quantitative real-time RT-PCR. The experiments 
tested silencing of the six-site luciferase reporter by 2´-O-methyl tethers that 
either recruit exogenous miR-166 or endogenous let-7 and compared silencing by 
a perfect or bulged pairing siRNA directly on the target mRNA (Figure 3.11).  
When comparing the target mRNA level to the luciferase activity, the tethers 
caused translational repression (Figure 3.12). Tethering RISC to the 3´ UTR at six 
sites induced repression similar to a bulged siRNA that bound directly to the 
target mRNA. Further analysis of the effect of tether silencing on target mRNA 
levels in wild-type and Ago MEF cells is required to understand whether or not 
the target mRNA is destabilized or translationally repressed when RISC is 
tethered to the target through different endogenous miRNAs. 
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Figure 3.11. Tether pairing schemes used in experiments to measure mRNA levels by qRT-PCR and 
luciferase activity. 
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Figure 3.12. Tethers that recruit RISC to six sites in the 3´ UTR of a reporter mRNA silence luciferase 
protein expression without destabilizing the mRNA. 
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Discussion 
Oligonucleotide tethers recruit RISC to a target mRNA 
The proof of principle experiments showed that it is possible to silence a target 
mRNA by tethering RISC to multiple sites in the 3´ UTR. These results suggest 
that Ago proteins can mediate silencing without being bound directly to the 
target mRNA and that a tether can exploit endogenous miRNAs to recruit RISC 
to a target mRNA that is not normally regulated by miRNAs. Tethering RISC to a 
target mRNA through an oligonucleotide tether causes translational repression 
similar to a more sophisticated RISC tethering scheme (Pillai et al., 2004). In those 
experiments, human Ago2 was fused to the small, basic RNA-binding N-peptide 
from bacteriophage. Next, they placed multiple N-peptide-binding sites in the 3´ 
UTR of a reporter mRNA and introduced both the Ago2 fusion protein and the 
reporter into human cells. The Ago2-N fusion protein bound the 3´ UTR sites 
through the N-peptide rather than via a small RNA guide and silenced reporter 
protein production without reducing reporter mRNA levels. Translational 
repression by the Ago2-N fusion protein required more than three binding sites 
to achieve robust repression, similar to that of bulged siRNA:target pairings. 
Preliminary experiments showed that the minimal length of an 
oligonucleotide required to tether RISC is 28 nucleotides, only ~7 nt longer than 
siRNAs or miRNAs. Since the tether is a single molecule, compared to exogenous 
duplex siRNA used for RNAi, it may be easier to deliver to target tissues than 
siRNA and prove to be an alternative strategy for silencing genes of interest. Our 
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data from HeLa cells showed that using a miRNA, the tether silences a target 
containing 4 target sites in the 3´ UTR by >50% and silences > 60% when 
targeting six sites. Notably, because it does not silence when the reporter 
contains only a single site, it is unlikely that a tether will have ‘off-target’ effects 
on other non-target mRNAs. This needs to be explored further by determining 
the IC50 for silencing an mRNA containing a single target sequence to bind a 
tether.  
Applications of tether silencing strategy 
One application for the tether strategy is to target a sequence in the 3´ UTR of 
huntingtin (htt) mRNA that contains a single nucleotide polymorphism which 
associates with the mutant allele of htt (Schwarz et al., 2006; DiFiglia et al., 2007; 
Liu et al., 2008; Pfister et al., 2009). This is dependent on the tether being able to 
discriminate target recognition to a single nucleotide difference that we may be 
able to achieve by using LNA modified tethers. If a tether can cause silencing of 
the mutant allele, then the progression of the disease may be slowed (Pfister and 
Zamore, 2009). 
A further application is that a tether can recruit RISC through pairing to a 
virally expressed miRNA in a cell infected by a virus that expresses miRNAs. 
Mammalian viruses produce at least 66 distinct miRNAs (Cullen, 2009; Cullen, 
2010). Viruses are able to manipulate the endogenous miRNA pathway in order 
to propagate. Some viral miRNAs collaborate with cellular miRNAs to silence 
mRNAs and thwart the immune response to infection. One known function of 
viral miRNAs is to thwart the immune response during infection by regulating 
the expression of the major histocompatibility complex class I chain-related 
molecule B (MICB), a natural killer cell ligand (Stern-Ginossar et al., 2007). A 
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second function for viral miRNAs may be to repress host mRNAs so as to 
maintain viral latency (Nachmani et al., 2010; Murphy et al., 2008). Exploiting 
viral miRNAs by using a tether to redirect viral miRNAs to silence viral mRNAs 
may some day be used to coax latent viruses into the more therapeutically 
tractable replicating state, allowing the elimination of reservoirs that enable viral 
reemergence after anti-viral therapy is completed. 
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 Table 3.1. Synthetic siRNAs used in this study. 
siRNA Guide strand Passenger strand 
CXCR4 perfect 5′-GUGUUAGCUUUGUGAAAACUU-3′ 5′-GUUUUCACAAAGCUAACAACG-3′ 
CXCR4 bulged 5′-UGUUAGCUGGAGUGAAAACUU-3′ 5′-GUUUUCACUCCAGCUAACCCA-3′ 
Rr ORF siRNA 5′-AUAGCUAUAAUGAAAUGCCUU-3′ 5′-GGCAUUUCAUUAUAGCUAGUU-3′ 
miR166* 5′-GGAUCAGGCUUCAUCCCACUU-3′ 5′-UUGGGAUGAAGCCUGAUCCGG-3′ 
miR166 5′-CCGGAUCAGGCUUCAUCCCAA-3′ 5′-GGGAUGAAGCCUGAUCCGUAU-3′ 
GFP 5′-GAACUUCAGGGUCAGCUUGCCG-3′ 5′-GCAAGCUGACCCUGAAGUUAAU-3′ 
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Table 3.2. Synthetic tether oligonucleotides used in this study. 
Tether name   Sequence 5'-3'  
T.13miR166/ 15 CXCR4/LNA1 aaGccTgaTccGgcmCggTgtTagmCttTg 
T.13miR166/ 15 CXCR4/LNA2 AagmCctGatmCcgGccGgtGttAgcTttG 
T.13 miR166/15 sense CXCR4/LNA1 aaGccTgaTccGggGccAcaAtcGaaAc 
T.13 miR166/15 sense CXCR4/LNA2 AagmCctGatmCcgGggmCcamCaaTcgAaamC 
T13 let7/ 15 CXCR4/LNA1 accTacTacmCtcAccGgtGttAgcTttg 
T13 let7/ 15 CXCR4/LNA2 AccTacTacmCtcAccGgtGttAgcTttG 
T.13 let7/15 sense CXCR4/LNA1 accTacTacmCtcAggmCcamCaaTcgAaac 
T.13 let7/15 sense CXCR4/LNA2 AccTacTacmCtcAggmCcamCaaTcgAaamC 
T.21miR166/24 CXCR4   mU.mU.mG.mG.mG.mA.mU.mG.mA.mA.mG.mC.mC.mU.mG.mA.mU.mC.mC.mG.mG.mC.mC.mG.mG.mU.mG.mU.mU.mA.mG.mC.mU.mU.mU.mG.mU.mG.mA.mA.mA.
mA.mC.mU.mU 
T.21miR166/21CXCR4 
mU.mU.mG.mG.mG.mA.mU.mG.mA.mA.mG.mC.mC.mU
.mG.mA.mU.mC.mC.mG.mG.mC.mC.mG.mG.mU.mG.m
U.mU.mA.mG.mC.mU.mU.mU.mG.mU.mG.mA.mA.mA.
mA 
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Tether name   Sequence 5'-3'  
T.21miR166/18CXCR4 
mU.mU.mG.mG.mG.mA.mU.mG.mA.mA.mG.mC.mC.mU
.mG.mA.mU.mC.mC.mG.mG.mC.mC.mG.mG.mU.mG.m
U.mU.mA.mG.mC.mU.mU.mU.mG.mU.mG.mA 
T.21miR166/15CXCR4   mU.mU.mG.mG.mG.mA.mU.mG.mA.mA.mG.mC.mC.mU.mG.mA.mU.mC.mC.mG.mG.mC.mC.mG.mG.mU.mG.mU.mU.mA.mG.mC.mU.mU.mU.mG 
T.21miR166/12CXCR4   mU.mU.mG.mG.mG.mA.mU.mG.mA.mA.mG.mC.mC.mU.mG.mA.mU.mC.mC.mG.mG.mC.mC.mG.mG.mU.mG.mU.mU.mA.mG.mC.mU 
T.21miR166/10.CXCR4   mU.mU.mG.mG.mG.mA.mU.mG.mA.mA.mG.mC.mC.mU.mG.mA.mU.mC.mC.mG.mG.mC.mC.mG.mG.mU.mG.mU.mU.mA.mG  
T.21miR166/9.CXCR4   mU.mU.mG.mG.mG.mA.mU.mG.mA.mA.mG.mC.mC.mU.mG.mA.mU.mC.mC.mG.mG.mC.mC.mG.mG.mU.mG.mU.mU.mA  
T.21miR166/24senseCXCR4   mU.mU.mG.mG.mG.mA.mU.mG.mA.mA.mG.mC.mC.mU.mG.mA.mU.mC.mC.mG.mG.mG.mG.mC.mC.mA.mC.mA.mA.mU.mC.mG.mA.mA.mA.mC.mA.mC.mU.mU.mU.
mU.mG.mA.mA 
T.21miR166/15senseCXCR4   mU.mU.mG.mG.mG.mA.mU.mG.mA.mA.mG.mC.mC.mU.mG.mA.mU.mC.mC.mG.mG.mG.mG.mC.mC.mA.mC.mA.mA.mU.mC.mG.mA.mA.mA.mC 
T13 let7/15CXCR4   mA.mC.mC.mU.mA.mC.mU.mA.mC.mC.mU.mC.mA.mC.mC.mG.mG.mU.mG.mU.mU.mA.mG.mC.mU.mU.mU.mG 
T.21let7/15CXCR4   mA.mC.mU.mA.mU.mA.mC.mA.mA.mC.mC.mU.mA.mC.mU.mA.mC.mC.mU.mC.mA.mC.mC.mG.mG.mU.mG.mU.mU.mA.mG.mC.mU.mU.mU.mG 
T.21let7/ 15 sense CXCR4   mA.mC.mU.mA.mU.mA.mC.mA.mA.mC.mC.mU.mA.mC.mU.mA.mC.mC.mU.mC.mA.mG.mG.mC.mC.mA.mC.mA.mA.mU.mC.mG.mA.mA.mA.mC 
T.21let7/24 sense CXCR4 
mA.mC.mU.mA.mU.mA.mC.mA.mA.mC.mC.mU.mA.mC
.mU.mA.mC.mC.mU.mC.mA.mG.mG.mC.mC.mA.mC.m
A.mA.mU.mC.mG.mA.mA.mA.mC.mA.mC.mU.mU.mU.
mU.mG.mA.mA 
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Tether name   Sequence 5'-3'  
T.let-7perfect/15 Rr 
5′-mAmCmUmAmUmAmCmAmAmCmCmUmAmCmUmAmCmCm 
UmCmAmCmUmAmUmAmAmUmGmAmAmAmUmGmCmC-3′  
T.let-7bulged/15 Rr 
5′-mAmCmUmAmUmAmCmAmAmCmUmCmCmUmAmCmC 
mUmCmAmCmUmAmUmAmAmUmGmAmAmAmUmGmCmC-3′ 
T.let-7seed13-16/15 Rr 
5′-mAmCmAmAmAmAmGmCmCmUmAmCmCmUmCmA 
mCmUmAmUmAmAmUmGmAmAmAmUmGmCmC-3′ 
T.let-7seed/15 Rr 
5′-mCmUmAmCmCmUmCmA 
mCmUmAmUmAmAmUmGmAmAmAmUmGmCmC-3′ 
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Table 3.3.  PCR primers used in this study. 
PCR Oligos Forward primer Reverse primer 
Reverse 
transcription  5′-CACTGCATTCTAGTTGTGGTTTGTCC-3′ 
Rr luc  5′-GTGAGGCACTGGGCAGGTGTCCAC-3′ 5′-CATTCATTTGTTTACATCTGGCCC-3′ 
Pp luc 5′-AGAGATACGCCCTGGTTCCT-3′ 5′-CCAACACCGGCATAAAGAAT-3′ 
GAPDH 5′-CGCTCTCTGCTCCTCCTGTT-3′ 5′-CCATGGTGTCTGAGCGATGT-3′ 
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Materials and Methods 
Plasmids 
Renilla luciferase vector pRL-TK (Promega, Madison, WI, USA) containing target 
sites 6, 4 or one site for CXCR4 and a modified linker sequence (Doench et al., 
2003) were used to test all tethers with complementarity to the CXCR4 target site. 
For tethers to test the different types of pairing to let-7, a separate six-site reporter   
in psiCheck2 was constructed as follows. Renilla luciferase vector pRL-TK 
(Promega, Madison, WI, USA) containing target sites for CXCR4 and a modified 
linker sequence (Doench et al., 2003) was mutated from TAG to CTC (lower case 
letters in the oligonucleotides) at nucleotides 387–389 of the Renilla luciferase 
open reading frame to generate mismatches with seed positions 5, 6, and 7 of the 
siRNA guide strand by PCR-directed mutagenesis using DNA oligonucleotides: 
5′-CTT GTT TGG CAT TTC ATT ACt ccT ATG AGC ATC AAG ATA AGA TC-3′ 
(sense), 5′-GAT CTT ATC TTG ATG CTC ATA Gga gTA ATG AAA TGC CAA 
ACA AG-3′ (antisense). Mutagenesis was confirmed by sequencing, and then 5′ 
phosphorylated oligos containing the target sites and pairing to create 
appropriate ends were cloned into the XbaI and ApeI sites of the mutant pRL-TK. 
The sequences of the DNA oligonucleotides used to construct the six target sites 
were sense :5′-CTA GAG GCA TTT CAT TAT AGC TAT GGC ATT TCA TTA 
TAG CTA TGG CAT TTC ATT ATA GCT ATG GCA TTT CAT TAT AGC TAT 
GGC ATT TCA TTA TAG CTA TGG CAT TTC ATT ATA GCT ATG GGC C-3′, 
antisense: 5′- CAT AGC TAT AAT GAA ATG CCA TAG CTA TAA TGA AAT 
GCC ATA GCT ATA ATG AAA TGC CAT AGC TAT AAT GAA ATG CCA 
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TAG CTA TAA TGA AAT GCC ATA GCT ATA ATG AAA TGC CT-3′. 
psiCheck2 (Promega) reporters were constructed by digesting psiCheck2 with 
NheI and NotI and inserting the 3′ UTR target site-containing NheI–NotI fragment 
from the mutant pRL-TK vectors.   
Cell Culture and Transfection 
HeLa CCL2 cell cultures were maintained at 37ºC and 5% CO2 in DMEM 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% heat inactivated FBS 
(Invitrogen) and 50 U/ml penicillin and streptomycin (Invitrogen). MEF cells 
were cultured in DMEM (Invitrogen) supplemented with 15% heat inactivated 
FBS (Invitrogen), 50 U/ml penicillin and streptomycin (Invitrogen), 0.1 mM 
NEAA (Invitrogen), 2 mM glutamine (Invitrogen). Cells were seeded at a density 
of 0.1 × 106 cells per well in 24 well plates in DMEM (Invitrogen) containing 10% 
heat inactivated FBS (Invitrogen). Twenty-four hours later, cells were washed 3 
times in 500 µl PBS (Invitrogen), and then 400 µl DMEM with serum was added 
to each well. Renilla luciferase plasmid pRL-TK (0.025 mg), firefly luciferase 
plasmid pGL3 (0.025 mg), or psiCheck2 (0.025 mg) and 20 nM siRNA were mixed 
with 99 µl DMEM and 1 µl DharmaFECT Duo (Dharmacon, Lafayette, CO, USA) 
per well. A control siRNA (CXCR4) was used to equalize the total amount of 
siRNA in each transfection. Cells are incubated with 0.5 ml final volume of 
DMEM plus serum containing 100 µl of transfection reagent nucleic acid mixture 
for 24 h. 
siRNA Annealing 
Single-stranded guide and passenger siRNA strands (Table 1; Dharmacon) were 
annealed by incubating 10 µM each strand in 500 µl annealing buffer (100 mM 
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potassium acetate, 30 mM HEPES-KOH, pH 7.4, 2 mM magnesium acetate) for 1 
min at 90°C, followed by 1 h at 37°C. 
Luciferase Assays 
Cells were washed once in 500 µl PBS and lysed in 100 ml of Passive Lysis Buffer 
(Promega) at room temperature for 20 min in 24 well plates. For each well 10 µl 
lysate was read in triplicate using dual luciferase reagents (Promega) in a Turner 
Biosystems luminometer controlled by Veritas software (Turner). Renilla 
luciferase activity for each concentration of transfected siRNA was normalized to 
the corresponding firefly luciferase activity. 
Data Analysis 
The individual biological replicates for normalized Renilla luciferase activity 
versus siRNA concentration was fit using Igor Pro 6.10 (Lake Oswego, Oregon, 
USA) to the Hill equation to determine IC50 and nH. Fitting was weighted using 
the standard error of each mean value.  
Quantitative RT-PCR 
Cells were harvested and total RNA purified using Trizol (Invitrogen, Carlsbad, 
CA, USA) according to manufacturer’s protocol, then 10 µg RNA was treated 
with 20 units of Turbo DNase (Ambion, Austin, TX, USA) in 100 µl at 37°C for 20 
min. RNA was extracted with 100 µl acid phenol (EMD Chemicals, Gibbstown, 
NJ, USA) and precipitated using 0.1 volume 3 M sodium acetate (pH 5.2) and 2.5 
volumes absolute ethanol. Precipitated RNA was washed with 900 µl 70% 
ethanol and then dissolved in 50 µl water. RNA purity and concentration was 
determined by absorbance. RNA (0.1 µg) was reversed transcribed using 
Superscript III Reverse Transcriptase (Invitrogen) with oligo(dT) primers 
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(Invitrogen) according to manufacturer’s protocol. A parallel reaction containing 
water instead of reverse transcriptase provided a negative control. After reverse 
transcription, quantitative PCR was performed using 1 µl of the cDNA reaction. 
PCR reactions (25 µl) used SYBR green PCR mix (Bio-Rad Laboratories, Hercules, 
CA, USA) and specific primers (Table 3). PCR conditions were: 94°C, 4 min, then 
40 cycles of 94°C, 15 sec; 60°C, 15 sec; 72°C, 30 sec; 72°C, 7 min using an Opticon 
2 instrument (Bio-Rad). PCR data was analyzed using the 2–ΔΔCT method (Livak 
and Schmittgen, 2001) and DART PCR (Pfaffl, 2001; Peirson et al., 2003). Cycle 
number data was analyzed by normalizing the cycle threshold for reporter 
mRNA to that of GAPDH; then for Rr luciferase mRNA, the cycle threshold was 
normalized to the cycle threshold for Pp luciferase mRNA. 
Quantitative RT-PCR References 
Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 
402-408. 
Peirson SN, Butler JN, Foster RG. 2003. Experimental validation of novel and 
conventional approaches to quantitative real-time PCR data analysis. 
Nucleic Acids Res 31: e73. 
Pfaffl MW. 2001. A new mathematical model for relative quantification in real-
time RT-PCR. Nucleic Acids Res 29: e45. 
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Chapter IV:  General Discussion  
Unique properties of Argonautes  
A priority for the future of RNA silencing for both basic research and 
therapeutic application is determining whether or not each mammalian 
Argonaute protein has a specialized function. Defining the properties of each 
Argonaute protein may lead to more efficient target silencing strategies and 
uncover roles for individual Argonaute function in normal cells, developmental 
pathways and disease. Why does Ago2 cleave and repress translation of targets? 
Why are non-catalytic Argonautes necessary when Ago2 is bifunctional and 
there is no sorting of small RNAs in mammals?  
One aspect of silencing to be considered is whether the expression level of 
Ago2 is modulated by the cell cycle or during stress response. Perhaps some 
target sites are not regulated until the concentration of Ago2 reaches a threshold. 
Interestingly, the IC50 for silencing by a perfect pairing to six sites is 10 fold lower 
for Ago2 than for Ago1 (Figure 2.5A,D). This could be because either Ago1 is 
much less abundant than Ago2 or that Ago1 uses only the seed of the guide to 
bind to target which reduces the on rate for Ago1 or the amount of time it 
remains bound to target. If the conformation of Ago1 protein allows pairing only 
with the seed, then this would explain why there is no difference in IC50 or Hill 
coefficient for silencing by the perfect or bulged pairing by Ago1 (Figure 2.5A). If 
Ago1 uses only the seed to pair to target, then that would mean that productive 
pairing to target beyond the seed region is only beneficial for silencing mediated 
by Ago2. A simple test to determine if pairing beyond the seed contributes to 
silencing by Ago1 would be to compare silencing by a seed only pairing to six 
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sites in the absence of Ago2 to that of the bulged and perfect pairings in the 
absence of Ago2.  
Another interesting idea that my data support is that silencing by a perfect 
pairing was not limited by the amount of Ago2 protein in the cell. When Ago2 
was over expressed in MEF cells, the IC50 for a perfect pairing to six sites is the 
same as in the Ago1-/- MEF cells, that express 10 fold less Ago2 (Figure 2.5B,D). 
This indicates that there might be a limiting factor required for ‘active’ RISC, 
whether for loading or function, that is less abundant than the over expressed 
Ago2. We suspected this could be heat shock protein HSP70 or HSP90, which is 
required for RISC loading, but western blot analysis showed it to be equally as 
abundant as Ago2 (W. Salomon, pers. comm.). It could also mean that excess 
Ago2 is sequestered or not available to engage targets in the cytoplasm.  
As more species of small RNAs are identified through cloning and deep 
sequencing of RNA from diverse tissues, perhaps new roles for Argonaute 
proteins will be revealed. A mystery that merits resolution is that Ago3 contains 
the catalytic triad, yet Ago3 has never been shown to be capable of cleaving a 
target mRNA. Perhaps Ago3 prefers an unidentified species of small RNA, 
containing modifications that have allowed them to evade capture by current 
small RNA cloning methods.  Alternatively, Ago3 may require activation, 
through post-translational modification in order to cleave a target mRNA, an 
activity that may be restricted to certain cell types or occur during certain periods 
of development. 
Generation of cooperativity 
My research revealed one functional distinction between Argonaute 
proteins is their capacity to generate cooperativity in silencing between multiple 
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target sites. Using a quantitative approach of measuring IC50 and Hill coefficients 
and subjecting them to statistical testing, I detected true biochemical 
cooperativity in RNA silencing. The Hill equation was originally deduced to 
explain the equilibrium relationship of oxygen binding to hemoglobin and its 
sigmoidal binding curve (A.V Hill, 1910). This equation makes no assumptions 
about the molecular mechanisms that generate cooperativity. It does not describe 
kinetic rates and is insensitive to the microscopic binding constants of the 
component processes therein. The Hill equation is a phenomenological model 
that provides a convenient function for fitting experimental data. When 
considering the simultaneous effect of ligand binding to multiple sites, no model 
like the Hill equation has been derived to assess the effect of an applied 
perturbation on a cooperative system.  
For Ago1, cooperativity between multiple miRNAs bound to adjacent 
sites in a target causes silencing and occurs regardless of the extent of target 
pairing. In contrast, Ago2 is sensitive to the extent of pairing between a small 
RNA guide and target, and silences non-cooperatively when perfectly paired to 
target and cooperatively when paired imperfectly to target. For Ago2, perfect 
pairing to a target may cause a conformational shift that precludes its association 
with other Argonautes or proteins that generate cooperativity. Yet to be 
discovered is whether cooperativity emanates solely from binding to target or 
from Ago:Ago interaction at nearby sites or Ago interaction with or recruitment 
of other proteins such as GW182.  
Multiple partially complementary miRNAs bound to target may have a 
cooperative influence on the function of recruited proteins that cause 
destabilization or translational repression. My data showed that Ago1 was 
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unable to silence a reporter when 3 target sites were separated by 19 nucleotides, 
but when the three sites were adjacent Ago1 cooperatively silenced the reporter. 
Cooperativity generated by a protein-protein interaction between Argonautes or 
other proteins would not be disrupted by a distance of 19 nucleotides between 
target sites. The model reporter system used in my research cannot isolate the 
cooperative binding model from a cooperative function model (Figure 2.1). 
Though my data support a model for cooperative binding of bulged miRNAs 
(Figure 2.1A), it cannot not exclude a cooperative function model that multiple 
bound RISCs on a target mRNA generate cooperative interactions with proteins 
that increase repression (Figure 2.1B).  
To illustrate the difference, consider cooperativity in transcriptional 
activation in eukaryotes and bacteriophage. Yeast GAL4 transcriptional 
activation protein and mammalian transcriptional activator ATF bind to DNA 
cooperatively. They also cooperatively increase transcription even when their 
target binding sites are saturated, indicating that they directly contact the 
transcriptional machinery (Carey et al., 1990; Lin et al., 1990). In contrast, λ 
repressor protein from λ bacteriophage binds multiple DNA sites cooperatively 
as a dimer at low concentrations of repressor protein, however, only one of the λ 
repressor dimers contacts the RNA polymerase to increase transcription non-
cooperatively (Hochschild et al., 1983). My data could represent cooperative 
function of Argonautes bound at multiple sites, similar to that of GAL4 and ATF, 
or it could represent cooperative binding of Argonautes to target, where only one 
Ago protein is required to recruit a protein that causes silencing by either 
destabilization or translational repression. To isolate the exact nature of the 
cooperativity in silencing requires further investigation with a different 
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experimental approach. Perhaps in the future single molecule experiments to 
observe Argonaute binding to multiple target sites combined with in vitro 
translation will reveal the source of cooperativity.  
Cooperativity between miRNAs that pair partially to target through Ago1 
or Ago2 provides a mechanism where the expression of a target can be finely 
tuned, depending on the levels of co-expressed miRNAs. One striking result 
from my experiments was the capacity for Ago2 to cooperatively silence the 
reporter when paired to three bulged sites separated by 19 nucleotides whereas 
Ago1 was unable to silence the same reporter with a perfect of bulged pairing. In 
my model reporter system, Ago1 can only generate cooperativity when sites are 
adjacent to each other and only Ago2 can generate cooperativity in silencing 
when bound at multiple distant sites. If cooperativity by Ago1 is limited to 
adjacent sites, then how many adjacent target sites occur in protein coding 
genes? Until we know all the criteria that define a target site, this is impossible to 
know. How often do target sites fall within 19 nucleotides of each other in real 
protein coding genes? Bioinformatics analysis of Ago1 PAR–CLIP deep 
sequencing data from flies (Y.Tomari, unpublished) showed that 4346 protein 
coding genes (of ~14,000 protein coding genes in flies) have peaks for Ago1. The 
presence of two peaks, or hits, in the same gene within 19 nucleotides of each 
other occurs in 288 of the genes that bound Ago1 (J. Xu, pers. comm.). I predict 
that the same analysis on the Ago2–CLIP deep sequencing data will reveal that 
fewer target sites fall within 19 nt of each other because Ago2 is able to 
cooperatively silence more distant or non-adjacent sites.  
Viral exploitation of cooperative regulation 
Potentially, a perfect pairing through Ago2 could disrupt regulation of the 
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target by miRNAs bound through Ago1, providing a functional reason for why 
few miRNAs pair to targets with perfect complementarity. One instance where 
disrupting cooperativity could be exploited is during viral infection. Mammalian 
viruses produce at least 66 distinct miRNAs (Cullen, 2009; Cullen, 2010). One 
known function of miRNAs is to thwart the immune response during infection 
by regulating the expression of the major histocompatability complex class I 
chain regulated molecule B (MICB), a natural killer cell ligand (Stern-Ginossar et 
al., 2007). Epstein-Barr virus, Kaposi’s sarcoma-associated herpes virus and 
human cytomegalovirus (HCMV) express miRNAs that target separate sites in 
the MICB mRNA to prevents its expression.  HCMV expresses a miRNA, miR-
UL112, that targets the 3´ UTR of MICB at a site overlapping the binding site for 
the cellular miRNA, miR-373. Interestingly, the MICB mRNA contains nearby 
sites for two other cellular miRNAs, miR-376a and miR-433. After 72 h of HCMV 
infection, the viral miRNA, miR-UL112, and the cellular miRNA, miR-376a, 
collaborate to silence the expression of MICB (Nachmani et al., 2010). Although it 
remains to be determined into which Argonaute protein viral miRNAs are 
loaded, a potential strategy used by viral miRNAs could be to load in Ago2 and 
pair extensively with target mRNAs in order to disrupt weaker regulation by 
cellular miRNAs of target mRNAs that impede successful infection. Perhaps 
viruses have evolved to exploit the unique properties of Argonaute proteins, 
thereby providing an advantage for the virus to propagate. 
Non-redundant Argonaute functions 
It will be important to look carefully at protein expression profiles of the 
three non-catalytic Argonautes to understand why mammals have retained 
them. Perhaps there is a developmental stage where expression of a specific non-
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catalytic Argonautes is required. Are non-catalytic Argonautes redundant and 
why can loss of miRNAs in conditional Dicer null ES cells be tolerated 
(Kanellopoulou et al., 2005)? How can Ago2 substitute for non-catalytic 
Argonautes? And how does a mouse that is a triple knockout for Ago1,3 and 4 
survive (G. Hannon, pers. comm.)? What if using miRNAs as guides for 
regulating targets is only a part-time function of Argonautes? Does the latest 
data, showing Argonaute cross-linked to mRNAs in the absence of a miRNA, 
hint at a novel mechanism of Argonautes associating with RNA binding proteins 
(Leung et al., 2011)?  In our lab, we have begun experiments to look at Argonaute 
protein purified from MEF cells binding to target sites at the single molecule 
level. This project should detect and help resolve whether or not there are 
differential requirements for individual Argonaute proteins for binding based on 
extent of pairing between miRNAs and target mRNA.  
Quantifying Argonaute expression profiles 
We still do not know how Argonaute protein expression and function are 
regulated. Current methods to quantitate Argonaute levels are limited to 
measuring mRNA by qRT-PCR and the last published report to quantitate 
Argonaute mRNA levels in various tissues was by Sasaki et al., in 2004. 
Experiments to define tissue specific levels of Argonaute proteins and their 
distinct functional properties have been limited by the difficult task of 
identifying unique antigenic peptides from each Argonaute protein that will not 
cross-detect multiple Argonaute proteins. In my work, I have tested antibodies to 
mouse Ago1, Ago2 and Ago3 that are specific when blotted against MEF cells 
that are knockout for the individual Argonautes, but without MEF cells that lack 
Ago4, there is still no way to determine specificity for anti-Ago4 antibody.  Once 
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we have the full complement of specific mammalian Argonaute antibodies, new 
experiments will be possible to look at regulation of Argonaute protein 
expression in all mammalian cell types. 
Like the post-transcriptional regulation Argonautes effect upon other 
mRNAs, regulation of Argonaute mRNAs by miRNAs is a possible mode to 
control Argonaute protein expression, especially for Ago1 that has nearly 5 
kilobases in its 3´ UTR and for Ago2 that contains almost 2 kilobases in its 3´ 
UTR. In Ago2-/- MEF cells the level of Ago1 protein is much higher than in wild 
type MEF cells suggesting that Ago2 regulates expression of Ago1 protein. I have 
identified several candidate miRNAs that are computationally predicted to target 
the 3´ UTRs of human Argonaute mRNAs. Additionally the stability of 
Argonaute proteins can be controlled by post-translational modifications such as 
hydroxylation, phosphorylation and ubiquitylation (Qi et al., 2008; Rybak et al., 
2009; Zeng et al., 2008). Argonaute proteins themselves regulate many processes 
and so determining how Argonaute protein expression and function are 
regulated requires carefully designed experimental approaches. Continuation of 
basic research to define the roles that Argonaute proteins command from the 
molecular level via small RNAs may provide solutions to many unresolved 
aspects of mammalian RNA silencing. 
Advancing therapeutic application of RNA silencing 
Exploitation of robust RNA silencing mechanisms for successful 
application in humans depends on delivery of modified RNA to target tissues. 
Expression of modified RNA is not possible through viral packaging. Further, 
unmodified RNA expression in cells would be subject to degradation and have 
limited activity, even when expressed at high levels. Currently, effective delivery 
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of therapeutic RNAs to the intended tissue apart from direct injection, is difficult 
to achieve, but progress in the design of lipid nanoparticles seems promising 
(Whitehead et al., 2009).  
In addition to delivery methods discussed in my review of microRNA 
therapeutics (see Appendix), innovative combinatorial formulation strategies are 
in progress. Before a therapeutic RNA can find its target mRNA or miRNA, it 
must make it through four barriers: 1) remain in the bloodstream (avoid filtering 
by kidneys), 2) extracellular matrix, 3) cellular uptake, 4) escape from endosomes 
(before lysosomal degradation). Some lipid-based formulations are able to pass 
through the cell membrane, but cannot escape the endosomes. Some 
formulations are great at releasing their cargo as the pH deceases in the 
lysosomal pathway, but cannot get through the cell membrane. Lipidoids are 
lipids with an amine-containing polar head group and nonpolar alkyl tails 
(Akinc et al., 2008). By combining two formulations that on their own were not 
able to silence a target in vitro, a library of ‘binary’ lipidoid formulations 
(combining two lipidoid formulations) was created and tested (Akinc et al., 2008; 
Siegwart et al., 2011; Whitehead et al., 2011). After screening the library by 
testing them in vitro in HeLa cells with luciferase reporters, an effective binary 
formulation, 86N15-98O13 was further tested in mice. 48 hours after tail vein 
injection of 5 mg/kg of siRNA, the formulation allowed silencing of factor VII 
protein expression in hepatocytes by 85% (Whitehead et al., 2011). Neither 
component of the formulation on its own was effective for silencing factor VII 
and ended up in the kidneys, similar to injection of naked (not formulated for 
delivery) siRNA. However, mixing the two lipidoids into binary nanoparticles 
allowed the siRNA to enter hepatocytes and silence the target with an IC50 of 1.5 
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mg/kg (Whitehead et al., 2011). Further analysis of the binary formulation 
revealed that one component was responsible for getting through the cell 
membrane and the other component was critical for escaping the endosomal 
compartment. Pushing ahead with such innovative solutions to systemic delivery 
of therapeutic RNA ensures that human health will benefit from our efforts to 
understand RNA silencing. 
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Summary 
MicroRNAs (miRNAs) provide new therapeutic targets for many diseases, 
while their myriad roles in development and cellular processes make them 
fascinating to study. We still do not fully understand the molecular 
mechanisms by which miRNAs regulate gene expression nor do we know the 
complete repertoire of mRNAs each miRNA regulates. However, recent 
progress in the development of effective strategies to block miRNAs suggests 
that anti-miRNA drugs may soon be used in the clinic. 
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Introduction 
MicroRNAs (miRNAs) are 21–23 nt long RNAs that direct Argonaute proteins to 
bind to and repress complementary mRNA targets. The human genome contains 
more than 500 miRNAs, and each miRNA can repress hundreds of genes, 
regulating almost every cellular process1,2. Individual miRNAs are often 
produced only in specific cell types or developmental stages. 
Inappropriate miRNA expression has been linked to a variety of 
diseases3,4. For example, the let-7 miRNA prevents proliferation of cancer stem 
cells. miRNAs have roles in metabolic diseases such as obesity and diabetes; 
differentiation of adipocytes is promoted by miR-143 and insulin secretion is 
regulated by miR-375 in pancreatic-islet cells. Mutation of just a single nucleotide 
in the sequence of a miRNA or its mRNA target can eliminate target regulation. 
Mutation of the fifth nucleotide of miR-96 is associated with autosomal 
dominant, progressive, high-frequency hearing loss in humans; the mutation 
decreases the levels of miR-96 and impairs target mRNA repression5. A different 
mutation in miR-96 was discovered in a mouse mutant with hair cell defects and 
progressive hearing loss6. In contrast to mutation of miRNAs, normal miR-122 
participates in the development of liver disease: hepatitis C virus (HCV) hijacks 
this miRNA, making miR-122 required for HCV to replicate in the liver7. Some 
viruses express their own miRNAs, presumably to repress cellular mRNAs that 
would otherwise interfere with viral infection8. Tissue-specific miRNAs may also 
be involved in the pathogenesis of cardiovascular, muscular and 
neurodegenerative diseases. Thus, molecules that alter the function or 
abundance of specific miRNAs represent a new strategy for treating human 
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disease. 
miRNAs are transcribed by RNA polymerase II and matured by RNase III 
enzymes in two steps 
miRNAs are transcribed from their own genes by RNA polymerase II. 
Consequently, miRNA primary transcripts (pri-miRNAs) begin with 5′ 7-
methylguanosine caps and end with 3′ poly(A) tails. The pre-miRNA, a ~65 nt 
stem-loop structure that contains the miRNA and its corresponding miRNA* 
within its stem, resides within the pri-miRNA (Figure A.1). Cleavage of the pri-
miRNA by the ribonuclease III (RNase III) enzyme, Drosha, releases the pre-
miRNA stem-loop, which bears the 2 nt 3′ overhanging ends characteristic of 
RNase III enzymes. The pre-miRNA is then exported to the cytoplasm, where its 
loop is removed by a second, RNase III enzyme, Dicer, that specifically 
recognizes the pre-miRNA structure, including its 2 nt 3′ overhanging end. The 
resulting miRNA/miRNA* duplex is then loaded into a member of the 
Argonaute family of proteins. Subsequently, the miRNA* strand departs from 
the Argonaute protein, producing a mature, active miRNA:protein complex. 
miRNAs provide the specificity determinants for Argonaute proteins 
Binding of a miRNA:Argonaute protein complex to the 3′ untranslated region 
(UTR) of an mRNA silences its expression1. The human genome encodes four 
closely related Argonaute proteins, Ago1, Ago2, Ago3, and Ago4, and most 
tissues and cultured mammalian cell lines express all four, albeit in different 
proportions. Argonaute proteins are structural homologs of the DNA-guided 
ribonuclease, RNase H. Ago2 can cleave its target RNAs (after the nucleotide 
paired to the tenth base of the small RNA guide), but the other three human 
 185  
Argonaute proteins have lost the capacity for such site-specific, small RNA-
directed, endonucleolytic target cleavage. 
Argonaute-catalyzed target cleavage requires extensive, but not complete, 
complementarity between the miRNA guide and an mRNA. However, human 
miRNAs generally base pair only partially with their target mRNAs. In fact, as 
few as six base pairs between a special region of the miRNA, the “seed sequence” 
(miRNA nucleotides 2 through 7 or 8), and an mRNA, may suffice to recruit 
Argonaute to repress the mRNA (Figure A.2). Consequently, most miRNAs do 
not direct Argonaute to slice the target mRNA, but instead the 
miRNA:Argonaute complex triggers general degradation of the target mRNA9. 
In some cases, the miRNA may block the translation of the mRNA into protein10. 
Because a miRNA need only pair only partially with its mRNA target, a single 
miRNA can repress hundreds of genes10-16. Most mRNAs contain multiple 
potential miRNA-binding sites in their 3′ UTRs1,12. Current computational 
estimates suggest that more than half of all human genes are regulated by 
miRNAs at some time or place in human development. 
Viral miRNAs target cellular and viral mRNAs 
Mammalian viruses produce at least 66 distinct miRNAs. Most miRNA-
producing viruses are double-stranded DNA (dsDNA) viruses from the herpes 
virus family; no miRNAs have been detected from RNA viruses such as 
retroviruses or flaviviruses, or the papillomavirus, a dsDNA virus17,18. One 
known function of viral miRNAs is to thwart the immune response during 
infection by regulating the expression of the major histocompatibility complex 
class I chain-related molecule B (MICB), a natural killer cell ligand19. Epstein-Barr 
virus (EBV), Kaposi’s sarcoma–associated herpesvirus (KSHV) and human 
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cytomegalovirus (HCMV) express miRNAs that target separate sites in the MICB 
mRNA to prevent its expression. Blocking these miRNAs might permit a more 
robust immune response to herpesvirus infection. 
HCMV expresses a miRNA, miR-UL112, that targets the 3′ UTR of MICB 
at a site overlapping the binding site for the cellular miRNA, miR-373. 
Interestingly, the MICB mRNA also contains nearby sites for two other cellular 
miRNAs, miR-376a and miR-433. After 72 hours of HCMV infection, the viral 
miR-UL112 and the cellular miR-376a collaborate to silence expression of MICB20. 
KSHV express three miRNAs, each with the same seed sequence as a cellular 
miRNA. One of the viral miRNAs, miR-K12-11, represses the same set of mRNAs 
as its cellular counterpart, miR-155. 
A second function for viral miRNAs may be to repress host mRNAs so as 
to maintain viral latency21,22. KSHV miR-9* binds the 3′ UTR of the major lytic-
switch mRNA, preventing expression of the protein that controls viral 
reactivation from latency23. Expression of two cellular miRNAs, miR-200b and 
miR-429, correlates with EBV lytic gene expression. These two microRNAs cause 
EBV to enter the lytic phase by repressing ZEB1 and ZEB2 protein expression24. 
miRNA inhibitors may some day be used to coax latent viruses into the more 
therapeutically tractable replicating state, allowing the elimination of reservoirs 
that enable viral reemergence after anti-viral therapy is completed. 
Artificially introducing or inhibiting miRNAs provides clues to their function 
To understand the role of miRNAs in normal cellular processes and in human 
disease, we need tools to increase and decrease miRNA function or abundance.  
Expression of exogenous small RNAs in cells is possible through transient or 
stable transfection or viral transduction of a pri-miRNA transgene, pre-miRNA, 
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mature miRNA/miRNA*, small interfering RNA (siRNA) or short hairpin RNA 
(Figure 3). Using this strategy, intratumoral injection of exogenous let-7 was 
found to block tumor development in a mouse model of non-small cell lung 
cancer25-28. Similarly, reintroduction of miR-26a in a mouse model of liver cancer 
caused regression of tumors29. The opposite strategy—targeting miRNAs for 
inhibition—has yielded interesting results in vivo. For example, inhibition of 
miRNA-132 prevented angiogenesis in an orthotopic mouse model of ovarian 
and breast carcinoma and inhibition of miRNA-21, a miRNA that promotes 
oncogenesis, led to regression of malignant pre-B lymphoid tumors30-32. 
Antisense oligonucleotides (ASOs) are short, single-stranded RNA or 
DNA molecules that bind other nucleic acids by Watson-Crick base pairing. 
Traditional ASOs target a specific mRNA in order to block its translation into 
protein (e.g., morpholino ASOs) or to trigger its destruction by recruiting RNase 
H to hydrolyze the RNA strand of an RNA:DNA duplex (“gapmer” ASOs). 
ASOs are used in vitro and in vivo to discover gene function, and some ASOs are 
being tested in clinical trials. ASOs were first shown to inhibit specific miRNAs 
in cultured cells and in invertebrates in 2004. Subsequent studies have examined 
various chemical modifications of ASOs to improve their in vitro and in vivo 
stability and to improve their in vivo delivery. Moreover, some ASO chemistries 
can trigger the destruction of a miRNA through a mechanism recently 
discovered by using miRNA inhibitors. The stability of a miRNA is determined 
by the Argonaute protein with which it associates and the degree of sequence 
complementarity between the miRNA and its target mRNA33. When a miRNA 
encounters a target to which it can pair extensively—including miRNA inhibitor 
oligonucleotides, it is tailed with adenosines or uridines and subsequently 
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degraded. This type of regulatory mechanism, dependent on the presence of a 
target and the extent of pairing to a complementary RNA, is critical to strategies 
that aim to inhibit or replace miRNAs to discover their roles in cellular processes 
or pathogenic mechanisms. 
Modified antisense oligonucleotides can help define the molecular function of an 
individual miRNA 
The molecular function of an individual miRNA can be discovered by inhibiting 
it and measuring the resulting changes in the levels of each mRNA or protein in 
the cell or by evaluating other phenotypic changes, such as developmental 
defects, cell proliferation, organ function, lipid metabolism, or behavior. ASOs 
engineered to withstand degradation by extra- and intracellular nucleases can 
effectively inhibit miRNAs in whole animals34,35. The first ASOs used to inhibit 
miRNAs were composed of 2′-O-methyl ribose-modified RNA. Such 2′-O-methyl 
oligonucleotides proved to be effective miRNA inhibitors when introduced by 
lipid-mediated transfection into cultured human cells or by injection in whole 
nematodes (Caenorhabditis elegans). Dextran-conjugated ASOs can be injected into 
the C. elegans germ line and block the function of a specific miRNA function in 
the progeny36. 
“Antagomirs” were the first miRNA inhibitors demonstrated to work in 
mammals (Figure A.3). Because the amount of pre-miRNA was unchanged by 
the antagomir, ASOs likely target the mature miRNA37,38. These synthetic ASOs 
contain 2′-O-methyl modified ribose sugars, terminal phosphorothioates, and at 
the 3′ end a cholesterol group, which helps deliver the antagomir to cells. 
Cholesterol conjugation causes cellular uptake of the modified nucleic acid 
oligonucleotide by promoting its association with high-and low-density 
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lipoproteins that can bind cell surface membrane receptors: the Scavenger 
receptor BI for HDL and the LDL receptor for LDL. Intravenous injection of 80 
mg of antagomir per kg mouse body weight on each of three successive days 
inhibited the corresponding miRNA in mouse liver, lung, kidney, heart, 
intestine, fat, skin, bone marrow, muscle, ovaries and adrenal glands. 
Nonetheless, antagomirs are unlikely to be used clinically, as they require higher 
doses to achieve the same efficacy as other ASO strategies. 
Alternative RNA chemistries (Figure A.4) such as 2′-O-methoxyethyl (2′-
MOE), 2′-fluoro, and 2′,4′ methylene (“locked nucleic acids” or LNAs) have 
greater affinity to bind and inhibit miRNA function in vivo than 2′-O-methyl 
RNA oligonucleotides39-41. Alternative chemistries are also more resistant to 
degradation. In a test of stability of modified RNAs in 10% fetal bovine serum, 2′-
fluoro RNA with LNA ends was less degraded after 24 hours than a 2′-O-methyl 
RNA with LNA ends or a DNA/LNA oligonucleotide, which was degraded 
within 2 hours35. Phosphorothioates substitute a non-bridging oxygen atom on 
the phosphate group with a sulfur. Phosphorothioate bonds promote serum 
protein binding, thereby increasing the in vivo distribution and bioavailability of 
the ASO. A direct comparison of anti-miRNA oligonucleotide chemistries in 
vitro revealed that combining 2′-O-methyl and LNA with phosphorothioate ends 
was ~10 times more effective than the 2′-O-methyl or phosphorothioate 
modifications alone and twice as effective as the 2′-O-methyl with LNA 
modifications35. 
The 2′,4′ methylene bridge in LNAs constrains the ribose to the C3′ endo 
conformation present in RNA:RNA and DNA:RNA helices. (DNA:DNA helices 
are C2′ endo.) LNAs cannot interconvert between the C3′ endo conformation, 
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which favors pairing with an RNA, and the C2′ endo conformation, which does 
not. Consequently, an LNA modification increases RNA:RNA melting 
temperature by 2.4℃ per modification and confers high specificity for their 
target sequences. Moreover, locked nucleic acids are resistant to many 
endonucleases. ASOs containing LNAs are effective probes for accurate detection 
of miRNAs by Northern blotting, in situ hybridization and, most importantly, 
are potent miRNA inhibitors in vivo. 
The unique target mRNA-binding properties of a miRNA bound to an 
Argonaute protein—nearly all the binding specificity comes from the seed 
sequence—allow antisense miRNA inhibitors to be shorter than the miRNA 
itself. A 16 nt LNA-modified oligonucleotide complementary to miRNA-122 
injected intravenously each day for five successive days at 10 mg/kg, lowered 
plasma cholesterol levels for more than 20 days in African green monkeys42. This 
pioneering non-human primate study established that LNA-modified anti-
miRNA oligonucleotides are specific, stable, and non-toxic when administered 
intravenously. A subsequent study showed that Hepatitis C virus (HCV) 
replication could be inhibited in chimpanzees by a 15 nt LNA oligonucleotide 
targeting miRNA-12243. Two chimpanzees were injected intravenously with 5 mg 
per kg of LNA inhibitor each week for 12 weeks. Two weeks after treatment 
ended, viral titer was 400- and 200-times lower in serum and liver, respectively. 
Free anti-miR-122 LNA was detected in liver for 8 weeks after treatment ceased, 
until week 25, at which point the drug had declined significantly and the level of 
miR-122 had increased. No liver toxicity was detected, and treatment was 
associated with improved liver histology, presumably due to prolonged 
suppression of viremia and normalization of the interferon pathway. No viral 
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escape was detected by sequence analysis of the HCV RNA target sites for miR-
122 at the 16th week, in contrast to treatment with an antiviral non-nucleoside 
polymerase inhibitor with which resistance mutations occur after 2 days of 
treatment. miRNA-122 inhibition by LNA-modified oligonucleotides is now 
being tested in humans. A successful phase 1 trial has paved the way for a phase 
2 study that will assess the safety and tolerability of weekly or bi-weekly 
subcutaneous injections of the anti-miR-122 LNA in 55 patients with chronic 
HCV genotype 1 infection. 
Advancements in delivery formulations reduce the effective dose of ASOs 
Delivering a therapeutic RNA to its target tissue starts with the challenge of its 
exiting the circulatory system into a target tissue, transiting the cell membrane, 
and, finally, escaping from endosomal vesicles into the cytoplasm. The size of an 
unconjugated therapeutic RNA is 7–20 kDa. Molecules smaller than 50 kDa are 
filtered by the kidneys and excreted. Transfer of therapeutic RNA from the blood 
to the target tissue is a challenge because anything longer than 5 nm diameter, 
including therapeutically complexed RNA, cannot cross the capillary 
endothelium and will remain in circulation until filtered by the kidneys. Local 
delivery of therapeutic RNA by injection increases its bioavailability in target 
tissue and minimizes uptake in non-target tissues, but is limited to eye, skin, 
mucous membranes and tumors. Systemic delivery into the bloodstream is 
challenged by phagocytic immune cells such as macrophages and monocytes, 
which remove complexed RNAs from the body. Most ASOs delivered to muscle, 
heart and bone end up not in the cytoplasm, where they can find their target 
mRNAs, but in phagolysosomes. Cells of the liver, spleen and some tumors 
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allow molecules up to 200 nm in diameter to enter and so the liver is among the 
most successful organs for delivering therapeutic RNAs. 
In cases where localized delivery is not possible, delivery using PEGylated 
liposomes, lipidoids and biodegradable polymers are alternatives (Figure A.5). 
To avoid being filtered by the kidneys and enhance intracellular delivery nucleic 
acids can be encapsulated in lipids forming vesicles between 50 and 500 nm. 
Liposomes are lipid bilayers with an aqueous core that contains the nucleic acid 
cargo. Lipoplexes are liposomes that contain cationic lipids that drive the 
interaction between the lipid bilayer and the negatively charged nucleic acid 
molecules. The anionic charge of the nucleic acids and their hydrophilicity is 
counterbalanced by the cationic lipids, resulting in a net positive charge, 
enabling the liposomes to bind to anionic cell surface molecules. The composition 
of these lipid particles can be tailored to facilitate fusion with the cytoplasmic, 
endosomal or nuclear membrane, as well as to promote endosomal release once 
inside the cell. The lipid head group, for example, can be pH sensitive, so that the 
liposomes interact with anionic phospholipids in the endosome, generating non-
bilayer structures that disrupt the endosomal membrane, liberating the RNA. 
In a screen of a library of ionizable cationic lipids with superior siRNA 
delivery capacity, a lipid nanoparticle (LNP) formulation was identified that 
substantially improved delivery. To test this delivery formulation, an siRNA that 
targets the hepatocyte mRNA transthyretin (TTR) was used because this protein 
has a short half-life and TTR protein levels can be easily measured in serum. The 
LNP delivery strategy in rodents and nonhuman primates was effective at 0.01 
mg per kg and 0.1 mg per kg, respectively, administered as a single dose of TTR 
siRNA by 15 minute, intravenous, cephalic vein infusion at 5 ml per kg44. Forty-
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eight hours later, the siRNA reduced TTR mRNA levels by 30% in the livers of 
three Cynomolgus monkeys. Another potent delivery formula, the lipidoid, 
contains lipids with an amine-containing polar head group and nonpolar alkyl 
tails that are 12 carbons in length. When tested in nonhuman primates, this 
delivery formulation was effective at 0.03 mg per kg of siRNA. Forty-eight hours 
after infusion, the 0.03 mg per kg dose of the TTR siRNA in the lipidoid 
formulation reduced TTR mRNA levels by 70%45. These advanced delivery 
formulations are almost 100 times more effective than typical lipid-based 
delivery carriers, which require doses of at least 1 mg/kg of siRNA to achieve 
50% gene silencing. We anticipate that such advanced lipid systems will be 
useful in delivering anti-miRNA ASOs to specific tissues and organs in humans. 
“Decoy” transcripts can compete for miRNAs, blocking their function 
ASOs act, at least in part, as competitive inhibitors of miRNAs, suggesting that 
miRNA-binding RNA transcripts may also be designed to sequester and thereby 
inhibit specific miRNAs. Such miRNA decoys could provide an inexpensive 
alternative to proprietary oligonucleotide chemistries and delivery formulations, 
enabling research laboratories to examine the consequence of inhibiting each 
known miRNA in a particular cultured cell46 or model animal47 or plant48. 
Moreover, miRNA-binding transcripts can be expressed from viral vectors, 
allowing the development of anti-miRNA gene therapy approaches. Ironically, 
the first demonstration of such transcripts, miRNA “decoys”49 or “sponges”46, 
preceded the discovery that plants naturally use such miRNA-binding 
transcripts to reduce the activity of specific miRNAs50. 
The first miRNA decoy consisted of an adenoviral vector with two sites 
for the muscle-specific miRNA-133 inserted in the 3′ UTR of a GFP reporter gene, 
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under control of an RNA polymerase II promoter from cytomegalovirus (CMV). 
This viral vector was used to confirm that loss of miRNA-133 expression, in 
mouse and human disease models, leads to cardiomyocyte hypertrophy49. Unlike 
chemically modified anti-miRNA oligonucleotides, miRNA decoys that include 
GFP allow one to determine the tissues or cell types where a miRNA is 
produced, as GFP will be repressed where the miRNA is present. “miRZips” and 
“TuD RNAs” (tough decoy RNAs) are microRNA decoy targets transcribed by 
RNA polymerase III (H1 or U6)51,52. Their nuclear export has been optimized to 
achieve high cytoplasmic expression. miRZips use the RNA polymerase III H1 
promoter to express a single microRNA decoy hairpin with one arm that is 
perfectly complementary to the microRNA. This strategy causes degradation of 
the microRNA. TuD RNAs use the RNA polymerase III U6 promoter to express 
an RNA that contains multiple microRNA binding sites between 18 bp stem 
regions that help prevent nuclease degradation of the RNA decoy targets. For the 
TuD RNAs, the binding site is perfectly complementary to the miRNA, but 
contains 4 nt inserted at the site of Ago2 cleavage to prevent the TuD RNA from 
being inactivated. Such adaptations of the miRNA sponge concept allow longer 
term inhibition of microRNAs than can be achieved by transient transfection of 
RNA polymerase II sponge reporter vectors or modified RNA oligonucleotides. 
miRNA sponges can be stably integrated into chromosomes, designed to 
be drug-inducible or controlled by promoters whose expression is restricted to a 
desired cell type, tissue, or developmental stage. For example, in Drosophila, a 
miRNA sponge for miR-8 revealed that post-synaptic expression of miR-8 is 
required for proper development of the neuromuscular junction47. Further 
modification of the sponge concept is underway to create separate sponge-
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expressing lines of transgenic fruit flies for each fly miRNA. Each line can be 
crossed with a second fly strain producing a transcription factor that promotes 
sponge expression in a specific cell type or developmental time, allowing 
discovery of the contribution of a miRNA to development, physiology or 
behavior47. In the future, we anticipate that transgenic sponges will be designed 
to permit their expression in mice at particular developmental stages or in 
specific tissues, perhaps by using the well established Cre-loxP system53,54. 
miRNA replacement therapy seeks to reintroduce a missing miRNA 
Some diseases may be due to loss or reduced expression of a particular 
microRNA. Interestingly, expression of most miRNAs in cancer is lower than 
normal. For example, the miRNA let-7 represses expression of the oncogenes Ras, 
Myc and HMGA-2, and let-7 levels were found to be low and HMGA2 mRNA 
high in primary tumors derived from 100 patients diagnosed with ovarian 
cancer. let-7 expression was also reduced in mammosphere-derived cancer stem 
cells when compared with normal breast or non-selected tumor cells, indicating 
that let-7 may prevent proliferation of cancer-initiating stem cells25,55. p53 
expression caused by DNA damage promotes transcription of the miRNA-34 
miRNA family, which is deleted in some cancers. miRNA-15 and 16 are 
frequently deleted in B-cell lymphocytic leukemia, and their expression is 
reduced by 80% in prostate cancer. Other miRNA genes, including let-7, reside at 
fragile sites where chromosomes often break, leading to cancer56. Thus, many 
miRNAs meet the classical definition of tumor suppressor genes. Replacement of 
such tumor suppressor miRNAs might augment traditional cancer 
chemotherapy. 
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miRNAs whose expression is lost or reduced can be replenished by 
adding back the miRNA. Adding the miRNA back in a single dose may not 
allow sustained target regulation due to inefficient delivery or degradation, but 
data from multiple doses of siRNAs suggest that three-to-five doses of 
replacement miRNA, modified or formulated for optimal delivery, might 
provide sufficient miRNA for 20 to 30 days. Alternatively, cells can be infected 
with viral vectors encoding short hairpin RNAs (Figure 3) that are processed in 
the cell into mature miRNAs26,27,56. Viral delivery of miRNAs can be optimized to 
achieve a specific and continuous level of expression. 
miRNA replacement therapy must be both effective and safe. Over 
expression of shRNA in rats caused hepatotoxicity, organ failure and death57. 
Argonaute proteins and the pre-miRNA export protein, Exportin-5 limit the 
amount of exogenous siRNA or miRNA that a cell can tolerate57-62. shRNAs that 
are more pre-miRNA-like or authentic pre-miRNAs themselves will likely 
minimize toxicity while retaining potency for their intended targets60,63. 
miRNA-directed regulation can improve traditional gene therapy approaches 
Gene therapy holds great promise to replace defective protein-coding genes 
underlying many genetic diseases. However, ensuring expression of the 
therapeutic transgene in the correct tissue while minimizing its expression 
elsewhere remains challenging because even tissue-specific promoters can be 
leaky. Combining miRNA regulation with gene therapy allows targeted and 
potent expression of transgenes. Such “de-targeting” strategies incorporate 
miRNA target sites in the 3′ UTR of the therapeutic transgene, preventing its 
expression in cells that express the corresponding miRNA. The transgene will be 
expressed in the intended cell-type, where the miRNA is not expressed. For 
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example, miRNA-122 is specific to the liver, so systemically delivered transgenes 
containing binding sites for miRNA-122 will be silenced in hepatocytes, but not 
cells elsewhere. This strategy was used to restrict the expression of a transgene in 
a lentiviral vector to astroglial cells64. Starting with a lentivirus engineered to 
preferentially infect neurons and glia, miRNA-124 target sites were inserted in 
the 3′ UTR to prevent transgene expression in neuronal cells, which express 
miRNA-124, and allow transgene expression in glial cells, which do not express 
miRNA-124. Injection of the vector into the hippocampus in mice produced 
transgene expression in astrocytes and Bergmann glial cells, but not in pyramidal 
neurons or Purkinje cells64. Since each site is only 21 nt long, binding sites for 
multiple, tissue-specific miRNAs can be incorporated in the 3′ UTR, 
extinguishing transgene expression in many different tissues simultaneously. 
miRNA-mediated transgene detargeting has also been used to promote 
immune tolerance of a transgene-encoded antigen. Annoni and colleagues 
exploited the tissue specificity of miRNA-142, which is expressed only in 
hematopoietic cells, to prevent a lentiviral vector from producing transgenic 
protein in antigen presenting cells65. By blocking transgene expression in 
immune cells, they avoided the common problem of T-cells detecting and 
eliminating cells expressing the foreign transgenic protein. Interestingly, a 
control experiment to prevent expression in the liver using miRNA-122 binding 
sites revealed that liver expression of the transgene was required to induce 
antigen tolerance. 
Replication-selective oncolytic viruses—genetically engineered 
adenoviruses that selectively infect and kill tumor cells—have been proposed as 
alternatives to standard chemotherapy. Avoiding expression in the liver is 
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particularly important as adenovirus-based therapies cause liver toxicity. Since 
neuroendocrine tumors of the ileum can metastasize to the liver66, a key 
challenge is to produce the transgenic protein in the cancer cells residing in the 
liver, but not in untransformed hepatocytes. Whyte and colleagues proposed a 
clever solution to this problem. They used the chromogranin-A promoter, which 
is active in neuroendocrine tumors, to specifically express the E1A protein, a 
viral protein that activates viral and cellular genes critical for viral infection, 
while adding miRNA-122 binding sites to the 3′ UTR of the E1A mRNA to 
prevent viral replication in hepatocytes67. In a mouse model, the miRNA-
regulated, oncolytic adenovirus killed tumor cells without detectable liver 
toxicity. 
Unique miRNA expression patterns in stem cells can be exploited to select 
for a specific cell type from a mixed cell population, before adding cells back to 
the patient and as a strategy for monitoring lineage-specific differentiation of 
induced pluripotent and embryonic stem cells. In stem cell therapy applications, 
where cells are engineered to express normal genes that are mutated in the 
patient, it is critical to remove the pluripotent cell population from the 
therapeutic differentiated cells before transplanting them back into the patient to 
prevent unwanted proliferation and tumor development.  Expression of a suicide 
gene or fluorescent reporter can be controlled by miRNAs whose expression is 
specific to a differentiated cell type in a population of pluripotent stem cells68. 
Differentiation-induced miRNA expression could turn off the reporter gene to 
allow separation of the differentiated cells from the pluripotent cells. A suicide 
gene can also be turned off by cell type specific miRNAs to allow differentiated 
cells of a specific lineage to proliferate. Additionally, by combining multiple 
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miRNA target sites, expression of a transgene can potentially be suppressed in 
multiple cell types or tissues. Such a strategy requires calibrating miRNA 
expression and target site affinity so that the desired level of regulation of the 
transgene is achieved.  
Prospects 
The realization that the inappropriate production of individual miRNAs 
contributes to disease has reinvigorated antisense oligonucleotide drug 
development. ASOs readily inhibit miRNAs—far more reliably than they do 
mRNAs, and the unique properties of Argonaute proteins permits the use of 
remarkably short ASOs: 15 nt oligonucleotide ASO are now in clinical trials and 
8 nt versions show promise in non-human primates. Many new roles for 
individual miRNAs in disease, aging and cancer are likely to emerge over the 
next five years. Once the role of a specific miRNA in disease pathogenesis is 
established, selecting specific anti-miRNA inhibitor chemistries and delivery 
strategies promises to be straightforward. Nonetheless, effective and safe 
delivery of anti-miRNA drugs remains difficult for many cell types such as brain 
and muscle. Thus, treating diseases with anti-miRNA oligonucleotides will 
require the development of novel modification, conjugation or formulation 
strategies. It is our hope that the anti-miRNA therapeutics field will soon 
converge on a small number of “platform” technologies that allow a rapid and 
safe development path from academic discovery to effective drug. 
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Figures 
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Figure A.1. microRNA biogenesis pathway. 
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Figure 1. miRNA biogenesis in mammals. 
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Figure A.2. miRNAs bind target mRNAs via their seed sequence. 
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Figure 2. miRNAs bind target mRNAs via their seed sequence. Typical miRNA-
binding sites also feature an adenosine (underlined) across from the first 
nucleotide of the miRNA, even though the structure of a miRNA bound to an 
Argonaute protein precludes base pairing at this position. 
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Figure A.3. miRNA replacement strategies. 
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Figure 3. miRNA replacement strategies: (A) mature miRNA/miRNA* duplex; 
(B) small interfering RNA duplex; (C) small hairpin RNA; (D) pre-miRNA; (E) 
pri-miRNA; (F) modified single stranded RNA. 
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Figure A.4. Strategies for delivery of anti-miRNA oligonucleotides to cells in vivo. 
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Figure 4. Strategies for delivery of anti-miRNA oligonucleotides to cells in vivo. 
(A) Modification. Black filled circles represent 2′-O-methyl, 2′-O-methoxyethyl, 
or 2′-fluoro modified nucleotides. (B) Conjugation. Antagomirs are 2′-O-methyl 
oligonucleotides conjugated to cholesterol at their 3′ ends, and contain 
phosphorothioate linkages between nucleotides at both ends in place of natural 
phosphate linkages. (C) Formulation. Lipid nanoparticles are lipid vesicles 
containing therapeutic RNA. The formulated lipid bilayer encapsulates the 
therapeutic RNA , delivering it to cells and promoting fusion with the 
phospholipid bilayer of cell membranes. Individual lipids within the vesicle 
bilayer can contain ionizable head groups that will disrupt the endosome at low 
pH to release the therapeutic RNA to the cytoplasm. 
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Figure A.5. Chemical modifications that improve the stability, biodistribution, and delivery of ASOs. 
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Figure 5. Chemical modifications that improve the stability, biodistribution, and 
delivery of ASOs. RNA (red; S indicates sulfur substitution of a non bridging 
oxygen to make a phosphorothioate linkage between nucleotides), 2′-O-methyl 
RNA contains a methyl group bound to the 2′ oxygen of the ribose; 2′-O-
methoxyethyl RNA contains a methoxy group bound to the 2′ oxygen of the 
ribose; 2′-fluoro RNA contains fluorine molecule bound to the 2′ oxygen of the 
ribose; and locked nucleic acid (red) introduces a 2′,4′ methylene bridge in the 
ribose to form a bicyclic nucleotide). 
 
Table A.1. miRNA therapeutics in commercial development. 
Company Diseases Chemistries Stage References 
Regulus 
Therapeutics 
immuno-inflammatory,  
cardiovascular, 
metabolic disease, 
oncology, fibrosis, and 
hepatitis C infection 
miRNA inhibitors using 
2′-methoxyethyl , 2′-
fluoro RNA, bicyclic 
ribose modifications 
pre-clinical 
Esau et al., 2006 
Esau et al.,  2007 
Krutzfeldt et al., 2005 
Krutzfeldt et al.,  2007 
www.regulusrx.com 
Santaris 
Pharma A/S 
cancer and 
inflammatory diseases, 
hepatitis C infection 
miRNA inhibitors using 
locked nucleic acid 
chemistry 
miR-122 inhibitor: 
Phase I 
completed, Phase 
  
Ørom et al., 2006 
Elmén et al., 2008 
www.santaris.com 
miRagen 
Therapeutics 
cardiovascular and 
muscle diseases 
miRNA inhibition and 
replacement 
pre-clinical www.miragentherapeutics.com 
Mirna 
Therapeutics 
non-small cell lung 
cancer and prostate 
 
miRNA replacement 
using siRNAs 
pre-clinical www.mirnatherapeutics.com 
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